Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2013

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number 1-10352

 

 

COLUMBIA LABORATORIES, INC.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   59-2758596

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

4 Liberty Square

Boston, Massachusetts

  02109
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 639-1500

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x     No   ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes   x     No   ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “small reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ¨    Accelerated filer   ¨
Non-accelerated filer   x   (Do not check if a smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   ¨     No   x

The number of shares outstanding of the registrant’s common stock as of November 1, 2013: 12,009,545.

 

 

 


Table of Contents

Columbia Laboratories, Inc. and Subsidiaries

Table of Contents

 

         Page  
Part I—Financial Information   

Item 1.

 

Financial Statements (unaudited)

  
 

Consolidated Balance Sheets as of September 30, 2013 and December 31, 2012

     3   
 

Consolidated Statements of Operations for the three and nine month periods ended September 30, 2013 and 2012

     4   
 

Consolidated Statements of Comprehensive (Loss) Income for the three and nine month periods ended September 30, 2013 and 2012

     5   
 

Consolidated Statements of Cash Flows for the nine month periods ended September 30, 2013 and 2012

     6   
 

Notes to Consolidated Financial Statements (unaudited)

     7   

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     16   

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

     26   

Item 4.

 

Controls and Procedures

     26   
Part II—Other Information   

Item 1.

 

Legal Proceedings

     27   

Item 1A.

 

Risk Factors

     27   

Item 6.

 

Exhibits

     30   

Signatures

       31   

 

2


Table of Contents

Columbia Laboratories, Inc. and Subsidiaries

Consolidated Balance Sheets

 

     September 30,
2013
    December 31,
2012
 
     (Unaudited)        
Assets     

Current assets:

    

Cash and cash equivalents

   $ 18,817,057      $ 13,204,067   

Short-term investments

     —          15,433,967   

Accounts receivable, net

     6,848,148        1,159,145   

Amounts due from related parties

     900,000        2,194,491   

Inventories

     1,994,454        2,626,606   

Prepaid expenses and other current assets

     2,808,954        1,284,279   
  

 

 

   

 

 

 

Total current assets

     31,368,613        35,902,555   

Property and equipment, net

     12,726,893        927,227   

Goodwill and intangibles, net

     15,560,287        —     

Other assets

     124,903        38,882   
  

 

 

   

 

 

 

Total assets

   $ 59,780,696      $ 36,868,664   
  

 

 

   

 

 

 
Liabilities and Shareholders’ Equity     

Current liabilities:

    

Accounts payable

   $ 2,556,163      $ 1,435,660   

Accrued expenses

     3,158,638        2,216,524   

Deferred revenue

     599,787        93,750   

Notes payable

     243,347        —     
  

 

 

   

 

 

 

Total current liabilities

     6,557,935        3,745,934   

Deferred revenue, net of current portion

     2,323,584        33,526   

Notes payable, net of current portion

     3,730,411        —     

Common stock warrant liability

     5,568,525        1,173,747   
  

 

 

   

 

 

 

Total liabilities

     18,180,455        4,953,207   
  

 

 

   

 

 

 

Commitments and contingencies

    

Contingently redeemable series C preferred stock, 550 shares issued and outstanding (liquidation preference of $550,000)

     550,000        550,000   
  

 

 

   

 

 

 

Shareholders’ equity:

    

Preferred stock, $.01 par value; 1,000,000 shares authorized

    

Series B convertible preferred stock, 130 shares issued and outstanding (liquidation preference of $13,000)

     1        1   

Series E convertible preferred stock, 22,740 shares issued and outstanding (liquidation preference of $2,274,000)

     227        227   

Common stock $.01 par value; 150,000,000 shares authorized; 12,020,442 issued at September 30, 2013 and 10,942,973 issued at December 31, 2012

     120,204        109,430   

Additional paid-in capital

     287,885,380        279,463,439   

Treasury stock (at cost), 10,897 shares at September 30, 2013, and 4,556 shares at December 31, 2012

     (156,074     (125,381

Accumulated deficit

     (247,621,276     (248,365,480

Accumulated other comprehensive income

     821,779        283,221   
  

 

 

   

 

 

 

Total shareholders’ equity

     41,050,241        31,365,457   
  

 

 

   

 

 

 

Total liabilities and shareholders’ equity

   $ 59,780,696      $ 36,868,664   
  

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

3


Table of Contents

Columbia Laboratories, Inc. and Subsidiaries

Consolidated Statements of Operations

(Unaudited)

 

     Three Months Ended September 30,     Nine Months Ended September 30,  
     2013     2012     2013     2012  

Revenues

        

Product revenues

   $ 5,456,152      $ 4,193,999      $ 17,848,180      $ 12,511,277   

Product revenues from related party

     —          1,426,890        —          3,590,073   

Royalties

     107,218        112,770        284,011        299,800   

Royalties from related party

     887,553        904,839        2,524,466        2,232,397   

Other revenues

     674,769        34,540        762,577        103,568   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenues

     7,125,692        6,673,038        21,419,234        18,737,115   

Cost of revenues

     3,238,215        1,889,749        8,910,550        6,392,248   

Cost of revenues from related party

     —          1,297,043        —          3,263,376   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total cost of revenues

     3,238,215        3,186,792        8,910,550        9,655,624   

Gross profit

     3,887,477        3,486,246        12,508,684        9,081,491   

Operating expenses

        

Sales and marketing

     78,777        —          78,777        —     

Research and development (net of reimbursement from related party of $3,092 and $435,199 for the three and nine months ended September 30, 2012, respectively)

     —          143,795        —          856,545   

Acquisition related expenses

     947,202        —          1,439,946        —     

General and administrative

     1,594,223        1,901,880        5,881,636        6,376,561   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     2,620,202        2,045,675        7,400,359        7,233,106   

Income from operations

     1,267,275        1,440,571        5,108,325        1,848,385   
  

 

 

   

 

 

   

 

 

   

 

 

 

Interest income

     641        35,880        95,996        158,625   

Change in fair value of stock warrants

     (4,444,804     (1,065,498     (4,394,778     5,399,569   

Other income (expense), net

     25,195        (19,882     (57,165     (115,629
  

 

 

   

 

 

   

 

 

   

 

 

 

(Loss) income before income taxes

     (3,151,693     391,071        752,378        7,290,950   

Provision for income taxes

     2,624       2,342        8,174        5,018   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss) income

   $ (3,154,317   $ 388,729      $ 744,204      $ 7,285,932   
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic net (loss) income per common share

   $ (0.28   $ 0.04      $ 0.07      $ 0.67   
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted net (loss) income per common share

   $ (0.28   $ 0.04      $ 0.07      $ 0.17   
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic weighted average common shares outstanding

     11,137,780        10,916,358        10,994,382        10,913,844   
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted weighted average common shares outstanding

     11,137,780        11,067,853        11,148,275        11,056,421   
  

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

4


Table of Contents

Columbia Laboratories, Inc. and Subsidiaries

Consolidated Statements of Comprehensive (Loss) Income

(Unaudited)

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2013     2012      2013     2012  

Net (loss) income

   $ (3,154,317   $ 388,729       $ 744,204      $ 7,285,932   

Other comprehensive income (loss) components:

         

Foreign currency translation

     637,710        3,195         635,778        (247

Unrealized gain (loss) on short term investments

     —          79,313         (80,223     175,201   

Reclassification adjustment for gains included in net income

     —          —           (16,997     —     
  

 

 

   

 

 

    

 

 

   

 

 

 

Comprehensive (loss) income

   $ (2,516,607   $ 471,237       $ 1,282,762      $ 7,460,886   
  

 

 

   

 

 

    

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

5


Table of Contents

Columbia Laboratories, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(Unaudited)

 

     Nine Months Ended
September 30,
 
     2013     2012  

Operating activities:

    

Net income

   $ 744,204      $ 7,285,932   

Reconciliation of net income to net cash provided by operating activities:

    

Depreciation and amortization

     376,530        440,779   

Change in fair value of stock warrants

     4,394,778        (5,399,569

Provision for sales returns

     (26,120     (222,764

Write-off of inventories

     —          867,316   

Stock-based compensation expense

     338,139        637,487   

Gain on short-term investments

     (16,997     —     

Loss on disposal of fixed assets

     36,900        6,225   

Changes in operating assets and liabilities:

    

Accounts receivable

     (2,026,081     (308,865

Due from related party

     1,294,491        (348,424

Inventories

     635,400        (938,288

Prepaid expenses and other current assets

     (547,306     164,196   

Other non-current assets

     (86,016     425,408   

Accounts payable

     95,482        (856,417

Accrued expenses

     (137,444     (397,590

Deferred revenue

     (160,485     (103,406
  

 

 

   

 

 

 

Net cash provided by operating activities

     4,915,475        1,252,020   

Investing activities:

    

Purchase of property and equipment

     (246,935     (985,930

Additions to short term investments

     —          (179,811

Cash paid for acquisition, net of cash received

     (14,516,297     —     

Proceeds from the sale of short-term investments

     15,353,744        —     
  

 

 

   

 

 

 

Net cash provided by (used in) investing activities

     590,512        (1,165,741

Financing activities:

    

Redemption of series C convertible preferred stock

     —          (50,000

Proceeds from exercise of stock options

     10,263        —     

Principal payments on note payable

     (7,297     —     

Dividends paid

     (20,625     —     
  

 

 

   

 

 

 

Net cash used in financing activities

     (17,659     (50,000

Effect of exchange rate changes on cash and cash equivalents

     124,662        35,140   
  

 

 

   

 

 

 

Net increase in cash and cash equivalents

     5,612,990        71,419   

Cash and cash equivalents, beginning of period

     13,204,067        10,114,163   
  

 

 

   

 

 

 

Cash and cash equivalents, end of period

   $ 18,817,057      $ 10,185,582   
  

 

 

   

 

 

 

Supplemental cash flow information

    

Cash paid for income taxes

   $ 2,876      $ 52,728   
  

 

 

   

 

 

 

Cash paid for interest

   $ 4,532      $ —     
  

 

 

   

 

 

 

Supplemental noncash financing activities

    

Common stock issued in connection with the acquisition of Molecular Profiles

   $ 8,105,700      $ —     
  

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

6


Table of Contents

Columbia Laboratories, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

(Unaudited)

(1) Interim Consolidated Financial Statements

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. It is recommended that these financial statements be read in conjunction with the consolidated financial statements and related notes that appear in the Annual Report on Form 10-K of Columbia Laboratories, Inc. (“Columbia”) for the year ended December 31, 2012 filed with the SEC on March 14, 2013. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the consolidated financial information for the interim periods reported have been made. Results of operations for the nine months ended September 30, 2013 are not necessarily indicative of the results for the year ending December 31, 2013 or any period thereafter.

Reclassifications

Certain amounts in the prior year’s financial statements have been reclassified to conform to the current year’s presentation within the consolidated balance sheets and consolidated statements of cash flows.

Basis of Presentation

On July 26, 2013, Columbia’s Board of Directors set a ratio of 1-for-8 for its previously approved reverse stock split which took effect on August 9, 2013. The reverse stock split was approved by Columbia’s shareholders at its annual meeting of shareholders on May 1, 2013. All share and per share amounts relating to the common stock, stock options and warrants included in the financial statements and accompanying footnotes have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an equal amount to the reduction in par value of common stock to additional paid-in capital. The reverse stock split did not result in a retroactive adjustment to the share amounts for any of the classes of the Company’s preferred stock.

(2) Actavis Transactions

Under a purchase agreement with Actavis, Inc. (“Actavis”, formerly Watson Pharmaceuticals, Inc.), Actavis has agreed to make royalty payments to Columbia of 10% to 20% of annual net sales of certain Progesterone Products provided, however, that royalty rates will be reduced by 50% in a particular country if a generic entry by a third party occurs in such country and certain other circumstances are fulfilled. In addition, if Actavis commercializes a Progesterone Product through a third party outside of the U.S., in lieu of royalties, Columbia will be entitled to 20% of gross profits associated with such commercialization. If Actavis or its affiliates effects a generic entry with respect to a Progesterone Product in a particular country in the circumstances permitted by the Purchase Agreement, in lieu of royalties payable in respect of net sales for such generic product, Columbia will be entitled to 20% of the gross profits associated with the commercialization of such generic product in such country.

Pursuant to the purchase agreement, Columbia and Actavis had also agreed to collaborate with respect to the development of Progesterone Products. Columbia was responsible for the costs of conducting the PREGNANT Study and the preparation, filing and approval process of the related new drug application (or the supplemental new drug application) up to a maximum of $7.0 million. All other development costs incurred in connection with the development collaboration were paid by Actavis. In the three and nine months ended September 30, 2012, Columbia was reimbursed $3,100 and $0.4 million by Actavis, respectively. These reimbursed costs were credited to research and development expense in the consolidated financial statements. There were no research and development expenses incurred for the three and nine months ended September 30, 2013.

As part of the purchase agreement, from the date of the closing of the Actavis Transactions until the second anniversary of the date on which Columbia and Actavis terminate their relationship with respect to the joint development of Progesterone Products, Columbia agreed not to manufacture, develop or commercialize products containing progesterone or any other products for the preterm birth indication, subject to certain exceptions. The joint development collaboration can be terminated by either party on or after July 2, 2015 (five years after the closing of the Actavis Transactions).

(3) Acquisition of Molecular Profiles Limited

On September 12, 2013, Columbia acquired all of the outstanding capital stock of Molecular Profiles Limited (“Molecular Profiles”), a U.K.-based pharmaceutical development services company. The main service lines that have been added to our portfolio as a result of the acquisition include:

 

    Formulation, scale-up and clinical trial manufacturing supply service;

 

    Advanced physical and chemical analysis; and,

 

    Consulting services.

 

7


Table of Contents

The acquisition expands Columbia’s business model and customer base while diversifying the Company’s revenue streams. With the addition of Molecular Profiles, the Company has broadened its technical expertise in the field of pharmaceutical development and analytical services. As a result of the transaction, former Molecular Profiles stockholders, in the aggregate received for their shares of Molecular Profiles common stock $16.7 million in cash and 1,051,323 shares of Columbia common stock. The total consideration is valued at $24.9 million, based upon the closing price of Columbia’s common stock on September 12, 2013. The goodwill recognized is attributable to expected synergies as the formulation, clinical trial manufacturing and consulting business lines are integrated into Columbia’s business model. The goodwill is deductible for tax purposes. Columbia accounted for this transaction using the acquisition method under the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combinations .

Columbia has retained an independent valuation firm to assess the fair value of the identifiable intangible assets acquired and is currently assessing the fair value of other assets acquired and liabilities assumed and plans to file pro forma financial information with the SEC within the applicable time period. Columbia has preliminarily allocated the purchase price to the net tangible and intangible assets based on their estimated fair values as of September 12, 2013. As such, the assets acquired and liabilities assumed, including intangible assets, presented in the table below are provisional and will be finalized in a later period once the fair value procedures are completed.

The following table summarizes the preliminary purchase price allocation, net of the cash and debt acquired:

 

Purchase price:

  

Cash and stock paid

   $ 24,852,511   

Cash acquired

     (2,230,514

Debt assumed

     3,889,486   
  

 

 

 

Purchase price, net

   $ 26,511,483   
  

 

 

 

Assets (liabilities) acquired:

  

Accounts receivable

   $ 3,583,614   

Prepaid expenses and other current assets

     970,380   

Property and equipment

     11,690,239   

Goodwill

     15,201,557   

Accounts payable

     (999,539

Accrued expenses

     (1,045,389

Deferred revenue

     (2,889,379
  

 

 

 

Total

   $ 26,511,483   
  

 

 

 

Revenue related to Molecular Profiles operations was $0.6 million following the September 12, 2013 acquisition date, and is included in Columbia’s consolidated statements of operations for the three and nine months ended September 30, 2013. As a result of the integration of the operations of Molecular Profiles into Columbia’s operations, disclosure of earnings included in the accompanying consolidated statements of operations since the acquisition date is not practicable.

The following unaudited pro forma condensed consolidated operating results for the three and nine months ended September 30, 2013 and 2012 summarize the combined results of operations for Columbia and Molecular Profiles. The unaudited pro forma consolidated operating results include the business combination accounting effects as if the acquisitions had been completed as of January 1, 2012 (for both the 2013 and 2012 period results). These pro forma amounts are for informational purposes only and are not indicative of the operating results that would have occurred if the transaction had occurred on such date. No effect has been given for synergies, if any, that may be realized through the acquisition.

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2013     2012      2013      2012  

Revenue

   $ 9,518,660      $ 8,967,687       $ 28,267,722       $ 23,874,436   

Pre-tax (loss) income

     (3,083,927     872,798         778,009         7,507,825   

For the three and nine months ended September 30, 2013, Columbia recorded $0.9 million and $1.0 million, respectively, in costs associated with the acquisition of Molecular Profiles. These amounts are recorded as operating expenses in the general and administrative line on the consolidated statements of operations.

 

8


Table of Contents

(4) Revenue Recognition and Sales Returns Reserves

Revenues include product revenues from sales of Progesterone Products to Actavis and Merck Serono S.A. (“Merck Serono”), royalty revenues (primarily royalty revenues from Actavis on sales of Progesterone Products), and other revenues (primarily service and deferred revenues).

Product revenues are recognized when shipped, except in the case of product shipments to Actavis, which are recognized when received at Actavis’ warehouse. Royalty revenues, based on sales by licensees, are recorded as revenues as those sales are made by the licensees. Service revenues are recognized over the period in which the services are performed and certain multiple-element arrangements are evaluated in accordance with the principles of Accounting Standards update (“ASU”) 2009-13, ( Revenue Recognition Topic – Multiple Element Arrangements ) and Columbia allocates revenue among the elements based upon each element’s relative fair value.

Sales to Merck Serono for CRINONE ® (progesterone gel) are determined on a country-by-country basis and are the greater of (i) thirty percent (30%) of the net selling price in the country, or (ii) Columbia’s direct manufacturing cost plus 20%. Columbia estimates net selling prices based on historical experience and other current information from Merck Serono; the amounts are reconciled on a quarterly basis when information is received from Merck Serono. Certain quantity discounts apply to annual purchases over 10 million, 20 million, and 30 million units. Columbia accrues an estimated volume discount on a quarterly basis and reconciles it on an annual basis.

Columbia is not responsible for returns on international sales. Sales adjustments for international sales are estimated to recognize changes in foreign exchange rates and changes in market prices that may fluctuate within a year. Columbia is responsible for sales returns for products sold to domestic customers prior to both the Actavis Transactions and the sale in April 2011 of STRIANT ® (testosterone buccal system) to Actient Pharmaceuticals LLC (“Actient”). Revenues from the sale of products to domestic customers were recorded at the time goods were shipped to customers. Except for sales to licensees, Columbia’s return policy allows product to be returned for a period beginning three months prior to the product expiration date and ending twelve months after the product expiration date. Products sold to Merck Serono and Actavis are not returnable to Columbia. Provisions for returns on sales to wholesalers, distributors and retail chain stores were estimated based on a percentage of sales, using such factors as historical sales information, distributor inventory levels and product prescription data, and were recorded as a reduction to sales in the same period as the related sales were recognized. Columbia evaluates its remaining provision for returns on a quarterly basis based on the rate of returns processed and adjusts the provision if its analysis indicates that the provision needs to be adjusted.

An analysis of the reserve for sales returns at September 30, 2013 is as follows:

 

     Total  

Balance — December 31, 2012

   $ 483,865   

Provision:

  

Related to current period sales

     —    

Related to prior period sales

     (26,120
  

 

 

 
     (26,120
  

 

 

 

Returns:

  

Related to current period sales

     —    

Related to prior period sales

     (98,855
  

 

 

 
     (98,855
  

 

 

 

Balance — September 30, 2013

   $ 358,890   
  

 

 

 

 

9


Table of Contents

(5) Inventories

Columbia states all inventories at the lower of cost or market, determined on a first-in, first-out method. Inventory includes material and overhead and consists of the following:

 

     September 30,
2013
     December 31,
2012
 

Raw materials

   $ 289,604       $ 685,578   

Work in process

     989,594         1,308,399   

Finished goods

     715,256         632,629   
  

 

 

    

 

 

 

Total Inventories

   $ 1,994,454       $ 2,626,606   
  

 

 

    

 

 

 

(6) Goodwill and Other Intangible Assets

Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination. Columbia does not amortize its goodwill, but instead tests for impairment annually and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than its carrying value of the asset.

Columbia has adopted ASU 2011-08, Intangibles—Goodwill and Other, an amendment to ASC 350, which updates how an entity will evaluate its goodwill for impairment. The guidance provides entities an option to perform a “qualitative” assessment to determine whether further impairment testing is necessary. If further testing is required, the test for impairment continues with the two step process. The first step compares the carrying amount of the reporting unit to its estimated fair value (Step 1). To the extent that the carrying value of the reporting unit exceeds its estimated fair value, a second step is performed, wherein the reporting unit’s carrying value is compared to the implied fair value (Step 2). To the extent that the carrying value exceeds the implied fair value, impairment exists and must be recognized.

Columbia is evaluating the reporting unit structure for it to establish the baseline for goodwill impairment testing in the future. Upon establishment of this baseline, Columbia will perform its annual test for impairment on the first day of the fourth quarter beginning in 2014.

Changes to goodwill during the nine months ended September 30, 2013 were as follows:

 

     Total  

Balance — December 31, 2012

   $ —    

Molecular Profiles acquisition

     15,201,557  

Translation adjustment

     358,730   
  

 

 

 

Balance — September 30, 2013

   $ 15,560,287  
  

 

 

 

Columbia is currently evaluating the fair value of assets acquired and liabilities assumed from the Molecular Profiles acquisition, including identifiable intangible assets and their related amortization periods. As such, the $15.6 million in goodwill presented in the table above is provisional and will be finalized in a later period once the fair value procedures are completed.

(7) Debt and other Contractual Obligations

As a part of the Molecular Profiles acquisition, Columbia assumed debt of $3.9 million that Molecular Profiles had entered into to fund the completion and building of a second facility in the United Kingdom. Molecular Profiles entered into a Business Loan Agreement (“Loan Agreement”) covering three loan facilities with Lloyds TSB Bank (“Lloyds”), as administrative agent. Molecular Profiles had withdrawn $3.9 million and as of September 30, 2013 owes $4.0 million due to foreign currency revaluation. The three loan facilities are each repayable by monthly installments, one started repayment in February 2013 and the remaining two commenced in October 2013. All facilities are due for repayment over 15 years from the date of drawdown. Two of the facilities bear interest at 2.45% and 3.05% per annum, respectively. The third facility is a fixed rate agreement bearing interest at 3.52% per annum. The weighted average interest rate for the period from September 12, 2013 to September 30, 2013 was 3.52%. The Loan Agreement is secured by the mortgaged property and an unlimited lien on other assets of Molecular Profiles. The Loan Agreement contains financial covenants that limit the amount of indebtedness Molecular Profiles may incur, requires Molecular Profiles to maintain certain levels of net worth, and restricts Molecular Profile’s ability to materially alter the character of its business. Molecular Profiles is currently in compliance with all of the covenants under the Loan Agreement.

        As part of the acquisition of Molecular Profiles, Columbia assumed a $2.5 million obligation under a grant arrangement with the Regional Growth Fund on behalf of the Secretary of State for Business, Innovation, and Skills in the United Kingdom. Molecular Profiles used this grant to fund the building of its second facility, which includes analytical labs, office space, and a manufacturing facility. As a part of the arrangement, Molecular Profiles is required to create and maintain certain full-time equivalent personnel levels through October 2017. As of September 30, 2013, Molecular Profiles is in compliance with the covenants of the arrangement.

 

10


Table of Contents

The income from the Regional Growth Fund will be recognized on a decelerated basis over the next four years. As of September 30, 2013, the obligation is valued at $2.6 million due to foreign currency revaluation and is recorded in deferred revenue on the consolidated balance sheets. The amount of other income on the obligation that will be recognized provided Molecular Profiles remains in compliance with the covenants will be the following:

 

Year

   Total  

Remainder of 2013

   $ 64,544   

2014

     322,720   

2015

     580,896   

2016

     839,072   

2017

     774,528   
  

 

 

 

Total

   $ 2,581,760   
  

 

 

 

(8) Geographic Information

Columbia and its subsidiaries are engaged in one line of business: the development, licensing, manufacturing, advanced analysis, consulting services and sale of pharmaceutical products. Columbia conducts the manufacturing of CRINONE through its Bermuda subsidiary which contracts with various manufacturers located in the United Kingdom and Switzerland to make product for both its international and domestic operations and through its subsidiary in the United Kingdom. Columbia conducts its advanced formulation, analytical and consulting services through its newly acquired subsidiary, Molecular Profiles.

Columbia’s international customer, Merck Serono, sells its products into several countries. Columbia’s primary domestic customer, Actavis, is responsible for the commercialization and sale of Progesterone Products in the United States. The following table shows selected information by geographic area:

Revenues:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2013      2012      2013      2012  

United States

   $ 1,026,022       $ 2,598,514       $ 2,928,348       $ 6,443,375   

Switzerland

     5,456,152         4,074,524         17,822,060         12,293,740   

Other countries

     643,518         —          668,826         —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 7,125,692       $ 6,673,038       $ 21,419,234       $ 18,737,115   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Assets:

 

     September 30,
2013
     December 31,
2012
 

United States

   $ 19,359,366       $ 31,898,401   

Switzerland

     4,088,611         1,189,183   

United Kingdom

     36,103,352         3,538,446   

Other countries

     229,367         242,634   
  

 

 

    

 

 

 

Total

   $ 59,780,696       $ 36,868,664   
  

 

 

    

 

 

 

 

11


Table of Contents

Long-lived Assets:

 

     September 30,
2013
     December 31,
2012
 

United States

   $ 354,961       $ 171,167   

Switzerland

     21,966         59,582   

United Kingdom

     12,473,761         734,280   

Other countries

     1,108         1,080   
  

 

 

    

 

 

 
   $ 12,851,796       $ 966,109   
  

 

 

    

 

 

 

The increase in the amount of total assets is due primarily to the Molecular Profiles acquisition. The increase in the amount of long-lived assets is due to the tangible net assets acquired in the Molecular Profiles acquisition. Columbia is currently evaluating the fair value of assets acquired and liabilities assumed.

(9) Net (Loss) Income Per Common Share

The calculation of basic and diluted (loss) income per common and common equivalent share is as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
   2013     2012      2013      2012  

Basic net (loss) income per share

          

Net (loss) income

   $ (3,154,317   $ 388,729       $ 744,204       $ 7,285,932   

Less: Preferred stock dividends

     (6,875     —           20,625         —     
  

 

 

   

 

 

    

 

 

    

 

 

 

Net (loss) income applicable to common stock

   $ (3,147,442   $ 388,729       $ 723,579       $ 7,285,932   
  

 

 

   

 

 

    

 

 

    

 

 

 

Basic weighted average number of common shares outstanding

     11,137,780        10,916,358         10,994,382         10,913,844   
  

 

 

   

 

 

    

 

 

    

 

 

 

Basic net (loss) income per share

   $ (0.28   $ 0.04       $ 0.07       $ 0.67   
  

 

 

   

 

 

    

 

 

    

 

 

 

Diluted net (loss) income per share

          

Net (loss) income applicable to common stock

   $ (3,147,442   $ 388,729       $ 723,579       $ 7,285,932   

Add: Preferred stock dividends

     (6,875 )     —           20,625         —     

Less: Fair value of stock warrants for dilutive warrants

     —          —           —           (5,399,569
  

 

 

   

 

 

    

 

 

    

 

 

 

Net (loss) income applicable to dilutive common stock

   $ (3,154,317   $ 388,729       $ 744,204       $ 1,886,363   
  

 

 

   

 

 

    

 

 

    

 

 

 

Basic weighted average number of common shares outstanding

     11,137,780        10,916,358         10,994,382         10,913,844   

Effect of dilutive securities

          

Dilutive stock awards

     —          9,045         11,443         127   

Dilutive preferred share conversions

     —          142,450         142,450         142,450   
  

 

 

   

 

 

    

 

 

    

 

 

 
     —          151,495         153,893         142,577   

Diluted weighted average number of common shares outstanding

     11,137,780        11,067,853         11,148,275         11,056,421   
  

 

 

   

 

 

    

 

 

    

 

 

 

Diluted net (loss) income per share

   $ (0.28   $ 0.04       $ 0.07       $ 0.17   
  

 

 

   

 

 

    

 

 

    

 

 

 

Basic net (loss) income per share is computed by dividing net income less preferred stock dividends by the weighted-average number of shares of Columbia’s common stock outstanding during the period. The diluted (loss) earnings per share calculation gives effect to dilutive options, warrants, convertible preferred stock, and other potential dilutive common stock, including selected restricted shares of common stock outstanding during the period. Diluted income per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options, assuming the exercise of all in-the-money stock options. Common share equivalents have been excluded where their inclusion would be anti-dilutive. The warrants related to the stock warrant liability were first evaluated on an “as if converted” basis; the change in the

 

12


Table of Contents

fair value of the stock warrants recognized in the periods presented was subtracted from earnings to calculate net income applicable to dilutive common stock. Then, the incremental shares for dilution were determined utilizing the treasury method. Since the average stock price for all periods presented was below the exercise price of the warrants, the calculation under the treasury method resulted in repurchasing more shares than would have been exercised and therefore, the inclusion of these shares were deemed to be anti-dilutive and excluded from the dilutive share calculation.

Shares to be issued upon the exercise of the outstanding options and warrants, convertible preferred stock and selected restricted shares of common stock excluded from the (loss) income per share calculation amounted to 1,733,398 and 1,925,760 for the three months ended September 30, 2013 and 2012, respectively, but were not included in the computation of diluted (loss) earnings per share because the awards were anti-dilutive. Shares to be issued upon the exercise of the outstanding options and warrants, convertible preferred stock and selected restricted shares of common stock excluded from the (loss) income per share calculation amounted to 1,590,948 and 1,947,819 for the nine months ended September 30, 2013 and 2012, respectively, but were not included in the computation of diluted (loss) earnings per share because the awards were anti-dilutive.

(10) Accumulated Other Comprehensive Income

Changes to accumulated other comprehensive income during the nine months ended September 30, 2013 were as follows:

 

     Unrealized Gain on
Marketable
Securities, net of tax
    Translation
Adjustment
     Accumulated Other
Comprehensive
Income
 

Balance—December 31, 2012

   $ 97,220      $ 186,001       $ 283,221   

Current period other comprehensive (loss) income

     (80,223     635,778         555,555   

Amounts reclassified from accumulated other comprehensive income

     (16,997     —          (16,997
  

 

 

   

 

 

    

 

 

 

Balance—September 30, 2013

   $ —       $ 821,779       $ 821,779   
  

 

 

   

 

 

    

 

 

 

(11) Stock-Based Compensation

Columbia recorded stock-based compensation expense of $0.1 million for both the three months ended September 30, 2013 and 2012. Columbia recorded stock-based compensation expense of $0.3 million and $0.6 million for the nine months ended September 30, 2013 and 2012, respectively. Stock-based compensation expense is included in the accompanying consolidated statements of operations as follows:

 

     Three Months Ended September 30,      Nine Months Ended September 30,  
     2013      2012      2013      2012  

Cost of revenues

   $ 4,922       $ 4,361       $ 9,790       $ 14,400   

Research and development

     —           16,942         —           78,192   

General and administrative

     60,177         128,203         328,349         544,895   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 65,099       $ 149,506       $ 338,139       $ 637,487   
  

 

 

    

 

 

    

 

 

    

 

 

 

Columbia granted 88,749 and 104,375 stock options during the nine months ended September 30, 2013 and 2012, respectively. Columbia has elected to use the Black-Scholes option pricing model to determine the weighted average fair value of options. The weighted average fair value of the options granted during the nine months ended September 30, 2013 and 2012 was $3.52 and $4.00, respectively, using the following assumptions:

 

     Nine Months Ended
September 30,
 
     2013    2012  

Risk free interest rate

   0.71%-0.76%      0.82

Expected term

   4.75      4.75   

Dividend yield

   —        —    

Expected volatility

   96.52%-97.02%      105.72

Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. Columbia’s estimated expected stock price volatility is based on its own historical volatility. Columbia’s expected term of options granted in the nine months ended September 30, 2013 and 2012 was derived from the simplified method. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

 

13


Table of Contents

Cash received from option exercises was $10,300 during the three and nine months ended September 30, 2013. There were no option exercises in the three and nine months ended September 30, 2012.

(12) Legal Proceedings

Claims and lawsuits may be filed against Columbia from time to time. Although the results of pending claims are always uncertain, Columbia believes that it has adequate reserves or adequate insurance coverage in respect of these claims, but no assurance can be given as to the sufficiency of such reserves or insurance coverage in the event of any unfavorable outcome resulting from such actions.

Between February 1, 2012 and February 6, 2012, two putative securities class action complaints were filed against Columbia and certain of its officers and directors in the United States District Court for the District of New Jersey. These actions were filed under the captions Wright v. Columbia Laboratories, Inc., et al ., and Shu v. Columbia Laboratories, Inc., et al and asserted claims under sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act on behalf of an alleged class of purchasers of the common stock during the period from December 6, 2010 through January 20, 2012. Both actions were consolidated into a single proceeding entitled In re Columbia Laboratories, Inc., Securities Litigation , under which Actavis, Inc., and one of its officers have been added as defendants. The Consolidated Amended Complaint alleged that Columbia and one of its officers and a director omitted to state material facts that they were under a duty to disclose, and made materially false and misleading statements that related to the results of Columbia’s PREGNANT study and the likelihood of approval by the U.S. Food and Drug Administration (“FDA”) of a New Drug Application (“NDA”) to market progesterone vaginal gel 8% for the prevention of preterm birth in women with premature cervical shortening. According to the complaint, these alleged omissions and misleading statements had the effect of artificially inflating the market price of the common stock. The plaintiffs sought unspecified damages on behalf of the putative class and an award of costs and expenses, including attorney’s fees. On June 11, 2013, the Court dismissed the complaint for failure to state a claim upon which relief could be granted, holding that the plaintiffs did not adequately plead facts supporting an inference of an intent to deceive investors. The Court permitted the plaintiffs to file a further amended complaint, and they did so on July 11, 2013. Columbia moved to dismiss the further amended complaint. On October 21, 2013, the Court dismissed the amended complaint. The Court ruled that changes the plaintiffs made to their first amended complaint “still do not create a strong inference that [Columbia] acted with an intent to deceive, manipulate or defraud.” The Court ordered that if the plaintiffs sought to attempt to plead a cognizable action for a third time, they must do so within thirty days and specifically address why the attempt would not be futile. Columbia believes that the amended action is without merit, and intends to defend it vigorously. At this time, it is not possible to determine the likely outcome of, or estimate the liability related to this action, and Columbia has not made any provision for losses in connection with it.

(13) Fair Value of Financial Instruments

U.S. GAAP establishes a framework for measuring fair value and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The fair value of cash and cash equivalents are classified as level 1 at September 30, 2013 and December 31, 2012. The fair value of short-term investments is determined based on quoted market prices on the balance sheet date and are classified as a Level 1 investment at December 31, 2012. There we no short-term investments at September 30, 2013.

The estimated fair value of the common stock warrant liability resulting from the October 2009 registered direct offering of 1,362,500 shares of common stock and warrants to purchase 681,250 shares of common stock and is determined by using the Black-Scholes option pricing model based on Columbia’s stock price at the measurement date, exercise price of the warrant, risk-free rate and historical volatility, and is classified as a Level 2 measurement. Columbia recorded an expense of $4.4 million for the three

 

14


Table of Contents

months ended September 30, 2013 as compared to an expense of $1.1 million for the three months ended September 30, 2012 as a result of the change in stock price. During the nine months ended September 30, 2013 and 2012, Columbia recorded an expense of $4.4 million and income of $5.4 million, respectively, as a result of the change in the stock price.

The fair value of accounts receivable and accounts payable approximate their carrying amount.

(14) Related Party Transactions

The table below presents the transactions between the Company and Actavis:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2013      2012      2013      2012  

Revenues

           

Product revenues

   $ —         $ 1,426,890       $ —         $ 3,590,073   

Royalties

     887,553         904,839         2,524,466         2,232,397   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenues

   $ 887,553       $ 2,331,729       $ 2,524,466       $ 5,822,470   
  

 

 

    

 

 

    

 

 

    

 

 

 

Cost of product revenues

           

Cost of product revenues

     —           1,297,043         —           3,263,376   
  

 

 

    

 

 

    

 

 

    

 

 

 

Gross profit

   $ 887,553       $ 1,034,686       $ 2,524,466       $ 2,559,094   
  

 

 

    

 

 

    

 

 

    

 

 

 

As of September 30, 2013 and December 31, 2012, amounts due from related party for these sales were $0.9 million and $2.2 million, respectively. There were no amounts due to Actavis as of September 30, 2013 and December 31, 2012.

In the three and nine months ended September 30, 2012, Actavis reimbursed Columbia $3,100 and $0.4 million, respectively, for research and development expenses pursuant to the purchase agreement. There are no further research and development expenses to be reimbursed by Actavis related to the purchase agreement.

 

15


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Information

This Quarterly Report on Form 10-Q contains forward-looking statements, that involve risk and uncertainties. The words “may,” “will,” “plan,” “believe,” “expect,” “intend,” “anticipate,” “potential,” “should,” “estimate,” “predict,” “project,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.

These forward-looking statements include, among other things, statements about:

 

    Successful marketing of CRINONE ® by Actavis and Merck Serono in their respective markets;

 

    The anticipated timing of future batch orders of CRINONE from our customers;

 

    The successful development by Actavis of a next-generation vaginal Progesterone Product for the U.S. market;

 

    Our ability to manufacture our product with minimal difficulties and delays;

 

    The availability and pricing of third-party sourced products and materials;

 

    Our ability to successfully integrate and strengthen the Molecular Profile business and brand;

 

    Our compliance with FDA, MHRA and other governmental regulations applicable to manufacturing facilities, products, and/or business;

 

    Our intellectual property portfolio;

 

    Our strategy of growing through acquisitions; and,

 

    Our estimates regarding expenses, future revenues, and capital requirements.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you are cautioned not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in our Annual Report on Form 10-K for the year ended December 31, 2012, particularly in Part 1 – Item 1A and in our other public filings with the Securities and Exchange Commission that could cause actual results or events to differ materially from the forward-looking statements that we make.

You should read this Quarterly Report and the documents that we have filed as exhibits to the Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect. While we may elect to update forward-looking statements at some point in the future, we do not undertake any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.

Company Overview

We are in the business of developing, licensing, manufacturing and selling to our marketing partners pharmaceutical products that utilize proprietary drug delivery technologies to treat various medical conditions. Our focus has been on utilizing our bioadhesive formulations for drug delivery across mucosal membranes, an area where we have a rich heritage and proven capabilities.

On September 12, 2013, we acquired all of the outstanding capital stock of Molecular Profiles Limited (“Molecular Profiles”), a U.K.-based pharmaceutical development services company. The main service lines that have been added to our portfolio as a result of the acquisition include:

 

    Formulation, scale-up and clinical trial manufacturing supply service;

 

    Advanced physical and chemical analysis; and,

 

    Consulting services.

The acquisition expands our business model and customer base while diversifying our revenue stream. With the addition of Molecular Profiles, we have broadened our technical expertise in the field of pharmaceutical development and analytical services. As a result of the transaction, former Molecular Profiles stockholders, in the aggregate, received for their shares of Molecular Profiles common stock $16.7 million in cash and 1,051,323 shares of our common stock. The total consideration is valued at $24.9 million, based upon the closing price of our common stock on September 12, 2013. This acquisition was considered a business acquisition for accounting purposes.

To date, we have developed and brought to market six products: five bioadhesive vaginal gel products that provide patient friendly solutions for infertility, pregnancy support, amenorrhea, and other women’s health conditions, and a testosterone bioadhesive buccal system for male hypogonadism. Our primary product is CRINONE (progesterone gel) which is formulated in a 4% and an 8% solution. We have licensed CRINONE to Merck Serono S.A. (“Merck Serono”), internationally, and to Actavis, Inc. (“Actavis”, formerly Watson Pharmaceuticals, Inc.), in the United States.

 

16


Table of Contents

Currently, we sell CRINONE 8% to Merck Serono at a price determined on a country-by-country basis that is the greater of (i) thirty percent (30%) of the net selling price in the country, or (ii) our direct manufacturing cost plus 20%. Certain quantity discounts apply to annual purchases over 10 million, 20 million, and 30 million units.

On April 4, 2013, our license and supply agreement with Merck Serono for the sale of CRINONE 8% outside the U.S. was renewed for an additional five year term, extending the expiration date from May 19, 2015, to May 19, 2020.

Under the terms of the amended license and supply agreement, we will continue to sell CRINONE to Merck Serono on a country-by-country basis at the greater of (i) cost plus 20% or (ii) a percentage of Merck Serono’s net selling price. From 2014 through 2020, the percentage of net selling price will convert to a tiered structure. Current volumes will be eligible to receive slightly lower rates than in 2013. As volumes reach higher thresholds, incremental sales will earn a lower percentage of net selling price. These thresholds have been agreed in order to incentivize Merck Serono to continue to develop existing markets and to enter new markets. Additionally, the parties will jointly cooperate to evaluate and implement manufacturing cost reduction measures, with both parties sharing any reductions realized from these initiatives. All other material terms remain substantially as before.

We manufacture and sell product to Actavis at our cost plus 10%; these revenues are recorded within net product revenues from related party. In addition, we receive royalties equal to a minimum of 10% of annual net sales by Actavis for annual net sales up to $150 million, 15% for sales above $150 million but less than $250 million; and 20% for annual net sales of $250 million and over. Due to a build-up of inventory by Actavis in advance of filing for FDA approval of 8% progesterone gel for use in the prevention of preterm birth in women with premature cervical shortening, and Actavis’ decision, in light of the FDA’s denial of both Actavis’ application and subsequent appeal, not to continue development of the proposed indication, Actavis currently has sufficient inventories of CRINONE; therefore we do not expect any material orders for the remainder of 2013. We continue to receive royalties on net sales of CRINONE by Actavis.

Future recurring revenues will be derived from product sales to and royalty streams from our partners, Actavis and Merck Serono and from pharmaceutical development contracts and analytical and consulting services provided through our wholly-owned subsidiary Molecular Profiles. Revenue results are difficult to predict, and any shortfall in revenue or delay in recognizing revenue could cause operating results to vary significantly from quarter to quarter. Because products shipped to our two major customers occur only in full batches, quarterly sales can vary widely and affect comparisons with prior periods and may not correlate to our customers’ in-market sales. Likewise, our revenues from Molecular Profiles are driven by obtaining and retaining our customer contracts and may vary widely from quarter to quarter.

All of our products are manufactured in Europe by third parties on behalf of our foreign subsidiaries who sell the products to our worldwide licensees, and to us, in the case of the products supplied for resale in the United States. Because our foreign subsidiaries recognize these sales and are reduced only by our product manufacturing costs, we have historically shown a profit from our foreign operations.

Workforce Reduction and Corporate Office Relocation

On March 1, 2012, we announced a 42% workforce reduction from 24 employees at December 31, 2011, to 14 employees. We recorded a severance charge of approximately $0.5 million in the nine months ended September 30, 2012. The reduction impacted research and development and general and administrative positions. Our remaining staff focuses its efforts on supporting our customers through existing product supply agreements, assuring compliance with all financial reporting requirements, and executing our strategies to build value for shareholders.

During the nine months ended September 30, 2013, we relocated our corporate facilities from Livingston, New Jersey to Boston, Massachusetts. On March 15, 2013, we entered into a lease agreement for our new location in Boston. We expect this lease will provide a significant cost saving compared to the lease for our corporate facilities in Livingston, which expired in October 2013. We have completed our process of hiring employees for the Boston office, which is comprised of accounting and finance, operations and other administrative staff. We incurred a charge of $0.6 million for the nine months ended September 30, 2013, related to severance and other relocation costs associated with the elimination of certain positions at the Livingston location. With the relocation now complete, going forward we expect reduced personnel and other related costs associated with our headquarters.

 

17


Table of Contents

Results of Operations

The following tables contain selected statement of operations information, which serves as the basis of the discussion surrounding our results of operations for the three and nine months ended September 30, 2013 and 2012:

 

     Three Months Ended
September 30,
             
     2013     2012              
     Amount     As a % of
Total
Revenues
    Amount     As a % of
Total
Revenues
    $
Change
    %
Change
 

Product revenues

   $ 5,456,152        77   $ 5,620,889        84   $ (164,737     (3 )% 

Royalties

     994,771        14        1,017,609        15        (22,838     (2

Other revenues

     674,769        9        34,540        1       640,229        1,854   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenues

     7,125,692        100        6,673,038        100        452,654        7   

Cost of revenues

     3,238,215        45        3,186,792        48        51,423        2   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     3,887,477        55        3,486,246        52        401,231        12   

Operating expenses

            

Sales and marketing

     78,777        1        —         —         78,777        100   

Research and development (net of reimbursement from related party: $3,092 for the three months ended September 30, 2012)

     —         —         143,795        2        (143,795     (100

Acquisition related expenses

     947,202        13        —         —         947,202        100   

General and administrative

     1,594,223        22        1,901,880        29        (307,657     (16
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     2,620,202        37        2,045,675        31        574,527        28   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from operations

     1,267,275        18        1,440,571        22        (173,296     (12

Interest income, net

     641        —         35,880        1        (35,239     (98

Change in fair value of stock warrants

     (4,444,804     (62     (1,065,498     (16     (3,379,306     317   

Other income (expense), net

     25,195        —         (19,882     —         45,077        227  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

(Loss) income before income taxes

     (3,151,693     (44     391,071        6        (3,542,764     (906 )

Provision for income taxes

     2,624       —         2,342        —         282        12  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss) income

   $ (3,154,317     (44 )%    $ 388,729        6   $ (3,543,046     (911 )% 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Revenues

 

     Three Months Ended
September 30,
     $
Change
    %
Change
 
     2013      2012       

Product revenues

   $ 5,456,152       $ 5,620,889       $ (164,737     (3 )% 

Royalties

     994,771         1,017,609         (22,838     (2

Other revenues

     674,769         34,540         640,229        1,854   
  

 

 

    

 

 

    

 

 

   

 

 

 

Total revenues

   $ 7,125,692       $ 6,673,038       $ 452,654        7
  

 

 

    

 

 

    

 

 

   

 

 

 

Revenues in the three months ended September 30, 2013 increased by $0.5 million, or 7%, as compared to the three months ended September 30, 2012. The increase was attributable to the following factors:

 

    Revenues from the sale of products decreased by approximately $0.2 million, or 3%, from the 2012 period primarily due to the absence of product revenue from Actavis in the three months ended September 30, 2013 as compared with $1.4 million in the three months ended September 30, 2012 due to sufficient inventory on hand at Actavis. This was offset by higher revenues from Merck Serono in the three months ended September 30, 2013 as compared with the three months ended September 30, 2012. Higher revenues from Merck Serono are a result of a 39% increase in volume quarter over quarter.

 

18


Table of Contents
    Royalty revenues remained consistent for the three months ended September 30, 2013 as compared to the three months ended September 30, 2012.

 

    Other revenues in the three months ended September 30, 2013, primarily consisted of $0.6 million in revenues associated with the acquisition of Molecular Profiles. These revenues are attributable to their formulation, advanced chemical analysis, and consulting services.

Cost of revenues

 

     Three Months Ended
September 30,
    $
Change
     %
Change
 
     2013     2012       

Cost of revenues

   $ 3,238,215      $ 3,186,792      $ 51,423         2

Cost of revenues (as a percentage of total revenues)

     45     48     

Total cost of revenues were $3.2 million for both three months ended September 30, 2013 and 2012. Cost of revenues remained relatively consistent, which is a reflection of increased costs of service associated with the Molecular Profiles revenues generated, offset by a decrease of cost of goods for net product revenues due to a more favorable product mix.

Sales and marketing

 

     Three Months Ended
September 30,
    $
Change
     %
Change
 
     2013     2012       

Sales and marketing

   $ 78,777      $ —       $ 78,777         100

Sales and marketing (as a percentage of total revenues)

     1     —       

Sales and marketing expenses were generated during the three months ended September 30, 2013. These expenses are attributable to the sales activities of our newly acquired subsidiary, Molecular Profiles, acquired on September 12, 2013.

Research and development

 

     Three Months Ended
September 30,
    $
Change
    %
Change
 
     2013     2012      

Research and development

   $ —       $ 143,795      $ (143,795     (100 )% 

Research and development (as a percentage of total revenues)

     —       2    

There were no research and development expenses in the three months ended September 30, 2013 because we have eliminated our research and development activities. Research and development expenses of $0.1million in the three months ended September 30, 2012 included costs for product development, clinical development and regulatory fees, which were a combination of internal and third-party costs.

Acquisition related expenses

 

     Three Months Ended
September 30,
    $
Change
     %
Change
 
     2013     2012       

Acquisition related expenses

   $ 947,202      $ —       $ 947,202         100

Acquisition related expenses (as a percentage of total revenues)

     13     —       

Total acquisition related expenses of $0.9 million for the three months ended September 30, 2013, were costs associated with the Molecular Profiles acquisition.

 

19


Table of Contents

General and administrative

 

     Three Months Ended
September 30,
    $
Change
    %
Change
 
     2013     2012      

General and administrative

   $ 1,594,223      $ 1,901,880      $ (307,657     (16 )% 

General and administrative (as a percentage of total revenues)

     22     29    

Total general and administrative expenses decreased by $0.3 million to $1.6 million for the three months ended September 30, 2013, compared with $1.9 million for the three months ended September 30, 2012. This decrease is primarily due to lower personnel costs associated with the workforce reduction in January 2013.

Other income and expense

 

     Three Months Ended
September 30,
    $
Change
    %
Change
 
     2013     2012      

Interest income, net

   $ 641      $ 35,880      $ (35,239     (98 )% 

Change in fair value of stock warrants

   $ (4,444,804   $ (1,065,498   $ (3,379,306     317

Other income (expense), net

   $ 25,195      $ (19,882   $ 45,077        227

The decrease in interest income, net primarily relates to the sales of our marketable securities in the second quarter of 2013.

Change in fair value of stock warrants for the three months ended September 30, 2013 was due to a $4.4 million expense associated with the fair value of the warrants issued in conjunction with the October 2009 stock issuance and resulted from an increase in our stock price during the period. Change in fair value of stock warrants for the three months ended September 30, 2012 was due to a $1.1 million expense associated with the fair value of the warrants issued in conjunction with the October 2009 stock issuance and resulted from an increase in our stock price during the period.

Other income (expense), net, for the three months ended September 2013 was primarily a result of net foreign currency remeasurement gains related to the strengthening of the euro and the British pound against the U.S. dollar. Other income (expense), net for 2012 related primarily to miscellaneous taxes.

 

20


Table of Contents

Nine Months Ended September 30, 2013 and September 30, 2012

 

     Nine Months Ended
September 30,
             
   2013     2012              
   Amount     As a % of
Total
Revenues
    Amount     As a % of
Total
Revenues
    $
Change
    %
Change
 

Product revenues

   $ 17,848,180        83   $ 16,101,350        86   $ 1,746,830        11

Royalties

     2,808,477        13        2,532,197        13        276,280        11   

Other revenues

     762,577        4        103,568        1        659,009        636   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenues

     21,419,234        100        18,737,115        100        2,682,119        14   

Cost of revenues

     8,910,550        42        9,655,624        52        (745,074     (8
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     12,508,684        58        9,081,491        48        3,427,193        38   

Operating expenses

            

Sales and marketing

     78,777        —         —         —         78,777        100  

Research and development (net of reimbursement from related party: $435,199 for the nine months ended September 30, 2012)

     —         —         856,545        5        (856,545     (100

Acquisition related expenses

     1,439,946        7        —          —          1,439,946        100   

General and administrative

     5,881,636        27        6,376,561        34        (494,925     (8
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     7,400,359        35        7,233,106        39        167,253        2   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from operations

     5,108,325        24        1,848,385        10        3,259,940        176   

Interest income, net

     95,996        —         158,625        1        (62,629     (39

Change in fair value of stock warrants

     (4,394,778     (21     5,399,569        29        (9,794,347     (181

Other expense, net

     (57,165     —         (115,629     (1     58,464        51   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

     752,378        4        7,290,950        39        (6,538,572     (90

Provision for income taxes

     8,174        —         5,018        —         3,156        63   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income

   $ 744,204        3   $ 7,285,932        39   $ (6,541,728     (90 )% 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Revenues

 

     Nine Months Ended
September 30,
     $
Change
     %
Change
 
     2013      2012        

Product revenues

   $ 17,848,180       $ 16,101,350       $ 1,746,830         11

Royalties

     2,808,477         2,532,197         276,280         11   

Other revenues

     762,577         103,568         659,009         636   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenues

   $ 21,419,234       $ 18,737,115       $ 2,682,119         14
  

 

 

    

 

 

    

 

 

    

 

 

 

Revenues in the nine months ended September 30, 2013 increased by $2.7 million, or 14%, as compared to the nine months ended September 30, 2012. The increase in attributable to the following factors:

 

    Revenues from the sale of products increased by approximately $1.7 million, or 11%, from the 2012 period. The increase primarily reflects higher revenues over last year from Merck Serono, offset by a decrease in sales from Actavis. Higher revenues from Merck Serono are a result of a 42% increase in volume from the 2012 period to the 2013 period, coupled with shipments to countries with higher net selling prices. There were no product revenues from Actavis in the nine months ended September 30, 2013 as compared with $3.6 million in the nine months ended September 30, 2012.

 

21


Table of Contents
    Royalty revenues increased by $0.3 million, or 11%, to $2.8 million for the nine months ended September 30, 2013 as compared to $2.5 million for the nine months ended September 30, 2012. This is a result of higher revenues earned by Actavis on sales of Progesterone Products.

 

    Other revenues in the nine months ended September 30, 2013, primarily consisted of $0.6 million in revenues associated with the acquisition of Molecular Profiles. These revenues are attributable to their formulation, advanced chemical analysis and consulting services. The remaining revenues are due to amounts of deferred revenue that were recognized during both periods.

Cost of revenues

 

     Nine Months Ended
September 30,
    $
Change
    %
Change
 
     2013     2012      

Cost of revenues

   $ 8,910,550      $ 9,655,624      $ (745,074     (8 )% 

Cost of revenues (as a percentage of total revenues)

     42     52    

Total cost of revenues decreased $0.7 million, or 8%, to $8.9 million for the nine months ended September 30, 2013, as compared to $9.7 million for the nine months ended September 30, 2012. This decrease was primarily a result of the absence of product sales to Actavis during the nine months ended September 30, 2013 as compared to $3.6 million of sales for the nine months ended September 30, 2012, partially offset by increased revenues from Merck Serono as well as revenues from our newly acquired subsidiary Molecular Profiles. Total cost of revenues decreased as a percentage of total revenues to 42% for the nine months ended September 30, 2013 from 52% for the nine months ended September 30, 2012, primarily due to a more favorable sales mix.

Sales and marketing

 

     Nine Months Ended
September 30,
    $
Change
     %
Change
 
     2013     2012       

Sales and marketing

   $ 78,777      $ —       $ 78,777         100 %

Sales and marketing (as a percentage of total revenues)

     —       —       

Sales and marketing expenses were generated during the nine months ended September 30, 2013. These expenses are attributable to the sales activities of our newly acquired subsidiary, Molecular Profiles, acquired on September 12, 2013.

Research and development

 

     Nine Months Ended
September 30,
    $
Change
    %
Change
 
     2013     2012      

Research and development

   $ —       $ 856,545      $ (856,545     (100 )% 

Research and development (as a percentage of total revenues)

     —       5    

There were no research and development expenses in the nine months ended September 30, 2013, as compared to $0.9 million in the nine months ended September 30, 2012, because we have eliminated our research and development activities. Research and development expenses in the nine months ended September 30, 2012 included costs for product development, clinical development and regulatory fees, which were a combination of internal and third-party costs.

 

22


Table of Contents

Acquisition related expenses

 

     Nine Months Ended
September 30,
    $
Change
     %
Change
 
     2013     2012       

Acquisition related expenses

   $ 1,439,946      $ —        $ 1,439,946         100

Acquisition related expenses (as a percentage of total revenues)

     7     —       

Total acquisition related expenses of $1.4 million in the nine months ended September 30, 2013, were costs associated with the Molecular Profiles acquisition and a failed transaction in the first quarter of 2013.

General and administrative

 

     Nine Months Ended
September 30,
    $
Change
    %
Change
 
     2013     2012      

General and administrative

   $ 5,881,636      $ 6,376,561      $ (494,925     (8 )% 

General and administrative (as a percentage of total revenues)

     27     34    

Total general and administrative expenses decreased by $0.5 million to $5.9 million for the nine months ended September 30, 2013, compared with $6.4 million for the nine months ended September 30, 2012. General and administrative expenses for the nine months ended September 30, 2013 decreased primarily due to lower personnel costs of $0.4 million associated with our workforce reduction in January 2013.

Other income and expense

 

     Nine Months Ended
September 30,
    $
Change
    %
Change
 
     2013     2012      

Interest income, net

   $ 95,996      $ 158,625      $ (62,629     (39 )% 

Change in fair value of stock warrants

     (4,394,778     5,399,569        (9,794,347     (181 )% 

Other expense, net

     (57,165     (115,629     58,464        51

The decrease in interest income, net primarily relates to an overall decrease of interest-bearing securities due to the sales of our marketable securities in the nine months ended September 30, 2013.

Change in fair value of stock warrants for the nine months ended September 30, 2013 was due to a $4.4 million expense, associated with the fair value of the warrants issued in conjunction with the October 2009 stock issuance and resulted from an increase in our stock price during the period. Change in fair value of stock warrants for the nine months ended September 30, 2012 was due to $5.4 million of income, associated with the fair value of the warrants issued in conjunction with the October 2009 stock issuance and resulted from a decrease in our stock price during the period.

Other expense, net, for the nine months ended September 2013 and 2012 was primarily a result of less net foreign currency remeasurement losses related to the strengthening of the euro and the British pound against the U.S. dollar.

Liquidity and Capital Resources

We require cash to pay our operating expenses, fund working capital needs, make capital expenditures and fund acquisitions. We have funded our operations through cash generated from our operations.

On September 12, 2013, we acquired all of the outstanding capital stock of Molecular Profiles. As a result of the transaction, former Molecular Profiles stockholders, in the aggregate, received for their shares of Molecular Profiles common stock $16.7 million in cash and 1,051,323 shares of our common stock. The total consideration is valued at $24.9 million, based upon the closing price of our common stock on September 12, 2013.

 

23


Table of Contents

As a part of the acquisition, we assumed debt of $3.9 million that Molecular Profiles had entered into to fund the completion and building of a second facility in the United Kingdom. Molecular Profiles entered into a Business Loan Agreement (“Loan Agreement”) covering three loan facilities with Lloyds TSB Bank (“Lloyds”), as administrative agent. Molecular Profiles had withdrawn $3.9 million and as of September 30, 2013 owes $4.0 million due to foreign currency revaluation. The three loan facilities are each repayable by monthly installments; one started repayment in February 2013 and the remaining two commenced in October 2013. All facilities are due for repayment over 15 years from the date of drawdown. Two of the facilities bear interest at 2.45% and 3.05% per annum, respectively. The third facility is a fixed rate agreement bearing interest at 3.52% per annum. The weighted average interest rate for the period from September 12, 2013 to September 30, 2013 was 3.52%. The Loan Agreement is secured by the mortgaged property and an unlimited debenture lien on other assets of Molecular Profiles. The Loan Agreement contains financial covenants that limit the amount of indebtedness we may incur, requires us to maintain certain levels of net worth, and restricts our ability to materially alter the character of the business. We are currently in compliance with all of the covenants under the Loan Agreement.

As part of the acquisition of Molecular Profiles, we assumed a $2.5 million obligation under a grant arrangement with the Regional Growth Fund on behalf of the Secretary of State for Business, Innovation, and Skills in the United Kingdom. Molecular Profiles used this grant to fund the building of their second facility, which includes analytical labs, office space, and a manufacturing facility. As a part of the arrangement, Molecular Profiles is required to create and maintain certain full-time equivalent personnel levels through October 2017. As of September 30, 2013, Molecular Profiles is in compliance with the covenants of the arrangement.

The income from the Regional Growth Fund will be recognized on a decelerated basis over the next four years. As of September 30, 2013, the obligation is valued at $2.6 million due to foreign currency revaluation and is recorded as deferred revenue on the consolidated balance sheets. The amount of other income on the obligation that will be recognized provided Molecular Profiles remains in compliance with the covenants will be the following:

 

Year

   Total  

Remainder of 2013

   $ 64,544   

2014

     322,720   

2015

     580,896   

2016

     839,072   

2017

     774,528   
  

 

 

 

Total

   $ 2,581,760   
  

 

 

 

At September 30, 2013, our cash and cash equivalents were $18.8 million. Our cash and cash equivalents are highly liquid investments with original maturities of 90 days or less at date of purchase and consist of cash in operating accounts and investments in money market funds.

Our future capital requirements depend on a number of factors, including the rate of market acceptance of our current and future products and the resources we devote to developing and supporting our products. Our capital expenditures decreased for the nine months ended September 30, 2013, as compared to the nine months ended September 30, 2012, primarily as a result of completing, during 2012, the addition of increased manufacturing capacity to ensure our ability to meet Actavis’ forecasts for the anticipated launch of progesterone vaginal gel 8% for preterm birth in women with premature cervical shortening and facility improvements to ensure compliant manufacturing operations. We expect our capital expenditures to increase for the remainder of 2013 due to the acquisition of Molecular Profiles, but still remain under the 2012 levels.

As of September 30, 2013, we had outstanding exercisable options and warrants that, if exercised, would result in approximately $20.0 million of additional capital and would cause the number of shares outstanding to increase; however, the cashless exercise feature of certain warrants may result in no cash to us. Options and warrants outstanding at September 30, 2013 were 279,151 and 9,893,455, respectively; however, there can be no assurance that any such options or warrants will be exercised. There was no aggregate intrinsic value of exercisable options and warrants for the periods ended September 30, 2013 and September 30, 2012.

On July 26, 2013, our Board of Directors set a ratio of 1-for-8 for its previously approved reverse stock split, which took effect on August 9, 2013. Our reverse stock split was approved by our shareholders at our annual meeting of shareholders on May 1, 2013. All share and per share amounts relating to the common stock, stock options and warrants included in the financial statements and accompanying footnotes have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an equal amount to the reduction in par value of common stock to additional paid-in capital. The reverse stock split did not result in a retroactive adjustment to the share amounts for any of the classes of our preferred stock.

We believe that our current cash and cash equivalents, as well as cash generated from operations, will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for the foreseeable future.

 

24


Table of Contents

Cash Flows

Net cash provided by operating activities for the nine months ended September 30, 2013 was $4.9 million and resulted primarily from $0.7 million of net income for the period, increased by approximately $0.7 million in depreciation and amortization and stock-based compensation expense and $4.4 million from the change in fair value of stock warrants. Net changes in working capital items reduced cash from operating activities by approximately $0.9 million, primarily due to an increase in accounts receivable of $2.0 million associated with increased product shipments offset by a decrease in amounts due from related party totaling $1.3 million primarily related to the absence of product shipments to Actavis during the nine months ended September 30, 2013. Net cash provided by investing activities was $0.6 million for the nine months ended September 30, 2013, which resulted primarily from the proceeds from the sale of short-term investments totaling $15.4 million partially offset by cash paid for the Molecular Profiles acquisition of $14.5 million and the purchase of property and equipment of $0.2 million. Net cash used in financing activities was $18,000 for the nine months ended September 30, 2013,

Net cash provided by operating activities for the nine months ended September 30, 2012 was $1.3 million and resulted primarily from $7.3 million of net income for the period, increased by approximately $1.1 million in depreciation and amortization and stock-based compensation expense as well as $0.9 million related to the write-off of certain inventories, and decreased by $5.4 million for the change in fair value of stock warrants. Net changes in working capital items reduced cash from operating activities by approximately $2.4 million, primarily relating to an increase in inventory of $0.9 million associated with the buildup of inventory to meet Actavis’ forecast requirements as well as a decrease in accounts payable and accrued expenses of $1.3 million. Net cash used in investing activities was for the nine months ended September 30, 2012 was $1.2 million resulting from the purchase of property and equipment of $1.0 million and the purchase of short-term investments of $0.2 million. Net cash used in financing activities was $50,000 for the nine months ended September 30, 2012.

Contractual Obligations, Commercial Commitments and Off-Balance Sheet Arrangements

As a result of the acquisition of Molecular Profiles on September 12, 2013, we have assumed debt totaling $3.9 million which is valued at $4.0 million as of September 30, 2013, due to foreign currency revaluation. Our future contractual obligations include the following:

 

     Total      1 year or less      1-3 years      3-5 years      More than 5
years
 

Operating lease obligations

   $ 274,923       $ 103,958       $ 170,965       $ —         $ —    

Loan agreements

     3,973,758         243,347         507,559         538,725         2,684,127   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 4,248,681       $ 347,305       $ 678,524       $ 538,725       $ 2,684,127   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations set forth above are based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our estimates and judgments, including those described in our Annual Report on Form 10-K for the year ended December 31, 2012. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities, and the reported amounts of revenues and expenses, that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The following accounting policies have been updated and adopted as of September 30, 2013:

Revenue Recognition

Multiple-element arrangements are evaluated in accordance with the principles of Accounting Standards update (“ASU”) 2009-13, ( Revenue Recognition Topic – Multiple Element Arrangements ) and we allocate revenue among the elements based upon each element’s relative fair value.

 

25


Table of Contents

Goodwill

Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination. We do not amortize our goodwill, but instead test for impairment annually and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than its carrying value of the asset.

We have adopted ASU 2011-08, Intangibles—Goodwill and Other, and amendment to ASC 350 , which updates how an entity will evaluate its goodwill for impairment. The guidance provides entities an option to perform a “qualitative” assessment to determine whether further impairment testing is necessary. If further testing is required, the test for impairment continues with the two step process. The first step compares the carrying amount of the reporting unit to its estimated fair value (Step 1). To the extent that the carrying value of the reporting unit exceeds its estimated fair value, a second step is performed, wherein the reporting unit’s carrying value is compared to the implied fair value (Step 2). To the extent that the carrying value exceeds the implied fair value, impairment exists and must be recognized.

We are evaluating our reporting unit structure to establish the baseline for goodwill impairment testing in the future. Upon establishment of this baseline, we will perform our annual test for impairment on the first day of the fourth quarter beginning in 2014.

The remainder of our critical accounting policies and the related judgments and estimates affecting the preparation of our consolidated financial statements are included in our Annual Report on Form 10-K for the year ended December 31, 2012. There have been no other material changes to our critical accounting policies as of September 30, 2013.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We do not believe that we have material exposure to market rate risk. We may, however, require additional financing to fund future obligations and no assurance can be given that the terms of future sources of financing will not expose us to material market risk.

A significant portion of our operations is conducted through operations in countries other than the United States. Revenues from our international operations were recorded in U.S. dollars. Since we conduct our business in U.S. dollars, our main exposure, if any, results from changes in the exchange rate between the euro, British pound, and Swiss franc. Our functional currency is the U.S. dollar. Our policy is to reduce exposure to exchange rate fluctuations by having most of our assets and liabilities, as well as most of our revenues and expenditures, in U.S. dollars, or U.S. dollar-linked. We have not historically engaged in hedging activities relating to our non-U.S. dollar operations.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Based on their evaluation at September 30, 2013, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.

 

26


Table of Contents

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Part II – Other Information

Item 1. Legal Proceedings

Claims and lawsuits may be filed against Columbia from time to time. Although the results of pending claims are always uncertain, Columbia believes that it has adequate reserves or adequate insurance coverage in respect of these claims, but no assurance can be given as to the sufficiency of such reserves or insurance coverage in the event of any unfavorable outcome resulting from such actions.

Between February 1, 2012 and February 6, 2012, two putative securities class action complaints were filed against us and certain of our officers and directors in the United States District Court for the District of New Jersey. These actions were filed under the captions Wright v. Columbia Laboratories, Inc., et al ., and Shu v. Columbia Laboratories, Inc., et al and asserted claims under sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act on behalf of an alleged class of purchasers of the common stock during the period from December 6, 2010 through January 20, 2012. Both actions were consolidated into a single proceeding entitled In re Columbia Laboratories, Inc., Securities Litigation , under which Actavis, Inc., and one of its officers have been added as defendants. The Consolidated Amended Complaint alleged that we and one of our officers and a director omitted to state material facts that they were under a duty to disclose, and made materially false and misleading statements that related to the results of Columbia’s PREGNANT study and the likelihood of approval by the FDA of a NDA to market progesterone vaginal gel 8% for the prevention of preterm birth in women with premature cervical shortening. According to the complaint, these alleged omissions and misleading statements had the effect of artificially inflating the market price of the common stock. The plaintiffs sought unspecified damages on behalf of the putative class and an award of costs and expenses, including attorney’s fees. On June 11, 2013, the Court dismissed the complaint for failure to state a claim upon which relief could be granted, holding that the plaintiffs did not adequately plead facts supporting an inference of an intent to deceive investors. The Court permitted the plaintiffs to file a further amended complaint, and they did so on July 11, 2013. We moved to dismiss the further amended complaint. On October 21, 2013, the Court dismissed the amended complaint. The Court ruled that changes the plaintiffs made to their first amended complaint “still do not create a strong inference that [Columbia] acted with an intent to deceive, manipulate or defraud.” The Court ordered that if the plaintiffs sought to attempt to plead a cognizable action for a third time, they must do so within thirty days and specifically address why the attempt would not be futile. We believe that the amended action is without merit, and we intend to defend it vigorously. At this time, it is not possible to determine the likely outcome of, or estimate the liability related to this action, and Columbia has not made any provision for losses in connection with it.

Item 1A. Risk Factors

Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described in our Annual Report on Form 10-K for the year ended December 31, 2012 in addition to the other information included in this quarterly report.

We may fail to obtain new contracts or renew existing contracts under our wholly-owned subsidiary, Molecular Profiles, which may adversely affect our business.

Many of Molecular Profile’s contracts with its customers are short-term in duration. As a result, we must continually replace our contracts with new contracts. In the event we are unable to replace these contracts in a timely manner or at all, or we are forced to accept terms, including pricing terms, less favorable to us, our revenues may not be able to be sustained or may decline. In addition, certain of our long-term contracts may be cancelled or delayed by clients for any reason upon notice. Multiple cancellations, non-renewals, or renewals on less favorable terms to us related to significant contracts could materially impact our business. While we intend to seek to negotiate new or extended agreements, if new contracts cannot be completed or existing contracts extended on terms acceptable to us or at all, our business, results of operation and financial condition could be materially adversely affected.

Uncertainty about the acquisition may adversely affect our relationships with our respective customers, suppliers and employees.

As a result of our acquisition of Molecular Profiles, our existing or prospective customers or suppliers may:

 

    Delay, defer or cease purchasing goods or services from or providing goods or services to us;

 

    Delay or defer other decisions concerning us or refuse to extend credit to us; or,

 

    Otherwise seek to change the terms on which they do business with us.

 

27


Table of Contents

Any such delays or changes to terms could seriously harm our business.

In addition, as a result of the acquisition, current and prospective employees could experience uncertainty about their future with us. These uncertainties may impair our ability to retain, recruit or motivate key personnel.

We may be unable to integrate successfully the business of Molecular Profiles and realize the anticipated benefits of the acquisition.

The combined company is requiring the devotion of significant management attention and resources to integrating the two companies. Delays in this process could adversely affect our business, financial results, financial condition and stock price.

Achieving the anticipated benefits of the acquisition will depend, in part, on the integration of operations, personnel and technology of Molecular Profiles into our company. If we are unable to successfully integrate Molecular Profile’s business into our business in a manner that permits the combined company to achieve the cost savings and operating synergies anticipated to result from the acquisition, the anticipated benefits of the acquisition may not be realized fully or at all or may take longer to realize than expected.

Potential difficulties the combined company may encounter in the integration process include the following:

 

    Lost revenues and customers as a result of Molecular Profile’s customers deciding not to do business with the combined company;

 

    The inability to procure goods and services on favorable terms as a result of our suppliers or Molecular Profile’s suppliers deciding not to do business with the combined company;

 

    The inability to retain, recruit or motivate key personnel;

 

    Managing the complexities associated with the combined businesses;

 

    Difficulties associated with integrating personnel from diverse corporate cultures while maintaining focus on providing consistent, high quality products and customer service;

 

    Potential unknown liabilities and unforeseen increased expenses or delays associated with the integration process;

 

    Performance shortfalls as a result of the diversion of management’s attention to the integration process;

 

    Disruption or interruption of, or loss of momentum in, our ongoing business; and,

 

    Inconsistencies in standards, controls, procedures and policies.

Any of these difficulties could adversely affect our ability to maintain relationships with suppliers, customers and employees or our ability to achieve the anticipated benefits of the acquisition, or could reduce our earnings or otherwise adversely affect the business and financial results of the combined company.

Even if we are able to integrate Molecular Profile’s business operations successfully, this integration may not result in the realization of the full benefits of synergies, cost savings, innovation and operational efficiencies that may be possible from this integration and these benefits may not be achieved within a reasonable period of time.

Charges to earnings resulting from the application of the acquisition method of accounting may adversely affect the market value of our common stock.

In accordance with generally accepted accounting principles in the United States, the acquisition is being accounted for using the acquisition method of accounting, which will result in charges to earnings that could have an adverse impact on the market value of our common stock. Under the acquisition method of accounting, the total estimated purchase price is being allocated to Molecular Profile’s net tangible assets and identifiable intangible assets based on their respective fair values as of the date of completion of the acquisition. Any excess of the purchase price over those fair values is being recorded as goodwill. The combined company will incur additional amortization expense based on the identifiable amortizable intangible assets acquired pursuant to the agreement and their relative useful lives. Additionally, to the extent the value of goodwill or identifiable intangible assets or other long-lived assets may become impaired, the combined company will be required to incur material charges relating to the impairment. These amortization and potential impairment charges could have a material impact on the combined company’s results of operations.

 

28


Table of Contents

Through the acquisition of Molecular Profiles, we have made significant capital investments with regard to the facilities to meet our potential future needs and, as a result, if we are not able to utilize the facilities to capacity, our margins could be adversely affected.

We have made substantial investments in all of our manufacturing facilities. With the acquisition of these facilities, our fixed costs have increased. In particular, Molecular Profiles completed the expansion of its development and manufacturing capacity to support expected growth in their business. If development or supply agreements do not generate the revenues that we expect, we may have excess fixed costs associated with development and manufacturing capacity due to the expansion, which could adversely affect our results of operations.

Integration of the Molecular Profiles business may cause a diversion of management’s attention that could harm us.

Integration of the Molecular Profiles business is requiring a significant amount of time and attention from our management. The diversion of management’s attention away from ongoing operations could adversely affect our ongoing operations and business relationships.

Any significant change in government regulation of the drug development process could have a material adverse effect on the Company.

The manufacturing of pharmaceutical products is subject to extensive regulation by governmental authorities, including the FDA, Medicines and Healthcare products Regulatory Agency (“MHRA”), the European Medicines Agency (“EMA”) and comparable regulatory authorities in other countries. Our business, as well as its customers’ business depends in part on strict government regulation of the drug development process. Legislation may be introduced and enacted to modify regulations administered by the FDA, MHRA or the EMA and governing the drug approval process. Any significant reduction in the scope of regulatory requirements or the introduction of simplified drug approval procedures could have a material adverse effect our business.

As of September 30, 2013, there have been no other material changes to the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, although we may disclose other changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

 

29


Table of Contents

Item 6. Exhibits

(a) Exhibits

 

    2.1   Share Purchase Agreement between the sellers listed on schedule 1 thereto, and the Company and Molecular Profiles Limited, dated September 12, 2013 (previously filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed September 18, 2013).
    3.1   Certificate of Amendment of the Restated Certificate of Incorporation of the Company, dated August 7, 2013 as filed with the Secretary of the State of Delaware on August 7, 2013 (previously filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed August 8, 2013).
    4.1   Specimen Stock Certificate of the Company (previously filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed August 8, 2013).
  10.1   Parent Guarantee of the Company, dated September 12, 2013 (previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed September 18, 2013).
  10.2   Employment Agreement between Dr. Nikin Patel and the Company, dated September 12, 2013 (previously filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed September 18, 2013).
  10.3*   Bank Loan Agreement between Molecular Profiles Limited and Lloyds TSB Bank plc, dated January 6, 2012.
  10.4*   Amendment letter between Molecular Profiles Limited and Lloyds TSB Bank plc, dated September 16, 2013.
  31.1*   Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer of the Company.
  31.2*   Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer of the Company.
  32.1**   Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  32.2**   Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101   The following materials from the Columbia Laboratories, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements of Operations for the three and nine months ended September 30, 2013 and 2012, (ii) Consolidated Balance Sheets at September 30, 2013 and December 31, 2012, (iii) Consolidated Statements of Comprehensive (Loss) Income for the three and nine months ended September 30, 2013 and 2012, (iv) Consolidated Statements of Cash Flows for the nine months ended September 30, 2013 and 2012, and (v) Notes to Consolidated Financial Statements.

 

* Filed herewith.
** Furnished herewith.

 

30


Table of Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

COLUMBIA LABORATORIES, INC.

/s/ Jonathan B. Lloyd Jones

Jonathan B. Lloyd Jones

Vice President, Chief Financial Officer and Treasurer

(Principal Financial and Accounting Officer)

DATE: November 6, 2013

 

31

Exhibit 10.3

 

LOGO

Business loan agreement
Lloyds TSB
Fixed rate only or Fixed rate followed by Variable rate using funds from European Investment Bank
For lending unregulated under the Consumer Credit Act 1974 to Companies, Sole Traders and Partnerships (including Limited Liability Partnerships) carrying on business in England and Wales and/or Scotland.
Guidance notes
Please write clearly in the white spaces with capital letters or cross the boxes.
Calls may be monitored or recorded in case we need to check we have carried out your instructions correctly and to help improve our quality of service.
We aim to provide the highest level of customer service possible. However if you experience a problem we will always seek to resolve this as quickly and efficiently as possible.
You can request a copy of our “How to voice your concerns” leaflet from your relationship team, business team or any branch. Our complaint procedures are also on our website www.lloydstsb.com
1 Customer details
We
Branch/office name and address
Lloyds TSB Bank plc x
Lloyds TSB Scotland plc ¨
3rd Floor, Old Market Square, Nottingham,
Postcode NG1 6FD
[the “Bank”] offer to you, the customer or customers referred to below, a loan on the following terms and conditions.
Where this agreement includes any optional wording (as noted by a box) the wording selected shall apply
Customer (other than Company or Limited Liability Partnership)
Customer’s full name(s)
Customer (if Company or Limited Liability Partnership)
Business name
Molecular Profiles Limited
Registered number
03397582
Business address
8 Orchard Place, Nottingham Business Park, Nottingham,
Postcode NG8 6PX
Continue listing of partners’ names on a separate sheet if necessary.
Business trading name
Business address
Postcode
2 Specific terms and conditions
Amount of the loan [excluding any amounts of interest that will be added to the loan if the agreement provides for this
£ 1,000,000
The proceeds of the loan are to be credited to:
Account name and amount (if not the amount of the loan)
Purpose of the loan
Molecular Profiles Limited
the continuation of your existing EIB loan, reference: 1199A/TM , it was agreed that this amount was to be used for: construction of new office & laboratory (the Project)
Branch sort code
301898
Account number
01056523
The loan is to be borrowed in:
One amount ¨
Several amounts x
Account name and amount (if not the amount of the loan)
If borrowed in several amounts each is to be not less than:
£ 10,000
Branch sort code
Account number
although the last amount borrowed may be smaller
If the loan is not borrowed within the period agreed or, as the case may be, on the date agreed, you shall pay to the Bank any costs or losses to the Bank that may arise. These costs and losses are set out in Clause 2.3 of the General Terms and Conditions
The loan must be borrowed on or before
30/12/2012
Unless the Bank agrees otherwise:
a) no borrowing may be made until all the conditions mentioned in Clause 2.1 of the Specific Terms and Conditions have been satisfied, and
b) you will not be entitled to borrow any amount which has not been borrowed by the agreed date.


LOGO

2 Specific terms and conditions continued
2.1 Preconditions and security
Unless received by the Bank prior to the date on which this agreement is signed by the Bank, the Bank is to receive in form and substance acceptable to the Bank the security (if any) listed in the Security Schedule and the documents, evidence or other requirements of the preconditions (if any) set out in the Preconditions Schedule.
Any security received should be accompanied by such evidence as the Bank may reasonably require to confirm the value of such security and to confirm that such security is fully effective.
2.2 Fees and costs
You shall pay any costs and expenses incurred by the Bank in assessing the loan, in the preparation of this agreement, in the preparation, valuation, taking or release of any guarantee or security at any time, given in connection with this agreement and in connection with the revaluation of any such security from time to time. The Bank will provide you with a written estimate of the amount of any such costs and expenses incurred by the Bank during the term of the loan before such costs are incurred
The following charges shall be paid by you on demand by the Bank. These charges are to be paid even if the loan is not borrowed. If these charges include any estimated costs or fees, such costs or fees are based on the facts known to the Bank at the date the Bank signed this agreement. The actual amount charged to you in respect of these initial costs and expenses may be more or less than the figure(s) quoted.
As mentioned in Clauses 2, 3 & 6 of the General Terms and Conditions, other costs may arise in connection with the loan.
If during any fixed rate period you repay or are required to repay the loan early or in part under Clauses 2.2, 3.4, 5.5 or 6.1 of the General Terms and Conditions or under any Additional Terms and Conditions, you shall pay to the Bank the administration fee and any Break Costs as provided in Clause 2.3 of the General Terms and Conditions and in addition (unless specified otherwise in this agreement) any early repayment charges required by Section 2.6 of the Specific Terms and Conditions.
If during any variable rate period you repay or are required to repay the loan early or in part under Clauses 2.2 or 5.5 of the General Terms and Conditions or under any Additional Terms and Conditions, you shall pay to the Bank (unless specified otherwise in this agreement any early repayment changes required by Section 2.6 of the Specific Terms and Conditions
Arrangement fee
£
Option fee
£
Security costs
Estimated
Actual
£
Valuation fee
Estimated
Actual
£
2.3 Interest
Please cross only one box.
The rate of interest payable on the loan will be.
+ Do not use this option if dealing direct with Treasury/Financial Markets division
‡ Use this option for Treasury/Finance Markets division fixed rate lending.
* Delete as appropriate.
¨ + Fixed Rate,
% per annum
* for the term of the loan/* until
the “Review Date”
x ‡Fixed Rate,
1.56%
per annum above the rate (inclusive of regulatory costs - see Clause 3.2 of the General Terms and Conditions) quoted by the Bank at about the time of borrowing
* for the term of the loan/* until
60 months after draw down
the “Review Date”
¨ ‡Fixed Rate,
%
per annum (inclusive of regulatory costs - see Clause 3.2 of the General Terms and Conditions)
* for the term of the loan/* until
the “Review Date”
If a fixed rate is specified above as being applicable to the loan for less than the term of the loan, the role of interest payable on the loan from the Review Date will (unless at any time you request otherwise and the Bank agrees to such request) be:
Base Rate plus
1.95%
per annum, currently
2.45%
per annum in total
2.4 Payment of interest
Please complete only one section.
Interest shall be:
¨ paid by you.
The first interest payment date will be:
After that interest will be paid by you.
Monthly ¨
Quarterly ¨
added to the loan,
The first date interest will be added to the loan is:
After that interest will be added to the loan:
Monthly ¨
Quarterly ¨
x paid by you until a certain date and then added to the loan.
The first interest payment date will be:
one month after drawdown
After that interest will be paid by you:
Monthly x
Quarterly ¨
The first date interest will be added to the loan is
61 months after draw down
After that interest will be added to the loan:
Monthly x
Quarterty ¨


LOGO

2 Specific terms and conditions
2.4 Payment of interest continued
Interest will also be payable, or as the case may be, added to the loan on the date of final repayment of the loan. Interest for any particular period is calculated on the number of days in that period and a year of 365 days.
Interest is calculated on a daily basis on the amount of the loan from time to time outstanding. The loan may include interest, costs and charges added to the loan account in accordance with the terms of this agreement.
If you fail to pay any amount payable under this agreement when due the rate of interest may be increased in accordance with Clause 6.3 of the General Terms and Conditions.
2.5 Repayment
Please cross the appropriate box(es) to indicate how the loan will be repaid
The loan is repayable in
¨ a single principal instalment on the payment date
Repayment amount
£
Repayment date
¨ consecutive instalments in respect of principal only on the dates and in the amounts set out in the Repayment Schedule. Any amount owing on the final repayment date is to be paid on that date.
Number of instalments
Final repayment date
x consecutive instalments commencing on the first repayment date and ending on the final repayment date. Any amount owing on the final repayment date is to be paid on that date.
First repayment date
one months after draw down
* As set out in the repayment Schedule to be Supplied by the Financial Markets Division on the date the loan is drawn.
x Monthly
¨ Quarterly
¨ Semi-annually
Repayment type (e.g. principal plus interest)
* principal plus interest
Repayment amount
£ *TBC
Number of instalments
60
Final repayment date
x consecutive instalments of principal and interest commencing on the First repayment date and ending on the final repayment date. The amounts will vary with changes in interest and the number of days in the charging period.
First repayment date
61 months after draw down
Monthly x
Quarterly ¨
Number of instalments
116
Final repayment date
176 months after draw down
¨ consecutive instalments representing principal and interest. If the interest on the loan is at any time to be calculated with reference to Base Rate you should note that variations in such rate after the date on which this agreement is signed by the Bank may affect either or both of the instalment amount and the term of the loan. Please see Clause 2.4 of the General Terms and Conditions for further details. At the date on which this agreement is signed by the Bank it is expected that final repayment of the loan will be made by the final repayment date.
First repayment date
Monthly ¨
Quarterly ¨
Repayment amount
£
Number of instalments
Final repayment date
2.6 Early repayment charges
Note: If you make an early repayment during any fixed rate period, an administration fee and Break Cost under Clause 2.3 of the General Terms and Conditions of this agreement may be payable irrespective of whether an early repayment charge applies.
Is an early repayment charge payable? Yes ¨ No x
(For loans with a term of 5 years or less from the date the loan is first borrowed)
On the date of each early repayment, you shall pay to the Bank an early repayment charge equal to 1% of the amount then being repaid.
(For loans with a term of over 5 years from the date the loan is first borrowed)
On the date of each early repayment made on or before the date which is 5 years after the date the loan is first borrowed, you shall pay to the Bank an early repayment charge equal to 1% of the amount then being repaid.
2.7 Period of offer
This agreement shall come into effect only if the Bank receives from you and finds in order a signed copy of this agreement on or before:
Date
03/02/2012


LOGO

3 The schedules
Preconditions Schedule
The Bank has received in form and substance acceptable to it a full appraisal of the Project, including a detailed cashflow of the projected cost. The appraisal is to be prepared by a party acceptable to the Bank and is to show no issues of concern to the Bank.
The Bank has received your written instruction for the loan monies to be placed in an account with the Bank and between the following parties: Molecular Profiles Limited, Nominated Signatory from Three Sixty Project Management Limited and a Representative of the Quantity Surveyor (to be) nominated on behalf of Wilson Bowden.
The Bank has received such evidence as it may require to confirm that no less than £500,000 of your own moneys to be spent towards the Project has been placed into an account with the Bank and between the following parties: Molecular Profiles Limited, Nominated Signatory from Three Sixty Project Management Limited and a Representative of the Quantity Surveyor (to be) nominated on behalf of Wilson Bowden.
Security Schedule
An unlimited debenture from Molecular Profiles Limited, and
A first legal charge from Molecular Profiles Limited over the freehold land and buildings at 8 Orchard Place, Nottingham Business Park, Nottingham, NG8 6PX.
Repayment Schedule
Date
Amount
Date
Amount


LOGO

4 General terms and conditions
Use of Loan Proceeds
1.1 You confirm that you will use the loan exclusively for the purposes specified in the Specific Terms and Conditions.
Payment
2.1 You will repay the loan on the dates, and in the manner set out in the Specific Terms and Conditions. If the full amount of the loan is not borrowed the amounts of the instalments detailed will reduce accordingly.
2 .2 When interest is charged at a variable rate, you may at any time after giving at least 5 business days notice to the Bank repay the whole or part of the loan early. Unless the whole loan is repaid, each early repayment must be of at least £2000. You cannot redraw any amount you have paid off. Where part of the loan is repaid early, the Bank will decide how to apply the early repayment, either by (of reducing subsequent repayments proportionately or (b) applying the early repayment to the then latest scheduled repayment instalments so as to reduce the term of the loan.
When interest is charged at a fixed rate, you may at any time after giving at least 5 business days notice to the Bank repay the whole or part of the loan early together with any amount that may be payable pursuant to Clause 2.3 below. Unless the whole loan is repaid, each early repayment must be of at least £5000. You cannot redraw any amount you have paid off. Where part of the loan is repaid early, the Bank will decide how to apply the early repayment, either by (a) reducing subsequent repayments proportionately or (b) applying the early repayment to the then latest scheduled repayment instalments so as to reduce the term of the loan.
2.3 The fixed rate of interest will protect you against the risk of an increase in interest rates during the time the fixed rate applies. The Bank, however, also needs to be, protected if you repay the loan early or for any reason you do not borrow the loan in full within the period or, as the case may be, on the date agreed, and owing to a fall in interest rates the Bank is not able to re-lend at the same interest rate as for the loan.
You, therefore, agree that, if interest on the loan is to be payable at a fixed rate of interest during any part of its term and (i) for any reason you do not borrow the loan in full within the period or, as the case may be, on the date agreed, or (ii) on any day during any fixed rate period you repay the loan early in whole or in part or are required (pursuant to the terms of this agreement to repay the loan early(the date referred to in (i) or, as the case may be, (ii) above being hereinafter referred to as the “Break Date”) you will pay to the Bank on the Break Date the Break Cast and, if the fixed rate of interest is or was provided by the Bank’s Treasury/Financial Markets division, you will also pay to the Bank an administration fee of £250. If this agreement is a Regulated Mortgage Contract, the maximum amount of Break Cost you will pay will not exceed the amount borrowed under this agreement
For the purposes of this agreement, the “Break Cost” is the amount by which:
(a) the gross interest which the Bank would have been entitled to receive on the amount not borrowed or, as the case may be, on the amount repaid early (had the loan been drawn in full and repaid in accordance with the originally agreed repayment structure) for the period from the Break Date to the last day of the fixed rate period less any amount payable in respect of the interest margin chargeable by the Bank, exceeds:
(b) the interest which the Bank would be able to obtain by placing an amount equal to the amount not borrowed or, as the case may be, the amount repaid early on deposit with a leading bank in the London Interbank market for the period from the Break Date to the last day of the fixed rate period and with the same repayment structure as agreed for the loan.
The Bank will certify (such certificate to be conclusive in the absence of fraud or manifest error) to you the Break Cost.
No Break Cost will be payable by you if you have entered into an option with the Bank and have paid the Option fee set out in the Fees and costs of the Specific Terms and Conditions and for any reason you do not borrow the loan in full within the period or, as the case may be, on the date agreed.
2.4 If the repayment details set out in the Specific Terms and Conditions make specific reference to this Clause:
(a) the Bank may (but is under no obligation) at any time after giving you at least 30 days’ written notice vary the repayment instalment amount to reflect any change in the rate of interest applicable to the loan, and
b) the Bank may, if changes in the rate of interest applicable to the loan are not taken into account by variations in the repayment instalment amount or if for any reason any amount remains owing to the Bank on the anticipated final repayment date, require you to continue the repayment instalments as set out in the Specific Terms and Conditions until such time as all amounts owing under and in connection with this agreement have been repaid in full.
2.5 Where the amount of the loan specified in Section 2 of the Specific Terms and Conditions does not exceed £25,000:
(a) the requirement to give at least 5 business days, notice to the Bank to make early repayment of all or any part of the loan and the minimum amount in respect thereof of £2,000 which applies when interest is charged at a variable rate, and the minimum amount of £5,000 in respect of early repayment of all or any part of the loan which applies when interest is charged at a fixed rate, each as set out in Clause 2.2 above, shall not apply and
(b) no administration fee or Break Cost as referred to in Clause 2.3 above will be payable.
2.6 Without prejudice to the Bank’s rights expressed in Clause 6.1 of the General Terms and Conditions, if you fail to pay an instalment in full and on time, and any part of that amount has not been paid by the time the Bank calculates your next instalment amount, the Bank may (at its discretion):
(a) increase the amount of that next instalment and each of your remaining regular instalments proportionally to ensure that the full balance of the loan is repaid within the agreed term,
(b) extend the term of the loan; or
(c) increase the amount of your final instalment
2.7 The Bank will apply any payments it receives from you against any interest before any other amounts on your account, including the outstanding principal of the loan. This will not apply to payments made specifically for fees and/or charges or where the Bank collects the interest and principal that make up your repayment from separate accounts.
2.8 All payments to be made by you shall be calculated and be made without (and free and clear of any deduction for) set-off or counterclaim.
Increased Costs and Changes In Circumstances
3.1 In running its business the Bank and any holding company of the Bank each has to comply with certain regulations and requirements laid down by regulatory and other official organisations or bodies as well as the law generally. The rate of interest quoted in the Specific Terms and Conditions has been set in the light of how this affects the cost (to the Bank and any such holding company) of the Bank funding, agreeing to make or of making the loan available at the time the Bank signed this agreement. If, as a result of any new laws, regulations or requirements or any changes in existing ones, such cost is increased the Bank may increase the rate of interest charged on the loan to compensate for that extra cost. The Bank will advise you in writing within 30 days of such increase taking effect.
3.2 If the rate of interest specified in the specific terms and conditions is stated as including regulatory costs, it includes the cost to the Bank at the time the Bank signed this agreement in funding, agreeing to make and making the loan available that results from complying with the liquidity, monetary control, prudential requirements and supervisory charge requirements of the Bank of England, the Financial Services Authority and any other regulatory authority. Regulatory costs may vary from time to time and any such variation may result in the Bank changing the rate of interest payable on the loan. The Bank will determine the regulatory costs on each date interest on the loan is due to be paid and, if in the Bank’s opinion there is then a material difference (either up or down) in regulatory costs it will advise you in writing within 30 days of any change of the new rate of interest then to apply to the loan.
3.3 The Base Rate may change from time to time. If so, the Bank will tell you about the change by putting notices in a selection of national newspapers, and its branches within three business days of the change. The Bank will also update its website and interest rate helpline within three business days of a Base Rate change taking effect.
3.4 (a) The Bank can change any term of this agreement at any time:
(i) if the change is to your advantage,
(ii) to reflect changes in law, codes of practice which apply to the Bank or the way the Bank is regulated; or
(iii) to reflect any changes the Bank makes to its systems or processes.
(b) If Clause 3.4(a) above permits the Bank to make any change, the Bank will left you personally at least 30 days before the Bank makes a change to your disadvantage (other than a change to the Base Rate, which will be made in accordance with Clause 3.3 above). If you close or change your account within 60 days of the Bank telling you about this change and repay the outstanding balance, the Bank will not charge you extra to do so. Where interest is charged at a fixed rate, any costs or losses to the Bank arising under Clause 2-3 above may be payable. However you will not be required to pay any early repayment charges under Section 2.6 of the Specific Terms and Conditions.
(c) The Bank can make any other changes straight away by telling you personally or by putting notices in a selection of national newspapers, in its branches or on its website within the next 30 days.
(d) When the Bank tells you personally about a change it will do so by letter, e-mail, text, statement inserts or messages or in any other way which is sent to you individually.
Representations
4.1 You represent that:
(a) all action required or necessary to authorise the execution of this agreement and the performance of your obligations under and in connection with this agreement has been taken and neither the execution at this agreement nor the performance of your obligations will constitute or result in any breach of any agreement, law, requirement or regulation,
(b) no material litigation, administrative or judicial proceedings are presently pending or threatened against you or your business or on your ability to meet your obligations under or in connection with this agreement or any security document given in connection with this agreement,
(c) there has been no material adverse change in the financial condition of your business since the date of the financial statement received by the Bank prior to the date on which this agreement is signed by the Bank, and
(d) no Event of Default (as described in Clause 6.1 below) has occurred and is continuing or will occur as the result of a borrowing under this agreement and no circumstance has occurred which, with the giving of notice or the passing of time, could become or cause an Event of Default.
4.2 You shall be deemed to repeat the above representations on each day (with reference to the facts and circumstances then existing) prior to borrowing the loan and thereafter until all amounts payable to the Bank under this agreement have been paid.
5 Undertakings
Prior to drawdown of the loan and thereafter until all amounts payable to the Bank under this agreement have been paid.
5.1 you shall not:
(a) without the Bank’s consent create or allow to be in place any mortgage, charge or other security interest or encumbrance over the whole or any part of your business or any of the property, income or other assets of your business or enter into any transaction which in the Bank’s opinion has a similar effect, or factor or assign any debts,
(b) sell, lease or otherwise dispose or attempt to dispose of the whole or any part of your business or any of the property, income or other assets of your business other than for a full and fair value (save that no such sale, lease or other disposal may be made or entered into (i) if it would breach the terms of any security document given to the Bank, or (ii) in respect of any undertaking, property, revenue or asset over which the Bank then has a fixed charge or fixed security interest).
(c) significantly change the nature of your business as it is now conducted, or
(d) in the case of a Company or a Limited Liability Partnership, allow any subsidiary to do any of the above.


LOGO

4 General terms and conditions continued
5.2 you shall promptly provide the Bank with copies of any financial information that the Bank may from time to time reasonably request, including but not limited to;
(a) copies of your financial statement within 180 days of the end of each financial year, and
(b) copies of your periodic management accounts of such intervals as the Bank may require in a form acceptable to the Bank within 30 days of the end of the period to which they relate. The Bank may at its option require such management accounts to incorporate an age-analysis of debtors, a schedule of all tenancies (if any) of any property held by the Bank as security at the date of the accounts, and/or a breakdown of stock in trade.
5.3 you shall maintain with reputable underwriters or insurance companies adequate insurance on and over your business and the assets of your business, such insurance to be against such risks and to the extent usual for persons carrying on a business such as that carried on by you and, from time to time upon request of the Bank, you shall furnish the Bank with evidence of such Insurance.
5.4 If you have taken out a general insurance policy in connection with the loan, the Bank will hold any money the Bank receives in relation to the insurance including any claims payments paid to the Bank by the Insured in its capacity as a bank approved by the Financial Services Authority, rather than as a trustee for you (or in Scotland as on agent for you), and the Financial Services Authority’s client money rules do not apply to the money so held. Any insurance benefits the Bank receives from your insurance company, relating to the repayment of the loan, will be used towards paying off what you owe in this agreement.
5.5 If the ratio of the loan to the value of the security given to the Bank is at any time higher than that applicable on the date this agreement was signed by the Bank and unless any specific requirement is set out in any Additional Terms and Conditions added to this agreement (which requirement shall take precedence over this Clause) you agree promptly to:
(a) reduce the loan (in accordance with Clause 2 above including paying any costs or losses to the Bank arising under Clause 2.3 above and any early repayment charges it required under Section 2.6 of the Specific Terms and Conditions), or
(b) provide the Bank with additional security acceptable to the Bank, and
(c) provide such evidence as the Bank may from time to time require to confirm the value of such security and to confirm that the security remains effective.
The Bank may have the security given to it revalued at any time during the term of the loan where, for example, the Bank needs to meet any regulatory requirements or to check that the value continues to be adequate security for repayment of the loan. You will pay the cost incurred by the Bank (acting reasonably) for each revolution.
5.6 you shall conform at all times with all applicable EU and national laws including, but not limited to, environmental laws (as defined in Clause 7.16 below).
5.7 you shall, from time to time and upon reasonable notice given by the Bank
(following a request made by the European Investment Bank to the Bank), permit any person(s) appointed by the European Investment Bank or any person(s) with appropriate authority from the Court of Auditors at the European Commission to inspect all sites. Installations and works used by you and connected in any way with the purposes specified In the Specific Terms and Conditions, the inspection being for the purpose of ascertaining whether you are using the loan exclusively for those purposes in accordance with the terms and conditions of this agreement, and you shall provide such persons with all necessary assistance and information for such on inspection [the Bank reserves the right to appoint a person to accompany the person appointed by the European Investment Bank or authorised by the European Commission on such an inspection), and
5.8 you shall deliver to the Bank such Information as the European Investment Bank shall reasonably require concerning your activities and general financial position and you hereby agree that the Bank may disclose such information including, but not limited to, the financial statement] to the European Investment Bank.
Default and Termination
6.1 The events listed in (a) to (j) of this Clause 6.1 are called “Events of Default” As
soon as an Event of Default happens or at any time thereafter, by giving notice to you, the Bank may cancel any obligations it has to fend money to you and may also make the loan become repayable on demand. When the loan is repayable on demand, you must repay the loan to the Bank together with all interest which has accrued on the loan and any other amounts owing under or in connection with this agreement including any costs and losses arising under Clause 2.3 above but you will not be required to pay any early repayment charges under Section 2.6 of the Specific Terms and Conditions) as soon as the Bank requests you to pay these amounts. The Bank may do this at the time the loan becomes repayable on demand or at any later time.
Events of Default
(a) you fail to pay when due any indebtedness owed by you to the Bank.
(b) you fail to comply with any other obligation or undertaking to the Bank, or with the terms of this agreement or any other agreement with the Bank, or an event of default arises in connection with any other agreement with the Bank,
(c) you fail to pay when due any indebtedness owed by you to another creditor or any of your creditors changes (or obtains the right to change the original date on which that indebtedness is or was due to be paid to an earlier date or a result of your failure to comply with obligations in connection with that Indebtedness.
(d) any representation or statement mode by you to the Bank, whether or not in connection with this agreement, proves to have been incorrect or inaccurate when made or deemed made.
(e) any guarantee, other security or other document or arrangement relied upon by the Bank in connection with the loan ceases to be continuing or ceases to remain fully effective or notice of discontinuance is received by the Bank or if the Bank reasonably believes that the effectiveness of any such document or arrangement is in doubt or If any provision of such document or arrangement Is not complied with for any reason or any favourable tax treatment afforded to any pension policy or to any life policy held by or charged to the Bank ceases to be available.
(f) In the case of a Company or a Limited Liability Partnership:
(i) any person with a legal claim takes possession or a receiver, administrator, custodian, trustee, liquidator or similar official is appointed of the whole or any part of your business or of any of the assets of your business or an administration application is presented or made for the making of an administration order or a notice of intention to appoint on administrator is issued by you or your directors or (in the case of a Limited Liability Partnership) your members or by the holder of a qualifying floating charge or notice of appointment of an administrator is filed by any person with the court or a Judgment, decree or diligence Is made or granted against you,
(ii) proceedings are commenced or a petition is presented or an order is made or a resolution is passed for your winding up or you are or become insolvent,
(iii) you stop or threaten to stop payment of your debts generally or you are deemed by law unable to pay your debts or you or your directors or (in the case of a Limited Liability Partnership) your members convene or become obliged to convene a meeting of shareholders, members or creditors with a view to winding up or an application is made in connection with a moratorium or a proposal to creditors for a voluntary arrangement is made by you or you take any action (including entering negotiations) with a view to readjustment, rescheduling, forgiveness or deferred of any part of your indebtedness,
(v) the persons who now control you cease to have such control, or
(v) any of the events set out in this Clause 6.1(f) occur in relation to any parent or subsidiary or any guarantor of or provider of security or the loan or, in the case of any individual that provides any guarantee or other security for the loan, a petition is presented for a bankruptcy or sequestration order against any such individual or any such individual dies or becomes incapable of managing his or her affairs by reason of mental disorder, or any action is taken in any jurisdiction which is similar or analogous to any of these events in respect of you or any of the aforementioned parties. (g) in all other cases
(i) any person with a legal claim takes possession or a receiver.
administrator judicial factor, interim trustee, trustee in sequestration or similar official is appointed of the whole or any part of your business or of any of your business assets or on application or a petition Is presented or made for either on administration or a bankruptcy order against you or a judgment, decree or diligence is made or granted against you,
(ii) a petition is presented or an order is made for your winding up (if you are a partnership) or you resolve either to cease trading or to wind up your business in any way or dissolve such business for any reason,
(iii) you stop or threaten to stop payment of your debts generally or you are deemed by tow unable to pay your debts or on application is made in connection with a moratorium or a proposal to creditors for a voluntary arrangement by you or you take any action (including entering negotiations) with a view to readjustment, rescheduling, forgiveness or deferral of any part of your indebtedness, (iv) you die or become Incapable of managing and administering your property and affairs by reason of mental disorder or (if you are a partnership) there is any change in the membership of partnership, or
(v) any of the events set out in this Clause 6.1(g) occur in relation to any guarantor of or provider of security for the loan or any action is taken In any jurisdiction which is similar or analogous to any of these events in respect of you or any guarantor of or provider of security,
(h) you cease or threaten to cease to carry on your business in the normal course or you fail to maintain or breach any franchise, licence or right necessary to conduct your business or breach any legislation relating to your business, inducing but not limited to any applicable environmental protection laws,
(i) you fail or have failed to disclose to the Bank any important Information that is relevant to the loan or the security required or you undertake or are subject to any action or occurrence which the Bank reasonably believes could place at risk the payment of any amount owing to the Bank, or
(j) you do not have a servicing account
6.2 If any Event of Default happens or anything happens that might reasonably be expected to lead to an Event of Default, you shall inform the Bank Immediately
6.3 If any amount payable to respect of this agreement is not paid when due (including any amount payable under this Clause 6) we may require you to pay interest on that amount at the default rate from the date on which the amount was due until it is paid to the Bank (whether before or after Judgment). Interest, if unpaid, may be added to the amount in default at monthly intervals. The default rate shall be the rate determined by the Bank to be 3% per annum higher than the rate of interest specified in the Specific Terms and Conditions that would normally apply.
6.4 You shall indemnify the Bank against any costs incurred or losses reasonably sustained by the Bank as the result of any Event of Default happening or any failure by you to pay any amount demanded by the Bank as a result of an Event of Default
6.5 You shall also pay any costs and expenses reasonably incurred by the Bank in enforcing or perfecting any security for the loan and in enforcing or preserving its rights under this agreement.
Other
7.1 This agreement (and any non-contractual obligations arising out of or in connection with this agreement) shall be construed and have effect in accordance with the applicable law and is subject to the jurisdiction of the Courts in the jurisdiction of the applicable law. The applicable law will be the laws of England and Wales or the laws of Scotland, it will be the governing law of the country in which the branch or office of the Bank given at the heading of this agreement is situated on the date this agreement is signed by the Bank. The Bank may take action against you in any other jurisdiction where proceedings may be lawfully commenced.


LOGO

4 General terms and conditions continued
7 2 No delay or omission by the Bank in exercising any of its rights hereunder shall operate or be construed as a waiver, nor shall any single or partial exercise of any such right prevent any other or further exercise of any other right.
7 3 if the loan is to be borrowed, or if any payment becomes due from you, on a day which is not a business day then the amount concerned will be borrowed or, as the case may be, will become payable on the next business day.
7 4 The Bank may use any credit balance there may be an any of your accounts held with the Bank towards payment of any amounts owed by you to the Bank under this agreement without notifying you beforehand, whether such credit balances are in sterling or any other currency or are deposited for fixed or determinable periods
7.5 Unless otherwise agreed by the Bank you shall at all times during the term of this agreement keep a servicing account with the Bank and all amounts from time to time due to the Bank under this agreement may be debited to that account. The Bank recommends that you make sure you have enough funds to meet all such payments as they become due. If you do not maintain such an account with the Bank, the Bank may (without prejudice to its rights under Cause 6.1 above) add to your loan account any interest that is to be paid by you but which is not paid on the date it is due for payment. The Bank may charge interest on any amount so added to the loan account.
7.6 Any security given to the Bank (whether given before the date on which this agreement is signed by the Bank or at any time in the future and whether or not specified in this agreement shall, unless otherwise agreed by the Bank, be security not only for the loan but also for all other moneys and liabilities whether certain or contingent at any time due, owing or incurred by you to the Bank.
7.7 The Bank may sell, assign, transfer, securities or otherwise dispose of in any manner its rights or obligations under this agreement to any other person, or enter into transactions which have the effect of transferring the economic or credit risks and/or rewards of the Bank under this agreement with any other person. You will promptly execute any documents that the Bank may reasonably require to give effect to any such assignment, assignation, transfer, securitisation or other disposal. You may not assign, transfer or otherwise dispose of any of your rights, obligations or benefits under this agreement.
7.8 In the event of, or in connection or contemplation of, a proposed sale, assignment, securitisation, transfer or other disposal of risks and/or rewards of the loan for part of it or sale, assignment, transfer, securitisation or other disposal of any of the Bank’s rights under this agreement the Bank may disclose information about you, your finances and this agreement to any potential purchaser, assignee, transferee, counterparty to an agreement transferring risks and/or rewards, rating agencies, listing authorities, their and our advisers, or any other person to whom the Bank may deem it necessary to disclose such information to in relation to any proposed sale, securitisation, transfer, assignment or transfer of risks and/or rewards,
7.9 You consent to the Bank disclosing information about you, your finances and this agreement to any person providing any security for any of your obligations, and to them giving us information about you
7.10 This agreement and all communications from you to the Bank in connection with this agreement and the loan (all of which are to be sent in writing to the Bank) shall, in the case of a Company or Limited Liability Partnership, be signed an your behalf either in accordance with the mandate given by you to the Bank, or if requested by the Bank, in accordance with a specific resolution of your Board of Directors/Members, or in the case of a partnership, shall be signed by all partners unless otherwise agreed by the Bank, or in all other cases, shall be signed in accordance with the mandate given by you to the Bank.
7.11 Any change to this agreement other than the changes to be made by the Bank as provided in this agreement must be mode in writing and be signed by the contracting parties.
7.12 If the loan is available to more than one person, each and every undertaking and liability of all of you under and in connection with this agreement shall be joint and several and references to you shall mean any one or more of you. Therefore each of you is jointly and separately responsible for complying with the terms and conditions of this agreement and for repaying all the liabilities under this agreement and not just a share of them. The Bank may take action against all or any one of you
7.13 This agreement is for the benefit of the contracting parties only and shall not confer any benefit on or be enforceable by a third party
7.14 The Specific Terms and Conditions and General Terms and Conditions together with any Additional Terms and Conditions attached to this agreement shall be read and construed as one agreement
7.15 In this agreement the following terms shall have the following meanings: the “Bank” includes its successors and assigns.
“Base Rates” means the official bank rate from time to time of Bank of England (or any rate at any time replacing that rate) which will be displayed in the Bank’s branch where your account is held and on the Bank’s website, currently www.lloydstsb.com/business, and may be varied (either up or down) by the Bank of England at any time. “a business day” means a day other than a Saturday or a Sunday on which banks are open for normal business in the jurisdiction of the applicable law “control” shall have the meaning given to it in Section 840 of the Income and Corporation Taxes Act 1906 or any amendment to or restatement of that Act for the time being in force “current account” means your main business current account with the Bank “environment” means the following, in so far as they affect human well-being (a) fauna and flora; (b) soil, water, air, climate and the landscape, and (c) cultural heritage and the built environment “environmental laws” means EU law and national laws and regulations as apply in the jurisdiction of the applicable law referred to in Clause 7.1 above, as well as applicable international treaties, of which a principal objective is the preservation, protection or improvement of the environment “financial statement” means at any particular time the latest balance sheet and profit and loss account of your business together with the notes to both. You must ensure they are audited or signed by an independent accountant if required by law or if reasonably required by the Bank. Y OU must also ensure that, unless the Bank allows otherwise (the Bank will not unreasonably withhold or delay its permission), they are prepared on the same basis and (except to the extent necessary to reflect any changes In generally accepted accounting principles) in accordance with the same accounting principles as the latest such balance sheet and profit and loss account received by the Bank prior to the date on which this agreement is signed by the Bank.
“loan” means, of any particular time, the total amount which may be borrowed by you under this agreement or, if appropriate, the total amount which has been debited to the loan account and remains outstanding at such time. The loan may, at any time, include any interest, costs and charges added to the loan account in accordance with this agreement.
“month” means a calendar month.
“parent” and subsidiary” shall have respectively the meaning given to parent undertaking and subsidiary undertaking in Section 1162 of the Companies Act 2006 or any amendment to or restatement of that Act for the time being in force. During any period in which you do not have a subsidiary, all references to your subsidiaries shall be ignored and the relevant text read and construed accordingly. “Regulated Mortgage Contract” means a contract where the loan is provided to on individual (i.e. sole trader or partnership) and the loan is secured by a first legal mortgage on land in the UK where at least 40% of that land is used or is intended to be used as or in the connection with a dwelling by the borrower or a close family member.
“servicing account” means an account through which the Bank channels your and the Bank’s payments under this agreement. You may use your current account with the Bank as your servicing account.
“your business” shall include, in the case of a Company or a limited liability Partnership, the business of your subsidiaries
7.16 The Bank will not be liable for any loss, damage, interruption, delay or non-performance in connection with this agreement to the extent that it is caused by events which are beyond the Bank’s reasonable control which may include for example explosion, terrorism, war, riot or other civil disturbance or failure or interruption of any electronic communications system caused by someone else
7.17 If you do not pay the Bank what you owe under this agreement and the Bank does not require you to pay interest on that amount at the default rate pursuant to Cause 6.3 above and the Bank obtains judgment against you in a court,
the Bank may continue to charge interest on the judgment amount at the role specified in Section 2.3 of the Specific Terms and Conditions of this agreement.
7.18 If any term or provision in this agreement shall in whole or in part be held to any extent to be invalid, void, illegal or unenforceable under any enactment or rule of law, that term or provision shall to that extent be deemed not to form part of
this agreement and the enforceability of the remainder of this agreement shall not be affected
7.19 You may at any time substitute any property charged to the Bank with alternative property If the alternative property has a value at least equal to the value of the property to be released. When the Bank is satisfied that the alternative security is fully effective, it will discharge the security being substituted. Use of Personal Information and Credit, Fraud and Identification Checks When you apply to open an account, we will check our own records for information on individuals who are Key Account Parties. “Key Account Parties” are individual who are sole traders, proprietors, partners, directors, members, beneficial owners, trustees or other controlling officials of the business or organisation including signatories to the account.
We may also carry out a search through credit reference agencies on these individuals. The credit reference agencies will keep a record of this search and this record may be used by other organisations to verify their identities. We may also check or share information with fraud prevention agencies to prevent fraud and money laundering. When you apply for credit and credit related or other facilities, we may carry out a search through credit reference agencies on you and/or Key Account Parties. The credit reference agencies will keep a record of this search whether or not the application proceeds. A record of the search on personal files will not be made available to other organisations. A record of the search on the business We will be made available to other organisations. We may also check or share Information with fraud prevention agencies to prevent fraud and money laundering
When you have an account with us, we may disclose how you have run your account(s) to credit reference agencies. If you borrow and do not repay in full and on time, we may tell the credit reference agencies. We may make periodic searches of the Lloyds Barking Group records and credit reference agencies to manage your account(s) including to make decisions whether to continue or extend existing credit The Lloyds Banking Group includes us and a number of other companies using brands including Lloyds T50, Halifax and Bank of Scotland, and their associated companies More information on the Lloyds Banking Group can be found at www.lloydsbankinggroup.com.
For these purposes “associated companies” includes Lloyds Banking Group plc and any subsidiary, affiliate or other firm directly or indirectly controlled from time to time by either Lloyds Banking Group plc or us.
We may also check and share information with fraud prevention agencies to prevent fraud and money laundering
If false or Inaccurate information is provided or fraud is suspected, details may be passed to fraud prevention agencies and other relevant agencies.
If you or Key Account Parties ask, we will let you or them which credit reference and fraud prevention agencies we have used so you or they can get a copy of your or their details from these agencies.
This is a condensed guide to the use of your personal and business information by us and at credit reference and fraud prevention agencies. If you would like to read full details of how data may be used, please visit our website at www.lloydslsb.com/commercial/customerdata or contact your relationship manager or relationship team
5 Declaration for exemption relating to businesses (sections 16B and 189(1) and (2) Consumer Credit Act 1974)
Only applicable if you are a sole trader or a partnership of two or three partners or on unincorporated body)
I am/We are* entering this agreement wholly or predominantly for the purposes of a business carried an by me/us* or intended to be carried on by me/us * l/We* understand that I/we* will not have the benefit of the protection and remedies that would be available to me/us* under the Consumer Credit Act 1974 II this agreement were a regulated agreement under that Act
I/We* understand that this declaration does not affect the powers of the court to make an order under section 140B of the Consumer Credit Act 1974 in relation to a credit agreement where it determines that the relationship between the creditor and the debtor is unfair to the debtor
I am/We are* aware that, If I am/we are* in any doubt as to the consequences of the agreement not being regulated by the Consumer Credit Act 1974 I/we should seek independent legal advice.
*Delete as appropriate.


LOGO

6 Your acceptance
By signing and returning this agreement:
(a) you acknowledge having received, read and understood a copy of this agreement and agree to the Specific: Terms and Conditions and to the General Terms and Conditions set out above and to the attached Additional Terms and Conditions forms numbered
10412-0811
(together “the agreement”), you acknowledge that this agreement comprises all the terms currently applicable to the loan and that no representation made In good faith, warranty or undertaking has been mode by the Bank in connection with the loan which Is not set out In this agreement, and you acknowledge that in deciding to enter into this agreement and to proceed with any transaction or project for which the loan has been sought you hove not received or relied upon any advice given by the Bank.
(b) (if you are a sole trader or a partnership of two or three partners or an unincorporated body) you also acknowledge that you have made a declaration for exemption relating to businesses as set out above.
This agreement creates legal obligations and therefore before signing we recommend that you consider taking independent advice. This may help you understand the potential consequences in the event that things go wrong.
Please note that if interest is to be, or is, payable at a fixed rate and you do not borrow the loan within period agreed or, as the case may be, on the date agreed or, for any reason, you repay early or are required to repay early, the loan or any part of the loan, you will have to compensate the Bank for its costs and losses.
For Company/Limited Liability Partnership
Signed for and on behalf of the customer by:
Director/name (delete as appropriate) Director/ Authorised signatory name (delete as appropriate)
Nikin Patel EMMA GAINFORD
Date 6 January 2012
Signature Signature
/s/ Nikin Patel /s/ EMMA GAINFORD
Date 6.1.12
Pursuant to a Resolution of the board/ members dated
This will be either the date of the account mandate, if an appropriate resolution is contained therein or the date of a specific resolution passed in respect of this agreement.
For Sole Trader/Partnership (other than Limited Liability Partnership)
Signed by
Signature
Date
Print name
Signature
Date
Print name
Signature
Date
Print name
Signature
Date
Print name
For bank use only Manager/Authorized Signatory
Signed for and on behalf of the Bank by : Manager/Authorised name /s/ Leo Magee
Date 6112
Please contact your relationship team or branch if you’d like this in Braille, large print or on audio tape
www.lloydslb.com/business
We accept calls made through RNID Typetalk. Calls may be monitored or recorded in case we need to check we have carried out your instructions correctly and to help improve our quality of service.
Lloyds TSB Commercial is a trading name of Lloyds TSB Bank plc and Lloyds TSB Scotland plc and serves customers with an annual turnover of up to £15M.
Lloyds TSB Bank plc Registered office 25 Gresham Street London EC2V Registered in England and Wales no. 2065 Telephone 020 7626 1500.
Lloyds TSB Scotland plc Registered office Henry Duncan House, 120 George Street, Edinburgh EH2 41H Registered in Scotland no 95237 Telephone 0131 225 4555
Authorised and regulated by the Financial Services Authority under numbers 119278 and 191240 respectively. We subscribe to The Lending Code, copies of the Code can be obtained from www.lendingstandardsabroad.org.uk.
12511-0211


Additional Terms and Conditions Financial Covenants    LOGO

Please contact your business team or branch if you’d like this in Braille, large print or on audio tape. We accept calls made through RNID Typetalk. Calls may be monitored or recorded in case we need to check we have carried out your instructions correctly and to help improve our quality of service.

When this document has been signed by x Lloyds TSB Bank plc              Lloyds TSB Scotland plc (the “ Bank ” and Molecular Profiles Limited                      *carrying on business under the name of                      the terms and conditions below marked with an “X” will be added to the terms and conditions set out in the BUSINESS LOAN AGREEMENT which was signed by the Bank on                     (the “ Agreement ”). These Additional Terms and Conditions shall apply for as long as any moneys are owing to the Bank under the Agreement or the Bank is under any obligation under the Agreement.

The covenants will be tested at the frequency annotated below against (a) each financial statement, if the covenant is marked as being tested annually, and/ or (b) against your management accounts or, if appropriate, against your tenancy schedules, if the covenant is marked as being tested monthly or quarterly For the avoidance of doubt:

 

(a) you are required to provide the Bank with sufficient information to enable the Bank to test the covenants. This information is to be provided pursuant to the Agreement, and

 

(b) the covenants will be tested for the period of the accounts unless, in the case of a monthly or quarterly test the covenant is also marked as being tested on a rolling 12 months. In this case, each test will be for the 12 month period ending on the test date.

 

              Frequency of Covenant testing
              Monthly    Quarterly    Annually    Rolling 12
months
  CFADS to debt service    CFADS is not at any time to be less than     % of the aggregate of the consolidated principal repayments and the consolidated interest paid and payable (whether to the Bank or to any other person,) for the period covered by the accounts.    ¨    ¨    ¨    ¨
  EBITDA to debt service    EBITDA is not at any time to be less than     % of the aggregate of the consolidated principal repayments and the consolidated interest paid and payable (whether to the Bank or to any other person) for the period covered by the accounts.    ¨    ¨    ¨    ¨
  Minimum retained profit    Retained Profit of not less than £             is to be reported in each financial statement (commencing with the financial statement as at          ¨   
  Interest cover    Your consolidated Profit Before Taxation and interest paid and payable is not at any time to be less than     % of the consolidated interest paid and payable (whether to the Bank or to any other person, for the period covered by the accounts    ¨    ¨    ¨    ¨
  Gross rental cover    The total Rental Income received by you from all Property is not at any time to be less than     % of the aggregate of the principal repayments and the interest paid and payable to the Bank for the period covered by the accounts    ¨    ¨    ¨    ¨
  Minimum gross rent    The total rental income received by you from all Property is not for any year to be less than £                ¨    ¨    ¨    ¨
                   Frequency of Covenant testing
                   Monthly    Quarterly    Annually
x   Minimum net worth    Net Worth is at all times to be maintained at not less than £ 4,000,000    ¨    ¨    x
  Gearing    Borrowing is not at any time to exceed     % of Net Worth    ¨    ¨    ¨
  Good trade debtors cover    Good Book Debts (after taking into account any amounts ranking in priority to amounts owing to the Bank) are not at any time to be less than     % of your utilisation of all facilities provided to you by the Bank.    ¨    ¨    ¨
  Loan to value    The total amount owing to the Bank (whether certain or contingent) by you is not at any time to exceed the aggregate of     % of the latest valuation received by the Bank of all Property (after taking into account any amounts ranking in priority to amounts owing to the Bank)    ¨    ¨    ¨

 

* delete as appropriate


Definitions

Borrowing shall include all your land, if you have any subsidiaries, all of your subsidiaries’) borrowed moneys and all liabilities and indebtedness, whether or not then due, under acceptance credits and hire purchase, instalment credit, factoring, invoice discounting or similar agreements but excluding trade debts and liabilities far the payment of tax. If you are a company or a limited liability partnership, Borrowing shall exclude all loans from your directors or, as the case may be, members.

CFADS (Cash Flow available for Debt Service) means your consolidated Profit Before Taxation and interest paid and payable after adding back depreciation, amortisation of goodwill and other non-cash profit and loss items, plus or minus net movements in working capital, less tax paid, dividends paid and payable or, as the case may be, drawings made available and capital expenditure paid (net of capital expenditure funded by asset disposals and/or hire purchase and/or finance leasing).

EBITDA means your consolidated Profit Before Taxation, depreciation, amortisation of goodwill and of other intangibles and interest paid and payable (but after dividends paid and payable or, as the case may be, after drawings made available).

Good Book Debts means those debts due to you in the normal course of business (over which a charge or security interest has been given to the Bank in a form acceptable to the Bank) but excluding (a) any debts arising from the sale of goods acquired which remain subject to reservation of title, (b) any debts more than 3 months old or considered by you or your auditors (if appropriate) to be irrecoverable, (c) any contract debtors, and (d) any contra or intra-group debts.

Net Worth shall mean at any particular time:

(a) if you are a company or a limited liability partnership the aggregate of the amount paid up on your issued share capital (if you have any) and the consolidated distributable and non-distributable reserves of you and your subsidiaries but (i) after deducting the total of any debit balance on profit and loss account and the book value of goodwill and any other intangible assets, and (ii) excluding any minority interests in subsidiaries and any increase in the valuation of assets subsequent to the date of the financial statement, or

(b) if you are not a company or a limited liability partnership, the net aggregate of all credit balances (after deducting any debit balances) of your Capital Accounts (or the accounts similarly styled in the financial statement which, for the avoidance of doubt, shall not include any loan moneys) less the book value of goodwill and any other intangible assets, excluding any increase in the valuation of assets subsequent to the date of the financial statement but, at the discretion of the Bank, increased to include the amount of (it any undrawn profits, and (ii) any taxation reserves

Profit After Taxation and Profit Before Taxation shall include items of an exceptional nature and shall exclude items of an extraordinary nature unless taken into account at the Bank’s discretion for the purpose of any relevant calculation.

Property means freehold and/or leasehold property (or, if in Scotland, heritable property owned or leased) over which a charge or security interest has been given to the Bank in a form acceptable to the Bank.

Rental Income means income derived from rents and service charges, excluding sums charged in respect of insurance premiums, any statutory charges and any intra-group rental income.

Retained Profit means your consolidated Profit After Taxation and dividends paid and payable (or, as the case may be, after drawings made available) and after deducting any profit attributable to minority interests in subsidiaries and after taking into account any items of an extraordinary nature and any items of an exceptional nature.

 

Note: If you do not have any subsidiaries, references in these Additional Terms and Conditions to “subsidiaries” and to “consolidated” shall be ignored and the relevant text shall be read and construed accordingly.


This document creates legal obligations and therefore before signing we recommend that you consider getting independent advice. This may help you in understanding the potential consequences in the event that things go wrong.

 

For Sole Trader/Partnership (other than Limited Liability Partnership)      
Signed by        
Print name       Print name  
Signature       Signature  
Date       Date  
Print name       Print name  
Signature       Signature  
Date       Date  
Print name       Print name  
Signature       Signature  
Date       Date  
For Company / Limited Liability Partnership      
Signed for and on behalf of      
MOLECULAR PROFILES LTD      
by       and by  
Print name       Print name  
NIKIN PATEL     EMMA GAINFORD
Signature       Signature  
/s/ Nikin Patel     /s/ Emma Gainford
Date 6 JANUARY 2012     Date 6-1-12
*Director/Member/Authorised Signatory     *Director/Member/Authorised Signatory/Secretary
Pursuant to a resolution of the board/members dated #      
      Date  
Signed for and on behalf of the Bank by      
*Manager/Authorised Signatory    

*  Delete as appropriate.

/s/ Leo Magee    

#  This will be either the date of the account mandate, if an appropriate resolution is contained therein or the date of a specific resolution passed in respect of the loan.

Date 6-1-12      

Lloyds TSB Bank plc Registered Office 25 Gresham Street, London EC2V 7HN Registered in England and Wales, no 2065

Lloyds TSB Scotland plc Registered Office Henry Duncan House, 120 George Street, Edinburgh EH2 4LH Registered in Scotland, no 95237

Authorised and regulated by the Financial Services Authority under numbers 119278 and 191240 respectively.

Licensed under the Consumer Credit Act 1974 under registration numbers 0004685 and 0198797 respectively

10412 0811


LOGO

Business loan agreement Lloyds TSB
Variable rate only using funds from European Investment Bank
For lending unregulated under the Consumer Credit Act 1974 to Companies, Sole Traders and Partnerships (including Limited Liability Partnerships) carrying on business in England and Wales and/or Scotland
Guidance notes
Please write clearly in the while spaces with capitol letters or cross the boxes.
Calls may be monitored or recorded in case we need to check we have carried out your instructors correctly and to help improve our quality of service.
We aim to provide the highest level of customer service possible. However if you experience a problem we will always seek to resolve this as quickly and efficiency as possible.
You can request a copy of our “How to voice your concerns” leaflet from your relationship team, business team or any branch. Our complaint procedures are also on our website www.llyodstsb.com
1 Customer details
We
Lloyds TSB Bank plc x Lloyds TSB Scotland plc
(the “Bank”) offer to you, the customer or customers referred to below, a loan on the following terms and conditions.
Where this agreement includes any optional wording (as noted by a box) the wording selected shall apply.
Customer (other than Company or Limited Liability Partnership)
Business name
Molecular Profiles Limited
Registered number
03397582
Business address
8 Orchard Place, Nottingham Business Park, Nottingham,
Postcode NG8 6PX
Branch/office name and address
3rd Floor, Old Market Square, Nottingham,
Postcode NG1 6FD
Customer (if Company or Limited Liability Partnership)
Customer’s full name(s)
Continue listing of partners’ names on a separate sheet if necessary.
Business trading name
Business address
Postcode
2 Specific terms and conditions
Amount of the loan (excluding any amounts of interest that will be added to the loan if the agreement provides for this)
£1,000,000
Purpose of the loan
Construction of new office & laboratory (the Project)
The loan is to be borrowed in One amount Several amounts
x
If borrowed in several amounts each is to be not less than:
£10,000
although the lost amount borrowed may be smaller
The loan must be borrowed on or before:
30/12/2012
Unless the Bank agrees otherwise:
a) no borrowing may be made until all the conditions mentioned in Clause 2.1 of the Specific Terms and Conditions have been satisfied, and
b) you will not be entitled to borrow any amount which has not been borrowed by the agreed date
The proceeds of the loan are to be credited to
Account name and amount (if not the amount of the loan)
Molecular Profiles Limited
Branch sort code Account number
301398 01056523
Account name and amount (if not the amount of the loan)
Branch sort code Account number


LOGO

2 Specific terms and conditions continued
2.1 Preconditions and security
Unless received by the Bank prior to the date on which this agreement is signed by the Bank, the Bank is to receive in form and substance acceptable to the Bank the security (if any) listed in the Security Schedule and the documents, evidence or other requirements of the preconditions (if any) set out in the Preconditions Schedule.
Any security received should be accompanied by such evidence as the Bank may reasonably require to confirm the value of such security and to confirm that such security is fully effective.
2.2 Fees and costs
You shall pay any costs and expenses incurred by the Bank in assessing the loan. In the preparation of this agreement, in the preparation, valuation, taking or release of any guarantee of security at any time given in connection with this agreement and in connection with the revaluation of any such security from time to time. The Bank will provide you with a written estimate of the amount of any such costs and expenses incurred by the Bank during the term of the loan before such costs are incurred.
The following charges shall be paid by you or demand by the Bank. These charges are to be paid even if the loan is not borrowed. If these charges include any estimated costs or fees, such costs of fees are based on the facts known to the Bank of the date the Bank signed this agreement. The actual amount charged to you in respect of these initial costs and expenses may be more or less than the figure(s) quoted.
As mentioned in Clauses 2, 3 & 6 of the General Terms and Conditions and, if required by Section 26 of the Specific Terms and Conditions, other costs may arise in connection with the loan.
Arrangement fee
£10,000
Security costs Estimated Actual
£ ¨ ¨
Valuation fee Estimated Actual
£ ¨ ¨
2.3 Interest
x Base Rate plus 1.95 % per annum Base Rate is currently 0.50 % per annum
2.4 Payment of interest
Please complete only one section. Interest shall be:
The first interest payment date will be:
x paid by you one month after draw down
After that interest will be paid by you:
Monthly Quarterly
x ¨
The first date interest will be added to the loan is:
added to the loan.
After that interest will be added to the loan:
Monthly Quarterly
¨ paid by you until a certain date and then added to the loan.
The first interest payment date will be: The first date interest will be added to the loan is:
After that interest will paid by you:
Monthly Quarterly
¨ ¨
After that interest will be added to the loan
Monthly Quarterly
¨ ¨
Interest will also be payable or as the case may be, added to the loan on the date of find repayment of the loan. Interest for any particular period is calculated on the number of days in that period and a year of 365 days.
Interest is calculated on daily basis on the amount of the loan from time to time outstanding. The loan may include interest, costs and charges added to the loan account in accordance with the terms of this agreement.
If you fail to pay any amount payable under this agreement when due the rate of interest may be increased in accordance with Clause 6.3 of the General Terms and Conditions.


LOGO

2 Specific terms and conditions
continued
2.5 Repayment
Please cross the appropriate box(es) to indicate how the loan will be repaid. The loan is repayable in:
ü a single principal instalment on the payment date.
Repayment amount
£ 1,000,000
Repayment date
4 months after draw down
consecutive instalments in respect of principal only on the dates and in the amounts set out in the Repayment Schedule. Any amount owing on the final repayment date is to be paid on that date.
Number of instalments
Find repayment date
consecutive instalments commencing on the first repayment date and ending on the final repayment date. Any amount owing on the final repayment date is to be paid on that date.
First repayment data
Monthly ¨
Quarterly ¨
Semi-annually ¨
Repayment type (e.g. principal plus interest)
Repayment amount
Number of instalments
£
Final repayment date
consecutive instalments of principal and Interest commencing on the first repayment date and ending on the final repayment date. The amounts will vary with charges in interest and the number of days in the changing period.
First repayment date
Monthly ¨
Quarterly ¨
Number of instalments
Find repayment date
consecutive instalments representing principal and interest. If the interest on the loan is at any time to be calculated with reference to Base Rate you should note that variations in such rate after the date on which this agreement is signed by the Bank may affect either or both of the instalment amount and the term of the loan Please see Clause 2.3 of the General Terms and Conditions for further details. At the date on which this agreement is signed by the Bank it is expected that final repayment of the loan will be made by the final repayment date.
First repayment date
Monthly ¨
Quarterly ¨
Repayment amount
£
Number of instalments
Find repayment date
is an early repayment charge payable?
2.6 Early repayment charges
Yes ¨
No ü
(For loans with a term of 5 years or less from the date the loan is first borrowed)
On the date of each early repayment, you shall pay to the Bank an early repayment charge equal to 1% of the amount then being repaid.
(For loans with a term of over 5 years from the date the loan is first borrowed)
On the date of each early repayment made on or before the date which is 5 years after the date the loan is first borrowed, you shall pay to the Bank an early repayment charge equal to 1% of the amount then being repaid.
2-7 Period of offer
This agreement shall come into effect only if the Bank receives from you and finds in order a signed copy of this agreement on or before:
Date
03/02/2012


LOGO

3 The Schedule
Preconditions Schedule
The Bank has received in form and substance acceptable to it a full appraisal of the Project, including a detailed cashflow of the projected cost. The appraisal is to be prepared by a party acceptable to the Bank and is to show no issues of concern to the Bank.
The Bank has received your written instruction for the loan monies to be placed in an account with the Bank and between the following parties: Molecular Profiles Limited, Nominated Signatory from Three Sixty Project Management Limited and a Representative of the Quantity Surveyor (to be) nominated on behalf of Wilson Bowden.
The Bank has received such evidence as it may require to confirm that no less than £500,000 of your own moneys to be spent towards the Project has been placed into an account with the Bank and between the following parties: Molecular Profiles Limited, Nominated Signatory from Three Sixty Project Management Limited and a Representative of the Quantity Surveyor (to be) nominated on behalf of Wilson Bowden.
Security Schedule
An unlimited debenture from Molecular Profiles Limited, and
A first legal charge from Molecular Profiles Limited over the freehold land and buildings at 8 Orchard Place, Nottingham
Business Park, Nottingham, NG8 6PX.
Repayment Schedule
Date
Amount
Date
Amount


LOGO

4 General terms and conditions
Use of Loan Proceeds
1.1 You confirm that you will use the loan exclusively for the purposes specified in the Specific Terms and Conditions
Payment
2.1 You will repay the loan on the dates, and in the manner set out in the Specific Terms and Conditions. If the full amount of the loan is not borrowed the amounts of the instalments detailed will reduce accordingly
2.2 You may at any time after giving at least 5 business days’ notice to the Bank repay the whole or part of the loan early. Unless the whole loan is repaid, each early repayment must be of at least £2000. You cannot redraw any amount you have paid off. Where part of the loan is repaid early, the Bank will decide how to apply the early repayment, either by
(a) reducing subsequent repayments proportionately, or
(b) applying the early repayment to the then latest scheduled repayment instalments so as to reduce the term of the loan.
2.3 If the repayment details set out in the Specific Terms and Conditions make specific reference to this clause:
(a) the Bank may (but is under no obligation) at any time after giving you at least 30 days’ written notice vary the repayment instalment amount to reflect any change in the rate of interest applicable to the loan, and
(b) the Bank may, if charges in the rate of interest applicable to the loan ore not taken into account by variations in the repayment instalment amount or if for any reason any amount remains owing to the Bank on the anticipated final repayment date, require you to continue the repayment instalments as set out in the Specific Terms and Conditions until such time as all amounts owing under and in connection with this agreement have been repaid in full
2.4 Where the amount of the loan specified in Section 2 of the Specific Terms and Conditions does not exceed £25,000, the requirement to give at least 5 business days’ notice to the Bank to make early repayment of all or any part of the loan and the minimum amount in respect thereof of £2,000, each as set out in Clause 2.2 above, shall not apply.
2.5 Without prejudice to the Bank’s rights expressed in Clause 6.1 of the General Terms end Conditions, if you fail to pay an instalment in full and on time, and any part of that amount has not been paid by the time the Bank calculates your next instalment amount, the Bank may (at its discretion).
(a) increase the amount of that next instalment and each of your remaining regular instalments proportionally to ensure that the full balance of the loan is repaid within the agreed term;
(b) extend the term of the loan; or
(c) increase the amount of your final instalment
2.6 The Bank will apply any payments it receives from you against any interest before any other amounts on your account, including the outstanding principal of the loan.This will not apply to payments made specifically for fees and/or charges or where the Bank collects the Interest and principal that make up your repayment from separate accounts.
2.7 All payments to be made by you shall be calculated and be made without (and free and clear of any deduction for) set-off or counterclaim.
Increased Costs and Changes in Circumstances
3.1 In running its business the Bank and any holding company of the Bank each has to comply with certain regulations and requirements laid down by regulatory and other official organisations or bodies as well as the law generally. The rate of interest quoted in the Specific Terms and Conditions has been set in the light of how this affects the cost (to the Bank and any such holding company) of the Bank funding, agreeing to make or of making the loan available at the time the Bank signed this agreement. If, as a result of any new laws, regulations or requirements or any changes in existing ones, such cost is increased the Bank may increase the rate of interest charged on the loan to compensate for that extra cost. The Bank will advise you in writing within 30 days of such increase taking effect.
3.2 The Base Rate may change from time to time. If so, the Bank will tell you about the change by putting notices in a selection of national newspapers, and its branches within three business days of the change. The Bank will also update its website and interest rate helpline within three business days of a Base Rate change taking effect.
3.3 (a) The Bank can change any term of this agreement at any time:
(i) if the change is to your advantage;
(ii) to reflect changes in law, codes of practice which apply to the Bank or the way the Bank is regulated, or
(iii) to reflect any changes the Bank makes to its systems or processes
(b) If Clause 3.3(a) of above permits the Bank to make any change, the Bank will tell you personally at least 30 days before the Bank makes a change to your disadvantage (other than a change to the Base Rate, which will be made in accordance with Clause 3.2 above). If you close or change your account within 60 days of the Bank telling you about this change and repay the outstanding balance, the Bank will not charge you extra to do so and you will not be required to pay any early repayment charges under Section 2 6 of the Specific Terms and Conditions
(c) The Bank can make any other changes straight away by telling you personally or by putting notices in a selection of national newspapers, in its branches or on its website within the next 30 days.
(d) When the Bank tells you personally about a change it will do so by letter, email, text, statement inserts or messages or in any other way which is sent to you individually
Representations
4.1 Y OU represent that
(a) all action required or necessary to authorise the execution of this agreement and the performance of your obligations under and in connection with this agreement has been taken and neither the execution of this agreement nor the performance of your obligations will constitute or result in any breach of any agreement, law, requirement or regulation,
(b) no material obligation, administrative or judicial proceedings are presently pending or threatened against you or your business or on your ability to meet your obligations under or in connection with this agreement or any security document given in connection with this agreement,
(c) there has been no material adverse change in the financial condition of your business since the date of the financial statement received by the Bank prior to the date on which this agreement is signed by the Bank, and
(d) no Event of Default (as described in Cause 6.1 below) has occurred and is continuing or will occur as the result of a borrowing under this agreement and no circumstance has occurred which, with the giving of notice or the passing of time, could become or cause an Event of Default.
4.2 You shall be deemed to repeat the above representations on each day (with reference to the facts and circumstances then existing) prior to borrowing the loan and thereafter until all amounts payable to the Bank under this agreement have been paid.
Undertakings
Prior to drawdown of the loan and thereafter until all amounts payable to the Bank under this agreement have been paid
5.1 you shall not
(a) without the Bank’s consent create or allow to be in place any mortgage, charge or other security interest or encumbrance over the whole or any part of your business or any of the property, income or other assets of your business or enter into any transaction which in the Bank’s opinion has a similar effect, or factor or assign any debts,
(b) sell, lease or otherwise dispose or attempt to dispose of the whole or any part of your business or any of the property, income or other assets of your business other than for a full and fair value (save that no such sale, lease or other disposal may be made or entered into (i) if it would breach the terms of any security document given to the Bank, or (ii) in respect of any undertaking, property, revenue or asset over which the Bank then has a fixed charge or fixed security interest).
(c) significantly change the nature of your business as it is now conducted, or
(d) in the case of a Company or a limited Liability Partnership, allow any subsidiary to do any of the above,
5.2 you shall promptly provide the Bank with copies of any financial information that the Bank may from time to time reasonably request, including but not limited to
(a) copies of your financial statement within 180 days of the end of each financial year, and
(b) copies of your periodic management accounts at such intervals as the Bank may require in a form acceptable to the Bank within 30 days of the end of the period to which they relate. The Bank may at its option require such management accounts to Incorporate an age-analysis of debtors, a schedule of all tenancies (if any) of any property held by the Bank as security of the date of the accounts, and/or a breakdown of stock in trade,
5.3 you shall maintain with reputable underwriters or insurance companies adequate insurance on and over your business and the assets of your business, such insurance to be against such risks and to the extent usual for persons carrying on a business such as that carried on by you and, from time to time upon the request of the Bank, you shall furnish the Bank with evidence of such insurance,
5.4 if you have taken out a general insurance policy in connection with the loan, the Bank will hold any money the Bank receives in relation to the insurance including any claims payments paid to the Bank by the Insurer) in its capacity as a bank approved by the Financial Services Authority, rather than as a trustee for you (or in Scotland as an agent for you), and the Financial Services Authority’s client money rules do not apply to the money so held. Any insurance benefits the Bank receives from your insurance company, relating to the repayment of the loan, will be used towards paying off what you owe in this agreement,
5.5 if the ratio of the loan to the value of the security given to the Bank is of any time higher than that applicable on the data this agreement was signed by the Bank and unless any specific requirement is set out in any Additional Terms and Conditions added to this agreement (which requirement shall take precedence over this Clause) you agree promptly to -
(a) reduce the loan (in accordance with Clause 2 above including paying any early repayment charges if required under Section 2.6 of the Specific Terms and Conditions), or
(b) provide the Bank with additional security acceptable to the Bank, and
(c) provide such evidence as the Bank may from time to time require to confirm the value of such security and to confirm that the security remains effective.
The Bank may have the security given to it revalued at any time during the term of the loan where, for example, the Bank needs to meet any regulatory requirements or to check that the value continues to be adequate security for repayment of the loan. You will pay the cost incurred by the Bank (acting reasonably) for each revolution,
5.6 you shall confirm at all times with all applicable EU and national laws Including, but not limited to, environmental laws (as defined in Clause 7.16 below),


LOGO

4. General terms and conditions
continued
5.7 you shall, from time to time and upon reasonable notice given by the Bank
(following a request made by the European Investment Bank to the Bank), permit any person(s) appointed by the European Investment Bank or any person(s) with appropriate authority from the Court of Auditors at the European Commission to inspect all sites, installations and works used by you and connected in any way with the purposes specified In the Specific Terms and Conditions, the inspection being for the purpose of ascertaining whether you are using the loan exclusively for those purposes in accordance with the terms and conditions of this agreement, and you shall provide such persons with all necessary assistance and information for such an Inspection (the Bank reserves the right to appoint a person to accompany the person appointed by the European Investment Bank or authorised by the European Commission on such an Inspection), and
5.8 you shall deliver to the Bank such information as the European Investment Bank shall reasonably require concerning your activities and general financial position and you hereby agree that the Bank may disclose such information (including, but not limited to, the financial statement) to the European Investment Bank.
Default and Termination
6.1 The events listed in (a) to (i) of this Clause 6.1 are called “Events of Default”. As soon as an Event of Default happens or at any time thereafter, by giving notice to you, the Bank may cancel any obligations it has to lend money to you and may also make the loan become repayable on demand. When the loan is repayable on demand you must repay the loan to the Bank together with all interest which has accrued on the loan and any other amounts owing under or in connection with this agreement as soon as the Bank requests you to pay these amounts. However you will not be required to pay any early repayment charges under Section 2.6 of the Specific Terms and Conditions. The Bank may do this at the time the loan becomes repayable on demand or at any later time.
Events of Default
(a) you fail to pay when due any Indebtedness owed by you to the Bank,
(b) you fail to comply with any other obligation or undertaking to the Bank, or with the terms of this agreement or any other agreement with the Bank, or an event of default arises in connection with any other agreement with the Bank.
(c) you fail to pay when due any Indebtedness owed by you to another creditor or any of your creditors changes (or obtains the right to change) the original date on which that Indebtedness is or was due to be paid to an earlier date as a result of your failure to comply with obligations in connection with that indebtedness,
(d) any representation or statement made by you to the Bank, whether or not in connection with this agreement, proves to have been incorrect or inaccurate when made or deemed made,
(e) any guarantee, other security or other document or arrangement relied upon by the Bank in connection with the loan ceases to be continuing or ceases to remain fully effective or notice of discontinuance is received by the Bank or if the Bank reasonably believes that the effectiveness of any such document or arrangement is in doubt or if any provision of such document or arrangement is not compiled with for any reason or any favourable tax treatment afforded to any pension policy or to any life policy held by or charged to the Bank ceases to be available.
(f) in the case of a Company or a Limited liability Partnership:
(i) any person with a legal claim takes possession or a receiver, administrator, custodian, trustee, liquidator or similar official is appointed of the whole or any part of your business or of any of the assets of your business or an administration application is presented or made for the making of an administration order or a notice of intention to appoint an administrator is issued by you or your directors or (in the case of a Limited Liability Partnership) your members or by the holder of a qualifying floating charge or notice of appointment of on administrator is filed by any person with the court or a judgment, decree or diligence is made or granted against you.
(ii) proceedings are commenced or a petition is presented or an order is made or a resolution is passed for your winding up or you are or become insolvent.
(iii) you stop or threaten to stop payment of your debts generally or you are deemed by law unable to pay your debts or you or your directors or (in the case of a Limited Liability Partnership) your members convene or become obliged to convene a meeting of shareholders, members or creditors with a view to winding up or an application is made in connection with a moratorium or a proposal to creditors for a voluntary arrangement is made by you or you take any action (including entering negotiations) with a view to readjustment, rescheduling, forgiveness or deferral of any part of your indebtedness.
(iv) the persons who now control you cease to have such control, or
(v) any of the events set out in this Clause 6.1(f) occur in relation to any parent or subsidiary or any guarantor of or provider of security for the loan or, in the case of any individual that provides any guarantee or other security for the loan, a petition is presented for a bankruptcy of sequestration order against any such individual or any such individual dies or becomes incapable of managing his or her affairs by reason of mental disorder, or any action is taken in any jurisdiction which is similar or analogous to any of these events in respect of you or any of the aforementioned parties,
(g) in all other cases:
(i) any person with a legal claim takes possession or a receiver, administrator, judicial factor, interim trustee, trustee in sequestration or similar official is appointed of the whole or any part of your business or of any of your business assets or an application or a petition is presented or made for either an administration or a bankruptcy order against you or a judgment, decree or diligence is made or granted against you,
(ii) a petition is presented or an order is made for your winding up (if you are a partnership or you resolve either to cease trading or to wind up your business in any way or dissolve such business for any reason.
(iii) you stop or threaten to stop payment of your debts generally or you are deemed by law unable to pay your debts or an application is made in connection with a moratorium or a proposal to creditors for a voluntary arrangement by you or you take any action (including entering negotiations) with a view to readjustment, rescheduling, forgiveness or deferral of any part of your Indebtedness.
(iv) you die or become incapable of managing and administering your property and affairs by reason of mental disorder or (if you are a partnership) there is any change in the membership of the partnership, or
(v) any of the events set out in this Clause 6.1(g) occur to relation to any guarantor of or provider of security for the loan or any action is taken in any Jurisdiction which is similar or analogous to any of these events in respect of you or any guarantor of or provider of security.
(h) you cease or threaten to cease to carry on your business in the normal course or you fail to maintain or breach any franchise, license or right necessary to conduct your business or breach any legislation relating to your business, including but not limited to any applicable environmental protection laws.
(i) you fail or have failed to disclose to the Bank any important information that is relevant to the loan or the security required or you undertake or are subject to any action or occurrence which the Bank reasonably believes could place at risk the payment of any amount owing to the Bank, or
(j) you do not have a servicing account.
6.2 If any Event of Default happens or anything happens that might reasonably be expected to lead to an Event of Default, you shall inform the Bank immediately.
6.3 If any amount payable in respect of this agreement is not paid when due
including any amount payable under this Clause 6) we may require you to interest on that amount of the default rate from the date on which the amount was
due until it is paid to the Bank (whether before or after judgment. Interest, if unpaid, may be added to the amount in default at monthly intervals. The default rate shall be the rate determined by the Bank to be 3% per annum higher than the rate of interest specified in the Specific Terms and Conditions that would normally apply
6.4 You shall indemnify the Bank against any costs incurred or losses reasonably
sustained by the Bank as the result of any Event of Default happening or any failure by to pay any amount demanded by the Bank as a result of an Event of Default
6.5 You shall also pay any costs and expenses reasonably incurred by the Bank in enforcing or perfecting any security for the loan and in enforcing or preserving its rights under this agreement
Other
7.1 This agreement (and any non-contractual obligations arising out of or in connection with this agreement) shall be construed and have effect in accordance with the applicable law and is subject to the jurisdiction of the Courts in the jurisdiction of the applicable law. The applicable law will be the laws of England and Wales or the laws of Scotland; it will be the governing law of the country in which the branch or office of the Bank given at the heading of this agreement is situated on the date this agreement is signed by the Bank. The Bank may take action against you in any other jurisdiction where proceedings may be lawfully commenced.
7.2 No delay or omission by the Bank in exercising any of its rights hereunder shall
operate or be construed as a waiver, nor shall any single or partial exercise of any such right prevent any other or further exercise of any other right
7.3 If the loan is to be borrowed, or if any payment becomes due from you, on a day which is not a business day then the amount concerned will be borrowed or, as the case may be, will become payable on the next business day.
7.4 The Bank may use any credit balance there may be on any of your accounts held with the Bank towards payment of any amounts owed by you to the Bank under this agreement without notifying you beforehand, whether such credit balances are in sterling or any other currency or are deposited for fixed or determinable periods.
7.5 Unless otherwise agreed by the Bank you shall at all times during the term of this agreement keep a servicing account with the Bank and of amounts from time to time due to the Bank under this agreement may be debited to that account. The Bank recommends that you make sure you have enough funds to meet all such payments as they become due. If you do not maintain such an account until the Bank, the Bank may (without prejudice to its rights under Clause 6.1 above) add to your loan account any interest that is to be paid by you but which is not paid on the date it is due for payment. The Bank may charge interest an any amount so added to the loan account
7.6 Any security given to the Bank (whether given before the date on which this agreement is signed by the Bank or at any time in the future and whether or not specified in this agreement) shall, unless otherwise agreed by the Bank, be security not only for the loan but also for all other moneys and liabilities whether certain or contingent at any time due, owing or incurred by you to the Bank.


LOGO

4 General terms and conditions
continued
7.7 The Bank may sell, assign/ transfer, securitise or otherwise dispose of in any manner its rights or obligations under this agreement to any other person, or enter into transactions which have the effect of transferring the economic or credit risks and/or rewards of the Bank under this agreement with any other person.
You will promptly execute any documents that the Bank may reasonably require to give effect to any such assignment, assignation, transfer, securitisation or other disposal. You may not assign, transfer or otherwise dispose of any of your rights, obligations or benefits under this agreement.
7.8 In the event of, or in connection or contemplation of, a proposed sale.
assignment, securitisation, transfer or other disposal of risks and/or rewards of the loan (or part of it) or sale, assignment, transfer, securitisation or other disposed of any of the Bank’s rights under this agreement the Bank may disclose information about you, your finances and this agreement to any potential purchaser, assignee, transferee, counterparty to an agreement transferring risks and/or rewards, rating agencies, listing authorities, their and our advisers, or any other person to whom the Bank may deem it necessary to disclose such information to in relation to any proposed safe, securitisation, transfer, assignment or transfer of risks and/or rewards.
7.9 You consent to the Bank disclosing information about you, your finances and this agreement to any person providing any security for any of your obligations, and to them giving us information about you.
7.10 This agreement and all communications from you to the Bank in connection with this agreement and the loan (all of which are to be sent in writing to the Bank) shall, in the case of a Company or limited Liability Partnership, be signed on your behalf either in accordance with the mandate given by you to the Bank, or if requested by the Bank, in accordance with a specific resolution of your Board of Directors/Members, or in the case of a partnership, shall be signed by all partners unless otherwise agreed by the Bank, or in all other cases, shall be signed in accordance with the mandate given by you to the Bank.
7.11 Any change to this agreement other than the changes to be made by the Bank as provided in this agreement must be made in writing and be signed by the contracting parties.
7.12 If the loan is available to more than one person, each and every undertaking and liability of all of you under and in connection with this agreement shall be joint and several and references to you shall mean any one or more of you. Therefore each of you is jointly and separately responsible for complying with the terms and conditions of this agreement and for repaying all the liabilities under this agreement and not just a share of them. The Bank may take action against all or any one of you.
7.13 This Agreement is for the benefit of the contracting parties only and shall not confer any benefit on or be enforceable by a third party.
7.14 The Specific Terms and Conditions and General Terms and Conditions together with any Additional Terms and Conditions attached to this agreement shall be read and construed as one agreement
7.15 In this agreement the following terms shall have the following meanings: the “Bank” includes its successors and assigns.
“Base Rate” means the official bank rate from time to time of Bank of England (or any rate at any time replacing that rate) which will be displayed in the Bank’s branch where your account is held and on the Bank’s website, currently: www.Iloydstsb.com/business, and may be varied (either up or down) by the Bank of England at any time
a “business day” means a day other than a Saturday or a Sunday on which banks in the jurisdiction of the applicable law are open for normal business.
“control” shall have the meaning given to it in Section 840 of the income and Corporation Taxes Act 1988 or any amendment to or restatement of that Act for the time being in force.
“current account” means your main business current account with the Bank.
“environment” means the following, in so far as they affect human well-being
(a) fauna and flora, (b) soil, water, air, climate and the landscape, and (c) cultural heritage and the built environment
“environmental laws” means EU law and national laws and regulations as apply in the jurisdiction of the applicable law referred to in Clause 7.1 above, as well as applicable international treaties, of which a principal objective is the preservation, protection or improvement of the environment.
“financial statement” means at any particular time the latest balance sheet and profit and loss account of your business together with the notes to both. You must ensure they are audited or signed by an independent accountant if required by law or if reasonably required by the Bank. You must also ensure that, unless the Bank allows otherwise (the Bank will not unreasonably withhold or delay its permission), they are prepared on the same basis and (except to the extent necessary to reflect any changes in generally accepted accounting principles in accordance with the same accounting principles as the latest such balance sheet and profit and loss account received by the Bank prior to the date on which this agreement is signed by the Bank.
“loan” means, at any particular time, the total amount which may be borrowed by you under this agreement or, if appropriate, the total amount which has been debited to the loan account and remains outstanding of such time. The loan may, at any time, include any interest, costs and charges added to the loan account in accordance with this agreement.
“month” means a calendar month.
“parent” and “subsidiary” shall have respectively the meaning given to parent undertaking and subsidiary undertaking in Section 1162 of the Companies Act 2006 or any amendment to or restatement of that Act for the time being in force, During any period in which you do not have a subsidiary, all references to your subsidiaries shall be ignored and the relevant text read and construed accordingly
“servicing account” means an account through which the Bank channels your and the Bank’s payments under this agreement. You may use your current account with the Bank as your servicing account
“your business” shall include, in the case of a Company or a Limited Liability Partnership, the business of your subsidiaries.
7.16 The Bank will not be liable for any loss, damage. Interruption, delay or nonperformance in connection with this agreement to the extent that it is caused by events which are beyond the Bank’s reasonable control which may include for example explosion, terrorism, war, not or other civil disturbance or failure or interruption of any electronic communications system caused by someone else.
7.17 If you do not pay the Bank what you owe under this agreement and the Bank does not require you to pay interest on that amount at the default rate pursuant to Clause 6.3 above and the Bank obtains judgment against you in a court, the Bank may continue to charge interest on the judgment amount at the rate specified in Section 2.3 of the Specific Terms and Conditions of the agreement.
7.18 If any term or provision in this agreement shall in whole or in port be held to any extent to be invalid, void, illegal or unenforceable under any enactment or rule of law. That term or provision shall to that extent be deemed not to form part of this agreement and the enforceability of the remainder of this agreement shall not be affected
7.19 You may at any time substitute any property charged to the Bank with alternative property if the alternative property has a value at least equal to the value of the properly to be released. When the Bank is satisfied that the alternative security is fully effective, it will discharge the security being substituted.
Use of Principal Information and Credit, Fraud and Identification Checks
When you apply to open on account we will check our own records for information on individuals who are Key Account Parties. “Key Account Parties” are individuals who are sole traders, proprietors, partners, directors, members, beneficial owners, trustees or other controlling of the business or organisation including signatories to the account. We may also carry out a search through credit reference agencies on these individuals. The credit reference agencies will keep a record of this search and this record may be used by other organisations to verify their identities. We may also check or share information with fraud prevention agencies to prevent fraud and money laundering.
When you apply for credit and credit related or other facilities, we may carry out a search through credit reference agencies on you and/or Key Account Parties. The credit reference agencies will keep a record of this search whether or not the application proceeds. A record of the search on personal files will not be made available to other organisations. A record of the search on the business file will be made available to other organisations. We may also check or share information with fraud prevention agencies to prevent fraud and money laundering,
When you have an account with us, we may disclose how you have run your account(s) to credit reference agencies. If you borrow and do not repay in full and on time, we may tell the credit reference agencies. We may make periodic searches of the Lloyds Banking Group records and credit reference agencies to manage your account(s) including to make decisions whether to continue or extend existing credit. The Lloyds Banking Group includes us and a number of other companies using brands including Lloyds TSB, Halifax and Bank of Scotland, and their associated companies. More information on the Lloyds Banking Group can be found at www.lloydsbankinggroup.com. For these purposes “associated companies” includes Lloyds Banking Group plc and any subsidiary, affiliate or other firm directly or indirectly controlled from time to time by either Lloyds Banking Group plc or us
We may also check and share information with fraud prevention agencies to prevent fraud and money laundering.
If false or inaccurate information is provided or fraud is suspected, details may be passed to fraud prevention agencies and other relevant agencies.
If you or Key Account Parties ask, we will tell you or them which credit reference and fraud prevention agencies we have used so you or they can get a copy of your or their details from these agencies.
This is a condensed guide to the use of your personal and business information by us and at credit reference and fraud prevention agencies. If you would like to read full details of how data may be used, please visit our website at www.lloydstsb.com/commerial/customerdate or contact your relationship manager or relationship team.
[Only applicable if you are a sole trader or a partnership of two or three partners or an unincorporated body)
I am/We are* entering this agreement wholly or predominantly for the purposes of a business carried on by me/us* or intended to be carried on by me/us *
I/We* understand that I/we* will not have the benefit of the protection and remedies that would be available to me/us* under the Consumer Credit Act 1974 if this agreement were a regulated agreement under that Act.
I/We* understand that this declaration does not affect the powers of the court to make an order under section 140B of the Consumer Credit Act 1974 in relation to a credit agreement where it determines that the relationship between the creditor and the debtor is unfair to the debtor.
I am/We are* aware that, if I am/we are* in any doubt as to the consequences of the agreement not being regulated by the Consumer Credit Act 1974 I/we should seek independent legal advice.
*Delete as appropriate.


LOGO

6 Your acceptance
By signing and returning this agreement:
(a) you acknowledge having received, read and understood a copy of this agreement and agree to the Specific Terms and Conditions and to the General Terms and Conditions set out above and to the attached Additional Terms and Conditions form numbered
10412-0811
(together “the agreement”), you acknowledge that this agreement comprises all the terms currently applicable to the loan and that no representation made in good faith, warranty or undertaking has been made by the Bank in connection with the loan which is not set out in this agreement, and you acknowledge that in deciding to enter into this agreement and to proceed with any transaction or project for which the loan has been sought you have not received or relied upon any advice given by the Bank.
(b) (if you are a sole trader or a partnership of two or three partners or an unincorporated body), you also acknowledge that you have made a declaration for exemption relating to businesses as set out above.
This agreement creates legal obligations and therefore before signing we recommend that you consider getting independent advice. This may help you in understanding the potential consequences in the event that things go wrong.
For Company/Limited Liability Partnership
Signed for and on behalf of the customer by:
Director/name (delete as appropriate)
NIKIN PATEL
Signature
/s/ Nikin Patel
EMMA GAINFORD
Signature
/s/ Emma Gainford
Date 6 JANUARY 2012
Date 6-1-12
Pursuant to a Resolution of the board/members dated
This will be either the date of the account mandate, if an appropriate resolution is contained therein, or the date of a specific resolution passed in respect of this agreement.
For Sole Trader/Partnership (other than Limited Liability Partnership)
Signed by:
Signature
Date
Print name
Signature
Date
Print name
Signature
Date
Print name
Signature
Date
Print name
For bank use only
Manager/Authorised signatory
/s/ Leo Magee
Signed for and on behalf of the Bank by Manager/Authorised name
Date 6-1-12
Please contact your relationship team or branch if you’d like this in Braille, large print or on audio tape
www.lloydstsb.com/business
We accept calls made through RNID Typetalk. Calls may be monitored or recorded in case we need to check we have carried out your instructions correctly and to help improve our quality of service.
Lloyds TSB Commercial is a trading name of Lloyds TSB Bank plc and Lloyds TSB Scotland plc and serves customers with an annual turnover of up to £15M.
Lloyds TSB Bank plc Registered office: 25 Gresham Street, London EC2V 7HN. Registered in England and Wales no. 2065 Telephone: 020 7626 1500.
Lloyds TSB Scotland plc Registered office: Henry Duncan House, 120 George Street, Edinburgh EH2 4LH. Registered in Scotland no. 95237 Telephone: 0131 225 4555
Authorised and regulated by the Financial Services Authority under numbers 119278 and 191240 respectively. We subscribe to the Lending Code; copies of the Code can be obtained from www.lendingstandardsboard.org.uk.
12512 0211


Additional Terms and Conditions Financial Covenants    LOGO

Please contact your business team or branch if you’d like this in Braille, large print or on audio tape. We accept calls made through RNID Typetalk. Calls may be monitored or recorded in case we need to check we have carried out your instructions correctly and to help improve our quality of service.

When this document has been signed by x Lloyds TSB Bank plc              Lloyds TSB Scotland plc (the “ Bank ”) and Molecular Profiles Limited                      *carrying on business under the name of                      the terms and conditions below marked with an “X” will be added to the terms and conditions set out in the BUSINESS LOAN AGREEMENT which was signed by the Bank                      on (the Agreement ”). These Additional Terms and Conditions shall apply for as long as any moneys are owing to the Bank under the Agreement or the Bank is under any obligation under the Agreement.

The covenants will be tested at the frequency annotated below against (a) each financial statement, if the covenant is marked as being tested annually, and/or (b) against your management accounts or, if appropriate, against your tenancy schedules, if the covenant is marked as being tested monthly or quarterly. For the avoidance of doubt:

 

(a) you are required to provide the Bank with sufficient information to enable the Bank to test the covenants. This information is to be provided pursuant to the Agreement, and

 

(b) the covenants will be tested for the period of the accounts unless, in the case of a monthly or quarterly test, the covenant is also marked as being tested on a rolling 12 months. In this case, each test will be for the 12 month period ending on the test date.

 

              Frequency of Covenant testing
              Monthly    Quarterly    Annually    Rolling 12
months
  CFADS to debt service    CFADS is not at any time to be less than     % of the aggregate of the consolidated principal repayments and the consolidated interest paid and payable (whether to the Bank or to any other person) for the period covered by the accounts.    ¨    ¨    ¨    ¨
  EBITDA to debt service    EBITDA is not at any time to be less than     % of the aggregate of the consolidated principal repayments and the consolidated interest paid and payable (whether to the Bank or to any other person) for the period covered by the accounts.    ¨    ¨    ¨    ¨
  Minimum retained profit    Retained Profit of not less than £             is to be reported in each financial statement (commencing with the financial statement as at          ¨   
  Interest cover    Your consolidated Profit Before Taxation and interest paid and payable is not at any time to be less than     % of the consolidated interest paid and payable (whether to the Bank or to any other person) for the period covered by the accounts.    ¨    ¨    ¨    ¨
  Gross rental cover    The total Rental Income received by you from all Property is not at any time to be less than     % of the aggregate of the principal repayments and the interest paid and payable to the Bank for the period covered by the accounts.    ¨    ¨    ¨    ¨
  Minimum gross rent    The total rental income received by you from all Property is not for any year to be less than £                ¨    ¨    ¨    ¨
                   Frequency of Covenant testing
                   Monthly    Quarterly    Annually
x   Minimum net worth    Net Worth is at all times to be maintained at not less than £ 4,000,000    ¨    ¨    x
  Gearing    Borrowing is not at any time to exceed     % of Net Worth    ¨    ¨    ¨
  Good trade debtors cover    Good Book Debts (after taking into account any amounts ranking in priority to amounts owing to the Bank) are not at any time to be less than     % of your utilisation of all facilities provided to you by the Bank.    ¨    ¨    ¨
  Loan to value    The total amount owing to the Bank (whether certain or contingent) by you is not at any time to exceed the aggregate of     % of the latest valuation received by the Bank of all Property (after taking into account any amounts ranking in priority to amounts owing to the Bank)    ¨    ¨    ¨

 

* delete as appropriate


Definitions

Borrowing shall include all your (and, if you have any subsidiaries, all of your subsidiaries) borrowed moneys and all liabilities and indebtedness, whether or not then due, under acceptance credits and hire purchase, instalment credit, factoring, invoice discounting or similar agreements but excluding trade debts and liabilities for the payment of tax. If you are a company or a limited liability partnership. Borrowing shall exclude all loans from your directors or, as the case may be, members.

CFADS (Cash Flow available for Debt Service) means your consolidated Profit Before Taxation and interest paid and payable after adding back depreciation, amortisation of goodwill and other non-cash profit and loss items, plus or minus net movements in working capital, less tax paid, dividends paid and payable or, as the case may be, drawings made available and capital expenditure paid (net of capital expenditure funded by asset disposals and/or hire purchase and/or finance leasing).

EBITDA means your consolidated Profit Before Taxation, depreciation, amortisation of goodwill and of other intangibles and interest paid and payable (but after dividends paid and payable or, as the case may be, after drawings made available).

Good Book Debts means those debts due to you in the normal course of business (over which a charge or security interest has been given to the Bank in a form acceptable to the Bank) but excluding (a) any debts arising from the sale of goods acquired which remain subject to reservation of title, (b) any debts more than 3 months old or considered by you or your auditors (if appropriate) to be irrecoverable, (c) any contract debtors, and (d) any contra or intra-group debts.

Net Worth shall mean at any particular time:

(a) if you are a company or a limited liability partnership the aggregate of the amount paid up on your issued share capital (if you have any) and the consolidated distributable and non-distributable reserves of you and your subsidiaries but (i) after deducting the total of any debit balance on profit and loss account and the book value of goodwill and any other intangible assets, and (ii) excluding any minority interests in subsidiaries and any increase in the valuation of assets subsequent to the date of the financial statement, or

(b) if you are not a company or a limited liability partnership, the net aggregate of all credit balances (after deducting any debit balances) of your Capital Accounts (or the accounts similarly styled in the financial statement which, for the avoidance of doubt, shall not include any loan moneys) less the book value of goodwill and any other intangible assets, excluding any increase in the valuation of assets subsequent to the date of the financial statement but, at the discretion of the Bank, increased to include the amount of (i) any undrawn profits, and (ii) any taxation reserves

Profit After Taxation and Profit Before Taxation shall include items of an exceptional nature and shall exclude items of an extraordinary nature unless taken into account at the Bank’s discretion for the purpose of any relevant calculation.

Property means freehold and/or leasehold property (or, if in Scotland, heritable property owned or leased) over which a charge or security interest has been given to the Bank in a form acceptable to the Bank.

Rental Income means income derived from rents and service charges, excluding sums charged in respect of insurance premiums, any statutory charges and any intra-group rental income.

Retained Profit means your consolidated Profit After Taxation and dividends paid and payable (or, as the case may be, after drawings made available) and after deducting any profit attributable to minority interests in subsidiaries and after taking into account any items of an extraordinary nature and any items of an exceptional nature.

 

Note:   if you do not have any subsidiaries, references in these Additional Terms and Conditions to “subsidiaries” and to “consolidated” shall be ignored and the relevant text shall be read and construed accordingly.


This document creates legal obligations and therefore before signing we recommend that you consider getting independent advice. This may help you in understanding the potential consequences in the event that things go wrong.

 

For Sole Trader/Partnership (other than Limited Liability Partnership)      
Signed by        
Print name       Print name  
Signature       Signature  
Date       Date  
Print name       Print name  
Signature       Signature  
Date       Date  
Print name       Print name  
Signature       Signature  
Date       Date  
For Company / Limited Liability Partnership      
Signed for and on behalf of      
MOLECULAR PROFILES LTD      
by       and by  
Print name       Print name  
NIKIN PATEL     EMMA GAINFORD
Signature       Signature  
/s/ Nikin Patel     /s/ Emma Gainford
Date 6 JANUARY 2012     Date 6-1-12
*Director/Member/Authorised Signatory     *Authorised Signatory
Pursuant to a resolution of the board/members dated #      
      Date  
Signed for and on behalf of the Bank by      
*Manager/Authorised Signatory    

*  Delete as appropriate.

/s/ Leo Magee    

#  This will be either the date of the account mandate, if an appropriate resolution is contained therein or the date of a specific resolution passed in respect of the loan

Date        

Lloyds TSB Bank plc Registered Office 25 Gresham Street, London EC2V 7HN Registered in England and Wales, no 2065

Lloyds TSB Scotland plc Registered Office Henry Duncan House, 120 George Street, Edinburgh EH2 4LH Registered in Scotland, no 95237

Authorised and regulated by the Financial Services Authority under numbers 119278 and 191240 respectively

Licensed under the Consumer Credit Act 1974 under registration numbers 0004685 and 0198797 respectively.

10412-0811


LOGO

Business loan agreement
Variable rate only using funds from European Investment Bank Lloyds TSB
For lending unregulated under the Consumer Credit Act 1974 to Companies, Sole Traders and Partnerships (including Limited Liability Partnerships) carrying on business In England and Wales and/or Scotland
Guidance notes
Please write clearly in the white spaces with capital letters or cross the boxes. We aim to provide the highest level of customer service possible. However if you experience a problem we will always seek to resolve this as quickly and efficiently as possible.
Calls may be monitored or recorded in case we need to check we have carried out your instructions correctly and to help improve our quality of service. You can request a copy of our “How to voice your concerns” leaflet from your relationship team, business team or any branch. Our complaint procedures are also on our website www.lloydstsb.com
1 Customer details
We Branch/office name and address
Lloyds TSB Bank plc Lloyds TSB Scotland plc 3rd Floor, Old Market Square, Nottingham,
(the “Bank”) offer to you, the customer or customers referred to below, a loan on the following terms and conditions.
Postcode NG1 6FD
Where this agreement includes any optional wording (as noted by a box) the wording selected shall apply. Customer (other than Company or Limited Liability Partnership)
Customer’s full name(s)
Customer (If Company or Limited Liability Partnership)
Business name
Molecular Profiles Limited
Registered number
03397582
Business address Continue listing of partners’ names on a separate sheet If necessary
8 Orchard Place, Nottingham Business Park, Nottingham, Business trading name
Postcode NG8 6PX Business address
Postcode
2 Specific terms and conditions
Amount of the loan (excluding any amounts of interest that will be added to the loan if the agreement provides for this) £1,000,000 The proceeds of the loan are to be credited to: Account name and amount (if not the amount of the loan)
Purpose of the loan Molecular Profiles Limited
Construction of new office & laboratory (the Project)
Branch sort code
Account number
301898
01056523
Account name and amount (If not the amount of the loan)
The loan is to be borrowed in: One amount Several amounts
If borrowed in several amounts each is to be not less than £10,000 Branch sort code
Account number
although the last amount borrowed may be smaller.
The loan must be borrowed on or before: 30/12/2012
Unless the Bank agrees otherwise: a) no borrowing may be made until all the conditions mentioned in Clause 2.1 at the Specific Terms and Conditions have been satisfied, and b) you will not be entitled to borrow any amount which has not been borrowed by the agreed date


LOGO

2 Specific terms and conditions continued
2.1 Preconditions and security
Unless received by the Bank prior to the date on which this agreement is signed by the Bank, the Bank is to receive in form and substance acceptable to the Bank the security (if any) listed in the Security Schedule and the documents, evidence or other requirements of the preconditions (if any) set out in the Preconditions Schedule Any security received should be accompanied by such evidence as the Bank may reasonably require to confirm the value of such security and to confirm that such security is fully effective.
2.2 Fees and costs
You shall pay any costs and expenses incurred by the Bank in assessing the loan, in the preparation of this agreement, in the preparation, valuation, taking or release of any guarantee or security at any time given in connection with this agreement and in connection with the revaluation of any such security from time to time. The Bank will provide you with a written estimate of the amount of any such costs and expenses incurred by the Bank during the term of the loan before such costs are incurred Arrangement fee £ 10,000 Security costs £ Estimated Actual
The following charges shall be paid by you on demand by the Bank. These charges are to be paid even if the loan is not borrowed. If these charges include any estimated costs or fees, such costs or fees are based on the facts known to the Bank at the date the Bank signed this agreement. The actual amount charged to you in respect of these initial costs and expenses may be more or less than the figure(s) quoted. Valuation fee £ Estimated Actual
As mentioned in Clauses 2, 3 & 6 of the General Terms and Conditions and, if required by Section 2.6 of the Specific terms and Conditions, other costs may arise in connection with the loan.
2.3 Interest Base Rate plus 1.95 % per annum Base Rate is currently 0.50 % per annum
2.4 Payment of Interest
Please complete only one section Interest shall be:
The first interest payment date will be: After that interest will be paid by you: Monthly Quarterly
paid by you.
The first date interest will be added to the loan is After that interest will be added to the loan: Monthly Quarterly
added to the loan. paid by you until a certain date and then added to the loan.
The first interest payment date will be: The first date Interest will be added to the loan is:
one month after draw down 13 months after draw down
After that interest will be paid by you: Monthly Quarterly After that interest will be added to the loan. Monthly Quarterly
Interest will also be payable, or as the case may be, added to the loan on the date of final repayment of the loan. Interest for any particular period is calculated on the number of days in that period and a year of 365 days If you fail to pay any amount payable under this agreement when due the rate of interest may be increased in accordance with Clause 6.3 of the General Terms and Conditions.
Interest is calculated on a daily basis on the amount of the loan from time to time outstanding. The loan may include interest, costs and charges added to the loan account in accordance with the terms of this agreement.


LOGO

2 Specific terms and conditions continued
2.5 Repayment
Please cross the appropriate box(es) to indicate how the loan will be repaid.
The loan is repayable in: a single principal instalment on the payment date Repayment amount £
Repayment date consecutive instalments in respect of principal only on the dates and in the amounts set out in the Repayment Schedule. Any amount owing on the final repayment date is to be paid on that date. Number of instalments
Final repayment date consecutive instalments commencing on the first repayment date and ending on the final repayment date. Any amount owing on the final repayment date is to be paid on that date. first repayment date
Monthly Quarterly Semi-annually Repayment type (e.g. principal plus interest)
Repayment amount Number of instalments £
Final repayment date consecutive instalments of principal and interest commencing on the first repayment date and ending on the final repayment date The amounts will vary with changes in interest and the number of days in the charging period. First repayment date 13 months after draw down
Monthly Quarterly Number of instalments 168
Final repayment date
180 months after draw down consecutive instalments representing principal and interest if the interest on the loan is at any time to be calculated with reference to Base Rate you should note that variations in such rate after the date on which this agreement is signed by the Bank may affect either or both of the instalment amount and the term of the loan. Please see Clause 2.3 of the General Terms and Conditions for further details. At the date on which this agreement is signed by the Bank it is expected that final repayment of the loan will be made by the final repayment date. First repayment date Monthly Quarterly Repayment amount £
Number of instalment
Final repayment date
2.6 Early repayment charges
Is an early repayment charge payable? Yes No (For loans with a term of 5 years or less from the date the loan is first borrowed) On the date of each early repayment, you shall pay to the Bank an early repayment charge equal to 1% of the amount then being repaid
(For loans with a term of over 5 years from the date the loan is first borrowed) On the date of each early repayment made on or before the date which is 5 years after the date the loan is first borrowed, you shall pay to the Bank an early repayment charge equal to 1% of the amount then being repaid.
2.7 Period of offer
This agreement shall come into effect only if the Bank receives from you and finds in order to signed copy of this agreement on or before: Date
03/02/2012


LOGO

3 The schedules
Preconditions Schedule
The Bank has received in form and substance acceptable to it a full appraisal of the Project, including a detailed cashflow of the projected cost. The appraisal is to be prepared by a party acceptable to the Bank and is to show no issues of concern to the Bank.
The Bank has received your written instruction for the loan monies to be placed in an account with the Bank and between the following parties: Molecular Profiles Limited, Nominated Signatory from Three Sixty Project Management Limited and a Representative of the Quantity Surveyor (to be) nominated on behalf of Wilson Bowden.
The Bank has received such evidence as it may require to confirm that no less than £500,000 of your own moneys to be spent towards the Project has been placed into an account with the Bank and between the fallowing parties: Molecular Profiles Limited, Nominated Signatory from Three Sixty Project Management Limited and a Representative of the Quantity Surveyor (to be) nominated on behalf of Wilson Bowden.
Security Schedule
An unlimited debenture from Molecular Profiles Limited, and
A first legal charge from Molecular Profiles Limited over the freehold land and buildings at 8 Orchard Place, Nottingham Business Park, Nottingham, NG8 6PX.
Repayment Schedule
Date Amount Date Amount


LOGO

4 General terms and conditions
Use of Loan Proceeds
1.1 You confirm that you will use the loan exclusively for the purposes specified in the Specific Terms and Conditions.
Payment
2.1 You will repay the loan on the dates, and in the manner set out in the Specific Terms and Conditions. If the full amount of the loan is not borrowed the amounts of the instalments detailed will reduce accordingly.
2.2 You may at any time after giving at least 5 business days’ notice to the Bank repay the whole or part of the loan early. Unless the whole loan is repaid, each early repayment must be of at least £2000 You cannot redraw any amount you have paid off Where part of the loan is repaid early, the Bank will decide how to apply the early repayment, either by
(a) reducing subsequent repayments proportionately, or
(b) applying the early repayment to the then latest scheduled repayment instalments so as to reduce the term of the loan
2.3 If the repayment details set out in the Specific Terms and Conditions make specific reference to this clause
(a) the Bank may (but is under no obligation) at any time after giving you at least 30 days’ written notice vary the repayment instalment amount to reflect any change in the rate of interest applicable to the loan, and
(b) the Bank may, if changes in the rate of interest applicable to the loan are not taken into account by variations in the repayment instalment amount or if for any reason any amount remains owing to the Bank on the anticipated final repayment date, require you to continue the repayment instalments as set out in the Specific Terms and Conditions until such time as all amounts owing under and in connection with this agreement have been repaid in full
2.4 Where the amount of the loan specified in Section 2 of the Specific Terms and Conditions does not exceed £25,000, the requirement to give at least 5 business days’ notice to the Bank to make early repayment of all or any part of the loan and the minimum amount in respect thereof of £2,000, each as set out in Clause 2.2 above, shall not apply.
2.5 Without prejudice to the Bank’s rights expressed in Clause 6.1 of the General Terms and Conditions, If you fail to pay an instalment in full and on time, and any part of that amount has not been paid by the time the Bank calculates your next instalment amount, the Bank may (at its discretion):
(a) increase the amount of that next instalment and each of your remaining regular instalments proportionally to ensure that the full balance of the loan is repaid within the agreed term;
(b) extend the term of the loan; or
(c) increase the amount of your final instalment.
2.6 The Bank will apply any payments it receives from you against any interest before any other amounts on your account, including the outstanding principal of the loan. This will not apply to payments made specifically for fees and/or charges or where the Bank collects the interest and principal that make up your repayment from separate accounts.
2.7 All payments to be made by you shall be calculated and be made without (and free and clear of any deduction for) set-off or counterclaim
Increased Costs and Changes in Circumstances
3.1 In running its business the Bank and any holding company of the Bank each has to comply with certain regulations and requirements laid down by regulatory and other official organisations or bodies as well as the law generally. The rate of interest quoted in the Specific Terms and Conditions has been set in the light of how this affects the cost (to the Bank and any such holding company) of the Bank funding, agreeing to make or of making the loan available at the time the Bank signed this agreement. If, as a result of any new laws, regulations or requirements or any changes in existing ones, such cost is increased the Bank may increase the rate of interest charged on the loan to compensate for that extra cost. The Bank will advise you in writing within 30 days of such increase taking effect
3.2 The Base Rate may change from time to time, if so, the Bank will tell you about the change by putting notices in a selection of national newspapers, and its branches within three business days of the change. The Bank will also update its website and interest rate helpline within three business days of a Base Rate change taking effect
3.3 (a) The Bank can change any term of this agreement at any time
(i) if the change is to your advantage;
(ii) to reflect changes in law, codes of practice which apply to the Bank or the way the Bank is regulated, or
(iii) to reflect any changes the Bank makes to its systems or processes
(b) If Clause 3.3(a) above permits the Bank to make any change, the Bank will tell you personally at least 30 days before the Bank makes a change to your disadvantage (other than a change to the Base Rate, which will be made in accordance with Clause 3.2 above). If you close or change your account within 60 days of the Bank telling you about this change and repay the outstanding balance, the Bank will not charge you extra to do so and you will not be required to pay any early repayment charges under Section 2. 6 of the Specific Terms and Conditions
(c) The Bank can make any other changes straight away by telling you personally or by putting notices in a selection of national newspapers, in its branches or on its website within the next 30 days
(d) When the Bank tells you personally about a change it will do so by letter, email, text, statement inserts or messages or in any other way which is sent to you individually.
Representations
4.1 You represent that
(a) all action required or necessary to authorise the execution of this agreement and the performance of your obligations under and in connection with this agreement has been taken and neither the execution of this agreement nor the performance of your obligations will constitute or result in any breach of any agreement, law, requirement or regulation,
(b) no material litigation, administrative or judicial proceedings are presently pending or threatened against you or your business or on your ability to meet your obligations under or in connection with this agreement or any security document given in connection with this agreement,
(c) there has been no material adverse change in the financial condition of your business since the date of the financial statement received by the Bank prior to the date on which this agreement is signed by the Bank, and
(d) no Event of Default (as described in Clause 6.1 below) has occurred and is continuing or will occur as the result of a borrowing under this agreement and no circumstance has occurred which, with the giving of notice or the passing of time, could become or cause an Event of Default
4.2 You shall be deemed to repeat the above representations on each day (with reference to the facts and circumstances then existing) prior to borrowing the loan and thereafter until all amounts payable to the Bank under this agreement have been paid.
Undertakings
Prior to drawdown of the loan and thereafter until all amounts payable to the Bank under this agreement have been paid:
5.1 you shall not:
(a) without the Bank’s consent create or allow to be in place any mortgage, charge or other security interest or encumbrance over the whole or any part of your business or any of the property, income or other assets of your business or enter into any transaction which in the Bank’s opinion has a similar effect, or factor or assign any debts.
(b) sell, lease or otherwise dispose or attempt to dispose of the whole or any part of your business or any of the property, income or other assets of your business other than for a full and fair value (save that no such sale, lease or other disposal may be made or entered into (i) if it would breach the terms of any security document given to the Bank, or (ii) in respect of any undertaking, property, revenue or asset over which the Bank then has a fixed charge or fixed security interest),
(c) significantly change the nature of your business as it is now conducted, or
(d) in the case of a Company or a Limited Liability Partnership, allow any subsidiary to do any of the above,
5.2 you shall promptly provide the Bank with copies of any financial information that the Bank may from time to time reasonably request, including but not limited to:
(a) copies of your financial statement within 180 days of the end of each financial year, and
(b) copies of your periodic management accounts at such intervals as the Bank may require in a form acceptable to the Bank within 30 days of the end of the period to which they relate. The Bank may at its option require such management accounts to incorporate on age-analysis of debtors, a schedule of all tenancies (if any) of any property held by the Bank as security at the date of the accounts, and/or a breakdown of stock in trade.
5.3 you shall maintain with reputable underwriters or insurance companies adequate Insurance on and over your business and the assets of your business, such insurance to be against such risks and to the extent usual for persons carrying on a business such as that carried on by you and, from time to time upon the request of the Bank, you shall furnish the Bank with evidence of such insurance.
5.4 if you have taken out a general insurance policy in connection with the loan, the Bank will hold any money the Bank receives in relation to the Insurance (including any claims payments paid to the Bank by the Insurer) in its capacity as a bank approved by the Financial Services Authority, rather than as a trustee for you (or in Scotland as an agent for you), and the Financial Services Authority’s client money rules do not apply to the money so held. Any insurance benefits the Bank receives from your insurance company, relating to the repayment of the loan, will be used towards paying off what you owe in this agreement,
5.5 if the ratio of the loan to the value of the security given to the Bank is at any time higher than that applicable on the date this agreement was signed by the Bank and unless any specific requirement is set out in any Additional Terms and Conditions added to this agreement (which requirement shall take precedence over this Cause) you agree promptly to -
(a) reduce the loan (in accordance with Clause 2 above including paying any early repayment charges if required under Section 2.6 of the Specific Terms and Conditions), or
(b) provide the Bank with additional security acceptable to the Bank, and
(c) provide such evidence as the Bank may from time to time require to confirm the value of such security and to confirm that the security remains effective
The Bank may have the security given to it revalued at any time during the term of the loan where, for example, the Bank needs to meet any regulatory requirements or to check that the value continues to be adequate security for repayment of the loan. You will pay the cost incurred by the Bank (acting reasonably) for each revaluation,
5.6 you shall conform at all times with all applicable EU and national laws including, but not limited to, environmental laws (as defined in Clause 7.16 below).


LOGO

4 General terms and conditions continued
5.7 you shall, from time to time and upon reasonable notice given by the Bank
(following a request made by the European Investment Bank to the Bank), permit any person(s) appointed by the European Investment Bank or any person(s) with appropriate authority from the Court of Auditors at the European Commission to inspect all sites, installations and works used by you and connected in any way with the purposes specified in the Specific Terms and Conditions, the inspection being for the purpose of ascertaining whether you are using the loan exclusively for those purposes in accordance with the terms and conditions of this agreement, and you shall provide such persons with all necessary assistance and information for such an inspection (the Bank reserves the right to appoint a person to accompany the person appointed by the European Investment Bank or authorised by the European Commission on such an inspection), and
5.8 you shall deliver to the Bank such information as the European Investment Bank shall reasonably require concerning your activities and general financial position and you hereby agree that the Bank may disclose such information (including, but not limited to, the financial statement) to the European Investment Bank
Default and Termination
6.1 The events listed in (a) to (j) of this Clause 6.1 are called “Events of Default” As soon as an Event of Default happens or at any time thereafter, by giving notice to you, the Bank may cancel any obligations it has to lend money to you and may also make the loan become repayable on demand. When the loan is repayable on demand, you must repay the loan to the Bank together with all interest which has accrued on the loan and any other amounts owing under or in connection with this agreement as soon as the Bank requests you to pay these amounts. However you will not be required to pay any early repayment charges under Section 2.6 of the Specific “ Terms and Conditions. The Bank may do this at the time the loan becomes repayable on demand or at any later time.
Events of Default
(a) you fail to pay when due any indebtedness owed by you to the Bank,
(b) you fail to comply with any other obligation or undertaking to the Bank, or with the terms of this agreement or any other agreement with the Bank, or an event of default arises in connection with any other agreement with the Bank,
(c) you fail to pay when due any indebtedness owed by you to another creditor or any of your creditors changes (or obtains the right to change) the original date on which that indebtedness is or was due to be paid to an earlier date as a result of your failure to comply with obligations in connection with that indebtedness,
(d) any representation or statement made by you to the Bank, whether or not in connection with this agreement, proves to have been incorrect or inaccurate when made or deemed made,
(e) any guarantee, other security or other document or arrangement relied upon by the Bank in connection with the loan ceases to be continuing or ceases to remain fully effective or notice of discontinuance is received by the Bank or if the Bank reasonably believes that the effectiveness of any such document or arrangement is in doubt or if any provision of such document or arrangement is not complied with for any reason or any favourable tax treatment afforded to any pension policy or to any life policy held by or charged to the Bank ceases to be available,
(f) in the case of a Company or a Limited Liability Partnership
(i) any person with a legal claim takes possession or a receiver, administrator, custodian, trustee, liquidator or similar official is appointed of the whole or any part of your business or of any of the assets of your business or an administration application is presented or made for the making of an administration order or a notice of intention to appoint an administrator is issued by you or your directors or (in the case of a Limited Liability Partnership) your members or by the holder of a qualifying floating charge or notice of appointment of an administrator is filed by any person with the court or a judgment, decree or diligence is made or granted against you,
(ii) proceedings are commenced or a petition is presented or an order is made or a resolution is passed for your winding up or you are or become insolvent,
(iii) you stop or threaten to stop payment of your debts generally or you are deemed by law unable to pay your debts or you or your directors or (in the case of a Limited Liability Partnership) your members convene or become obliged to convene a meeting of shareholders, members or creditors with a view to winding up or an application is made in connection with a moratorium or a proposal to creditors for a voluntary arrangement is made by you or you take any action (including entering negotiations) with a view to readjustment, rescheduling, forgiveness or deferral of any part of your indebtedness,
(iv) the persons who now control you cease to have such control, or
(v) any of the events set out in this Clause 6.1(f) occur in relation to any parent or subsidiary or any guarantor of or provider of security for the loan or, in the case of any individual that provides any guarantee or other security for the loan, a petition is presented for a bankruptcy or sequestration order against any such individual or any such individual dies or becomes incapable of managing his or her affairs by reason of mental disorder, or any action is taken in any jurisdiction which is similar or analogous to any of these events in respect of you or any of the aforementioned parties,
(g) in all other cases
(i) any person with a legal claim takes possession or a receiver, administrator, judicial factor, interim trustee, trustee in sequestration or similar official is appointed of the whole or any part of your business or of any of your business assets or an application or a petition is presented or made for either an administration or a bankruptcy order against you or a judgment, decree or diligence is made or granted against you,
(ii) a petition is presented or an order is made for your winding up (if you are a partnership) or you resolve either to cease trading or to wind up your business in any way or dissolve such business for any reason,
(iii) you stop or threaten to stop payment of your debts generally or you are deemed by law unable to pay your debts or on application is made in connection with a moratorium or a proposal to creditors for a voluntary arrangement by you or you take any action (including entering negotiations) with a view to readjustment, rescheduling, forgiveness or deferral of any part of your indebtedness,
(iv) you die or become incapable of managing and administering your property and affairs by reason of mental disorder or (if you are a partnership) there is any change in the membership of the partnership, or
(v) any of the events set out in this Clause 6.1(g) occur in relation to any guarantor of or provider of security for the loan or any action is taken in any jurisdiction which is similar or analogous to any of these events in respect of you or any guarantor of or provider of security,
(h) you cease or threaten to cease to carry on your business in the normal course or you fail to maintain or breach any franchise, license or right necessary to conduct your business or breach any legislation relating to your business, including but not limited to any applicable environmental protection laws,
(i) you fail or have failed to disclose to the Bank any important information that is relevant to the loan or the security required or you undertake or are subject to any action or occurrence which the Bank reasonably believes could place at risk the payment of any amount owing to the Bank, or
(j) you do not have a servicing account.
6.2 If any Event of Default happens or anything happens that might reasonably be expected to lead to an Event of Default, you shall inform the Bank immediately.
6.3 If any amount payable in respect of this agreement is not paid when due (including any amount payable under this Clause 6) we may require you to pay interest on that amount at the default rate from the date on which the amount was due until it is paid to the Bank (whether before or after judgment), interest, if unpaid, may be added to the amount in default at monthly intervals. The default rate shall be the rate determined by the Bank to be 3% per annum higher than the rate of interest specified in the Specific Terms and Conditions that would normally apply.
6.4 You shall indemnify the Bank against any costs incurred or losses reasonably sustained by the Bank as the result of any Event of Default happening or any failure by you to pay any amount demanded by the Bank as a result of an Event of Default,
6.5 You shall also pay any costs and expenses reasonably incurred by the Bank in enforcing or perfecting any security for the loan and in enforcing or preserving its rights under this agreement
Other
7.1 This agreement (and any non-contractual obligations arising out of or in connection with this agreement) shall be construed and have effect in accordance with the applicable law and is subject to the jurisdiction of the Courts in the jurisdiction of the applicable law. The applicable law will be the laws of England and Wales or the laws of Scotland; It will be the governing law of the country in which the branch or office of the Bank given at the heading of this agreement is situated on the date this agreement is signed by the Bank. The Bank may take action against you in any other jurisdiction where proceedings may be lawfully commenced
7.2 No delay or omission by the Bank in exercising any of its rights hereunder shall operate or be construed as a waiver, nor shall any single or partial exercise of any such right prevent any other or further exercise of any other right
7.3 if the loan is to be borrowed, or if any payment becomes due from you, on a day which is not a business day then the amount concerned will be borrowed or, as the case may be will become payable on the next business day.
7.4 The Bank may use any credit balance there may be on any of your accounts held with the Bank towards payment of any amounts owed by you to the Bank under this agreement without notifying you beforehand, whether such credit balances are in sterling or any other currency or are deposited for feud or determinable periods.
7.5 Unless otherwise agreed by the Bank you shall at all times during the term of this agreement keep a servicing account with the Bank and all amounts from time to time due to the Bank under this agreement may be debited to that account. The Bank recommends that you make sure you have enough funds to meet all such payments as they become due if you do not maintain such an account with the Bank, the Bank may (without prejudice to its rights under Clause 6.1 above) add to your loan account any interest that is to be paid by you but which is not paid on the date it is due for payment. The Bank may charge interest on any amount so added to the loan account.
7.6 Any security given to the Bank [whether given before the date on which this agreement is signed by the Bank or at any time in the future and whether or not specified in this agreement] shall, unless otherwise agreed by the Bank, be security not only for the loan but also for all other moneys and liabilities whether certain or contingent at any time due, owing or incurred by you to the Bank.


LOGO

4 General terms and conditions continued
7.7 The Bank may sell, assign, transfer, securitise or otherwise dispose of in any manner its rights or obligations under this agreement to any other person, or enter into transactions which have the effect of transferring the economic or credit risks and/or rewards of the Bank under this agreement with any other person.
You will promptly execute any documents that the Bank may reasonably require to give effect to any such assignment, assignation, transfer, securitisation or other disposal. You may not assign, transfer or otherwise dispose of any of your rights, obligations or benefits under this agreement
7.8 In the event of, or in connection or contemplation of, a proposed sole, assignment, securitisation, transfer or other disposal of risks and/or rewards of the loan (or part of it) or sale, assignment, transfer, securitisation or other disposal of any of the Bank’s rights under this agreement the Bank may disclose information about you, your finances and this agreement to any potential purchaser, assignee, transferee, counterparty to an agreement transferring risks and/or rewards, rating agencies, listing authorities, their and our advisers, or any other person to whom the Bank may deem it necessary to disclose such information to in relation to any proposed sale, securitisation, transfer, assignment or transfer of risks and/or rewards.
7.9 You consent to the Bank disclosing Information about you, your finances and this agreement to any person providing any security for any of your obligations, and to them giving us information about you.
7.10 This agreement and all communications from you to the Bank. In connection with this agreement and the loan (all of which are to be sent in writing to the Bank) shall, in the case of a Company or Limited Liability Partnership, be signed on your behalf either in accordance with the mandate given by you to the Bank, or if requested by the Bank, in accordance with a specific resolution of your Board of Directors/Members, or in the case of a partnership, shall be signed by all partners unless otherwise agreed by the Bank, or in all other cases, shall be signed in accordance with the mandate given by you to the Bank
7.11 Any change to this agreement other than the changes to be made by the Bank as provided In this agreement must be made in writing and be signed by the contracting parties
7.12 If the loan is available to more than one person, each and every undertaking and liability of all of you under and in connection with this agreement shall be joint and several and references to you shall mean any one or more of you. Therefore each of you is jointly and separately responsible for complying with the terms and conditions of this agreement and for repaying all the liabilities under this agreement and not just a share of them. The Bank may take action against all or any one of you.
7.13 This agreement is for the benefit of the contracting parties only and shall not confer any benefit on or be enforceable by a third party
7.14 The Specific Terms and Conditions and General Terms and Conditions together with any Additional Terms and Conditions attached to this agreement shall be read and construed as one agreement.
7.15 In this agreement the following terms shall have the following meanings:
the “Bank” includes its successors and assigns
“Base Rate” means the official bank rate from time to time of Bank of England (or any rate at any time replacing that rate) which will be displayed in the Bank’s branch where your account is held and on the Bank’s website, currently www.lloydstsb.com/business, and may be varied (either up or down) by the Bank of England at any time.
a “business day” means a day other than a Saturday or a Sunday on which banks in the jurisdiction of the applicable law are open for normal business.
“control” shall have the meaning given to it in Section 840 of the Income and Corporation Taxes Act 1988 or any amendment to or restatement of that Act for the time being in force.
“current account” means your main business current account with the Bank.
“environment” means the following, in so far as they affect human well-being
(a) fauna and flora; (b) soil, water, air, climate and the landscape, and (c) cultural heritage and the built environment.
“environmental laws” means EU law and national laws and regulations as apply in the jurisdiction of the applicable law referred to in Clause 7.1 above, as well as applicable international treaties, of which a principal objective is the preservation, protection or improvement of the environment
“financial statement” means at any particular time the latest balance sheet and profit and loss account of your business together with the notes to both. You must ensure they are audited or signed by an independent accountant if required by law or if reasonably required by the Bank. You must also ensure that, unless the Bank allows otherwise (the Bank will not unreasonably withhold or delay its permission), they are prepared on the same basis and (except to the extent necessary to reflect any changes in generally accepted accounting principles) in accordance with the same accounting principles as the latest such balance sheet and profit and loss account received by the Bank prior to the date on which this agreement is signed by the Bank
“loan” means, at any particular time, the total amount which may be borrowed by you under this agreement or, if appropriate, the total amount which has been debited to the loan account and remains outstanding at such time. The loan may, at any time, include any interest, costs and charges added to the loan account in accordance with this agreement
“month” means a calendar month
“parent” and “subsidiary” shall have respectively the meaning given to parent undertaking and subsidiary undertaking in Section 1162 of the Companies Act 2006 or any amendment to or restatement of that Act for the time being in force. During any period in which you do not have a subsidiary, all references to your subsidiaries shall be ignored and the relevant text read and construed accordingly.
“servicing account” means an account through which the Bank channels your and the Bank’s payments under this agreement. You may use your current account with the Bank as your servicing account.
“your business” shall include, in the case of a Company or a Limited Liability
Partnership, the business of your subsidiaries.
7.16 The Bank will not be liable for any loss, damage, interruption, delay or non-performance in connection with this agreement to the extent that it is caused by events which are beyond the Bank’s reasonable control which may include for example explosion, terrorism, war, riot or other civil disturbance or failure or interruption of any electronic communications system caused by someone else.
7.17 If you do not pay the Bank what you owe under this agreement and the Bank does not require you to pay interest on that amount at the default rate pursuant to Clause 6.3 above and the Bank obtains judgment against you in a court, the Bank may continue to charge interest on the judgment amount at the rate specified in Section 2.3 of the Specific Terms and Conditions of this agreement
7.18 If any term or provision in this agreement shall in whole or in part be held to any extent to be invalid, void, illegal or unenforceable under any enactment or rule of law, that term or provision shall to that extent be deemed not to form part of this agreement and the enforceability of the remainder of this agreement shall not be affected.
7.19 You may at any time substitute any property charged to the Bank with alternative property if the alternative property has a value at least equal to the value of the property to be released. When the Bank is satisfied that the alternative security is fully effective, it will discharge the security being substituted.
Use of Personal Information and Credit, Fraud and Identification Checks
When you apply to open an account, we will check our own records for information on Individuals who are Key Account Parties. “Key Account Parties” are Individuals who are sole traders, proprietors, partners, directors, members, beneficial owners, trustees or other controlling officials of the business or organisation including signatories to the account. We may also carry out a search through credit reference agencies on these Individuals. The credit reference agencies will keep a record of this search and this record may be used by other organisations to verify their Identities. We may also check or share information with fraud prevention agencies to prevent fraud and money laundering.
When you apply for credit and credit related or other facilities, we may carry out a search through credit reference agencies on you and/or Key Account Parties. The credit reference agencies will keep a record of this search whether or not the application proceeds. A record of the search on personal files will not be made available to other organisations. A record of the search on the business file will be made available to other organisations. We may also check or share information with fraud prevention agencies to prevent fraud and money laundering.
When you have an account with us, we may disclose how you have run your account(s) to credit reference agencies. If you borrow and do not repay in full and on time, we may tell the credit reference agencies. We may make periodic searches of the Lloyds Banking Group records and credit reference agencies to manage your account(s) including to make decisions whether to continue or extend existing credit. The Lloyds Banking Group includes us and a number of other companies using brands including Lloyds TSB, Halifax and Bank of Scotland, and their associated companies. More information on the Lloyds Banking Group can be found at www.lloydsbankinggroup.com. For these purposes “associated companies” includes Lloyds Banking Group plc and any subsidiary, affiliate or other firm directly or indirectly controlled from time to time by either Lloyds Banking Group plc or us.
We may also check and share information with fraud prevention agencies to prevent fraud and money laundering.
If false or inaccurate information is provided or fraud is suspected, details may be passed to fraud prevention agencies and other relevant agencies.
If you or Key Account Parties ask, we will tell you or them which credit reference and fraud prevention agencies we have used so you or they can get a copy of your or their details from these agencies.
This is a condensed guide to the use of your personal and business information by us and at credit reference and fraud prevention agencies. If you would like to read full details of how data may be used, please visit our website at www.lloydstsb.com/commercial/customerdata or contact your relationship manager or relationship team.
5. Declaration for exemption relating to business (sections 16B and 189(1) and (2) Consumer Credit Act 1974)
(Only applicable if you are a sole trader or a partnership of two or three partners or an unincorporated body)
I am/We are* entering this agreement wholly or predominantly for the purposes of a business carried on by me/us* or intended to be carried on by me/us.*
I/We* understand that I/we* will not have the benefit of the protection and remedies that would be available to me/us* under the Consumer Credit Act 1974 if this agreement were a regulated agreement under that Act.
I/We* understand that this declaration does not affect the powers of the court to make an order under section 1408 of the Consumer Credit Act 1974 in relation to a credit agreement where it determines that the relationship between the creditor and the debtor is unfair to the debtor.
I am/We are* aware that, if I am/we are* in any doubt as to the consequences of the agreement not being regulated by the Consumer Credit Act 1974 I/We should seek independent legal advice.
*Delete as appropriate.


LOGO

6 Your acceptance
By signing and returning this agreement:
(a) you acknowledge having received, read and understood a copy of this agreement and agree to the Specific Terms and Conditions and to the General Terms and Conditions set out above and to the attached Additional Terms and Conditions form numbered
10412-0811
(together “the agreement”), you acknowledge that this agreement comprises all the terms currently applicable to the loan and that no representation made in good faith, warranty or undertaking has been made by the Bank in connection with the loan which is not set out in this agreement, and you acknowledge that in deciding to enter into this agreement and to proceed with any transaction or project for which the loan has been sought you have not received or relied upon any advice given by the Bank.
(b) (If you are a sole trader or a partnership of two or three partners or an unincorporated body), you also acknowledge that you have made a declaration for exemption relating to businesses as set out above.
This agreement creates legal obligations and therefore before signing we recommend that you consider getting independent advice. This may help you in understanding the potential consequences in the event that things go wrong.
For Company/Limited Liability Partnership
Signed for and on behalf of the customer by:
Director/ name (delete as appropriate) /Authorised signatory name (delete as appropriate)
NIKIN PATEL EMMA GAINFORD
Signature Signature
/s/ Nikin Patel /s/ Emma Gainford
Date 6 JANUARY 2012 Date 6.1.12
Pursuant to a Resolution of the board/members dated
This will be either the date of the account mandate, if an appropriate resolution is contained
therein, or the date of a specific resolution passed in respect of this agreement
For Sale Trader/Partnership (other than Limited Liability Partnership)
Signed by
Signature Signature
Date Date
Print name Print name
Signature Signature
Date Date
Print name Print name
For bank use only Manager/Authorised signatory
Signed for and on behalf of the Bank by: Manager/Authorised name /s/ Leo Magee
Date 6.1.12
Please contact your relationship team or branch if you’d like this in Braille, large print or on audio tape www.lloydstsb.com/business
We accept calls made through RND Typetalk. Calls may be monitored or recorded in case we need to check we have carried out your instructions correctly and to help improve our quality of service
Lloyds TSB Commercial is a trading name of Lloyds TSB Bank plc and Lloyds TSB Scotland plc and serves customers with an annual turnover of up to £15M.
Lloyds TSB Bank plc Registered office 25 Gresham Street, London EC2V 7HN. Registered in England and Wales no. 2065 Telephone 020 7626 1500.
Lloyds TSB Scotland plc Registered office: Henry Duncan House, 120 George Street, Edinburgh EH2 4LH. Registered in Scotland no. 95237 Telephone 0131 225 4555
Authorised and regulated by the financial Services Authority under numbers 119278 and 191240 respectively.
We subscribe to The Lending Code, copies of the Code can be obtained from www.lendingstandardsboard.org.uk 12512 0211


Additional Terms and Conditions Financial Covenants   LOGO

Please contact your business team or branch if you’d like this in Braille, large print or on audio tape. We accept calls made through RNID Typetalk. Calls may be monitored or recorded in case we need to check we have carried out your instructions correctly and to help improve our quality of service.

When this document has been signed by x Lloyds TSB Bank plc              Lloyds TSB Scotland plc (the “ Bank ”) and Molecular Profiles Limited                      *carrying on business under the name of                      the terms and conditions below marked with an “X” will be added to the terms and conditions set out in the BUSINESS LOAN AGREEMENT which was signed by the Bank                      on                      (the “ Agreement ”). These Additional Terms and Conditions shall apply for as long as any moneys are owing to the Bank under the Agreement or the Bank is under any obligation under the Agreement

The covenants will be tested at the frequency annotated below against (a) each financial statement, if the covenant is marked as being tested annually, and/or (b) against your management accounts or, if appropriate, against your tenancy schedules, if the covenant is marked as being tested monthly or quarterly. For the avoidance of doubt:

 

(a) you are required to provide the Bank with sufficient information to enable the Bank to test the covenants. This information is to be provided pursuant to the Agreement, and

 

(b) the covenants will be tested for the period of the accounts unless, in the case of a monthly or quarterly test, the covenant is also marked as being tested on a rolling 12 months. In this case, each test will be for the 12 month period ending on the test date.

 

              Frequency of Covenant testing
              Monthly    Quarterly    Annually   

Rolling 12

months

  CFADS to debt service    CFADS is not at any time to be less than     % of the aggregate of the consolidated principal repayments and the consolidated interest paid and payable (whether to the Bank or to any other person) for the period covered by the accounts.    ¨    ¨    ¨    ¨
  EBITDA to debt service    EBITDA is not at any time to be less than     % of the aggregate of the consolidated principal repayments and the consolidated interest paid and payable (whether to the Bank or to any other person) for the period covered by the accounts.    ¨    ¨    ¨    ¨
  Minimum retained profit    Retained Profit of not less than £             is to be reported in each financial statement (commencing with the financial statement as at          ¨   
  Interest cover    Your consolidated Profit Before Taxation and interest paid and payable is not at any time to be less than     % of the consolidated interest paid and payable (whether to the Bank or to any other person) for the period covered by the accounts.    ¨    ¨    ¨    ¨
  Gross rental cover    The total Rental Income received by you from all Property is not at any time to be less than     % of the aggregate of the principal repayments and the interest paid and payable to the Bank for the period covered by the accounts.    ¨    ¨    ¨    ¨
  Minimum gross rent    The total rental income received by you from all Property is not for any year to be less than £    ¨    ¨    ¨    ¨
                   Frequency of Covenant testing
                   Monthly    Quarterly    Annually
x   Minimum net worth    Net Worth is at all times to be maintained at not less than £ 4,000,000    ¨    ¨    x
  Gearing    Borrowing is not at any time to exceed     % of Net Worth    ¨    ¨    ¨
  Good trade debtors cover    Good Book Debts (after taking into account any amounts ranking in priority to amounts owing to the Bank) are not at any time to be less than     % of your utilisation of all facilities provided to you by the Bank.    ¨    ¨    ¨
  Loan to value    The total amount owing to the Bank (whether certain or contingent) by you is not at any time to exceed the aggregate of     % of the latest valuation received by the Bank of all Property (after taking into account any amounts ranking in priority to amounts owing to the Bank).    ¨    ¨    ¨

 

* delete as appropriate


Definitions

Borrowing shall include all your (and, if you have any subsidiaries, all of your subsidiaries’) borrowed moneys and all liabilities and indebtedness, whether or not then due, under acceptance credits and hire purchase, instalment credit, factoring, invoice discounting or similar agreements but excluding trade debts and liabilities for the payment of tax. If you are a company or a limited liability partnership. Borrowing shall exclude all loans from your directors or, as the case may be, members.

CFADS (Cash Flow available for Debt Service) means your consolidated Profit Before Taxation and interest paid and payable after adding back depreciation, amortisation of goodwill and other non-cash profit and loss items, plus or minus net movements in working capital, less tax paid, dividends paid and payable or, as the case may be, drawings made available and capital expenditure paid (net of capital expenditure funded by asset disposals and/or hire purchase and/or finance leasing)

EBITDA means your consolidated Profit Before Taxation, depreciation, amortisation of goodwill and of other intangibles and interest paid and payable (but after dividends paid and payable or, as the case may be, after drawings made available).

Good Book Debts means those debts due to you in the normal course of business (over which a charge or security interest has been given to the Bank in a form acceptable to the Bank) but excluding (a) any debts arising from the sale of goods acquired which remain subject to reservation of title, (b) any debts more than 3 months old or considered by you or your auditors (if appropriate) to be irrecoverable, (c) any contract debtors, and (d) any contra or intra-group debts.

Net Worth shall mean at any particular time:

(a) if you are a company or a limited liability partnership the aggregate of the amount paid up on your issued share capital (if you have any) and the consolidated distributable and non-distributable reserves of you and your subsidiaries but (i) after deducting the total of any debit balance on profit and loss account and the book value of goodwill and any other intangible assets, and (ii) excluding any minority interests in subsidiaries and any increase in the valuation of assets subsequent to the date of the financial statement, or

(b) if you are not a company or a limited liability partnership, the net aggregate of all credit balances (after deducting any debit balances) of your Capital Accounts (or the accounts similarly styled in the financial statement which, for the avoidance of doubt, shall not include any loan moneys) less the book value of goodwill and any other intangible assets, excluding any increase in the valuation of assets subsequent to the date of the financial statement but, at the discretion of the Bank, increased to include the amount of (i) any undrawn profits, and (ii) any taxation reserves.

Profit After Taxation and Profit Before Taxation shall include items of an exceptional nature and shall exclude items of an extraordinary nature unless taken into account at the Bank’s discretion for the purpose of any relevant calculation.

Property means freehold and/or leasehold property (or, if in Scotland, heritable property owned or leased) over which a charge or security interest has been given to the Bank in a form acceptable to the Bank.

Rental Income means income derived from rents and service charges, excluding sums charged in respect of insurance premiums, any statutory charges and any intra-group rental income.

Retained Profit means your consolidated Profit After Taxation and dividends paid and payable (or, as the case may be, after drawings made available) and after deducting any profit attributable to minority interests in subsidiaries and after taking into account any items of an extraordinary nature and any items of an exceptional nature.

 

Note:   If you do not have any subsidiaries, references in these Additional Terms and Conditions to “subsidiaries” and to “consolidated” shall be ignored and the relevant text shall be read and construed accordingly.


This document creates legal obligations and therefore before signing we recommend that you consider getting independent advice. This may help you in understanding the potential consequences in the event that things go wrong.

For Sole Trader/Partnership (other than Limited Liability Partnership)

 

Signed by        
Print name       Print name  
Signature       Signature  
Date       Date  
Print name       Print name  
Signature       Signature  
Date       Date  
Print name       Print name  
Signature       Signature  
Date       Date  
For Company / Limited Liability Partnership      
Signed for and on behalf of      
MOLECULAR PROFILES LTD      
by       and by  
Print name       Print name  
NIKIN PATEL     EMMA GAINFORD
Signature       Signature  
/s/ Nikin Patel     /s/ Emma Gainford
Date 6 JANUARY 2012     Date 6-1-12
*Director/Member/Authorised Signatory     *Authorised Signatory/Secretary
Pursuant to a resolution of the board/members dated #      
      Date  
Signed for and on behalf of the Bank by      
*Manager/Authorised Signatory    

*  Delete as appropriate.

/s/ Leo Magee    

#  This will be either the date of the account mandate, if an appropriate resolution is contained therein or the date of a specific resolution passed in respect of the loan

Date        

Lloyds TSB Bank plc Registered Office 25 Gresham Street, London EC2[ILLEGIBLE] 7HN. Registered in England and Wales, no 2065

Lloyds TSB Scotland plc Registered Office: Henry Duncan House, 120 George Street, Edinburgh EM2 4LH Registered in Scotland, no 95237

Authorised and regulated by the Financial Services Authority under numbers 119278 and 191240 respectively

Licensed under the Consumer Credit Act 1974 under registration numbers 0004685 and 0198797 respectively


LOGO    BUSINESS LOAN AGREEMENT

We LLOYDS TSB BANK PLC (the “ Bank ”) of Credit Fulfilment and Monitoring, Level 5, 110 St. Vincent Street, Glasgow G2 5ER offer you MOLECULAR PROFILES LIMITED (company registered number 03397582) of 8 Orchard Place, Nottingham Business Park, Nottingham, NG8 6PX a loan on the following terms and conditions.

SPECIFIC TERMS AND CONDITIONS

THE LOAN

The maximum amount of the loan (excluding any amounts of interest that will be added to the loan) shall be £1,500,000. This amount is to be used for to assist you with the construction of new offices and laboratory. The loan may be borrowed in several amounts on or before 30th November 2012 or such later date as the Bank may agree. You will not be entitled to borrow any amount that has not been borrowed by the agreed date. The proceeds of the loan will be credited to your current account no. 301898 01056523.

Unless the Bank agrees otherwise, no borrowing may be made until all the PRECONDITIONS set out below have been satisfied.

PRECONDITIONS

Unless received by the Bank prior to the date on which this agreement is signed by the Bank, the Bank is to receive in form and substance acceptable to the Bank the security and other documents (if any) listed in the Security Schedule to this agreement and the documents, evidence or other requirements of the preconditions (if any) set out in the Preconditions Schedule to this agreement. Any security received should be accompanied by such evidence as the Bank may reasonably require to confirm the value of such security and to confirm that such security is fully effective.

FEES AND COSTS

You shall pay any costs and expenses incurred by the Bank in assessing the loan, in the preparation of this agreement and of any amendment, waiver or consent letter at any time entered into, in the preparation, valuation, taking or release of any guarantee or security at any time given in connection with this agreement and in connection with the revaluation of any such security from time to time. These costs and expenses may arise whether or not the loan is made available to you. The Bank will provide you with an estimate of the amount of any such costs and expenses before they are payable.

An arrangement fee of £15,000 is also payable. This fee shall be paid to the Bank by you on the date the first amount is borrowed under this agreement.

As mentioned in clauses 3 & 6 of the GENERAL TERMS AND CONDITIONS , other costs may arise in connection with the loan or in connection with the repayment of the loan.

INTEREST

The rate of interest payable on the loan will be Base Rate plus an interest margin of 2.55% per annum, currently 3.05% per annum in total.

Interest shall be paid by you prior to the first repayment date and added to the loan from and after the first repayment date. Interest shall be paid or, as the case may be, added to the loan 1 month after the date of the first borrowing, at monthly intervals thereafter and on the date of final repayment of the loan.

Interest is calculated on a daily basis on the amount of the loan from time to time outstanding. Interest for any particular period is calculated on the number of days in that period and a year of 365 days.

If you fail to pay any amount payable under this agreement when due the rate of interest may be increased in accordance with clause 6.3 of the GENERAL TERMS AND CONDITIONS .

REPAYMENT

The loan is repayable in 168 consecutive monthly instalments representing principal and interest commencing on the date which is 13 month after the date the loan is first borrowed. The amount of these instalments will vary with changes in the interest rate and the number of days in the charging period.

If the full amount of the loan is not borrowed the amounts of the instalments detailed above will be reduced accordingly.

EARLY REPAYMENT

The loan may be repaid early in accordance with clause 2 of the GENERAL TERMS AND CONDITIONS .

FINANCIAL COVENANTS

For as long as any moneys are owing to the Bank under this agreement or the Bank is under any obligation under this agreement you shall comply with the financial covenant set out below.

Net Worth is at all times to be maintained at not less than £4,000,000.

This covenant will be tested against each financial statement.


Continuation of a LOAN AGREEMENT between

LLOYDS TSB BANK PLC and MOLECULAR PROFILES LIMITED

2

 

PERIOD OF OFFER

This agreement shall come into effect only if the Bank receives from you and finds in order a signed copy of this agreement on or before 8th January 2012 (or such later date as the Bank may agree).

GENERAL TERMS AND CONDITIONS

Use of Loan Proceeds

 

  1.1 Unless the loan is only for working capital or general business purposes, each amount borrowed shall be held in trust for the Bank until used for the purpose stated in the SPECIFIC TERMS AND CONDITIONS .

Repayment

 

  2.1 You will repay the loan on the dates and in the manner set out in the REPAYMENT section of the SPECIFIC TERMS AND CONDITIONS .

If you fail to make any repayment in full and by the time the Bank calculates the next repayment instalment amount, the Bank may (at its discretion and without prejudice to the Bank’s rights expressed in clause 6.1 below):

 

  (a) increase the amount of that next instalment and each of your remaining regular instalments proportionately to ensure that the full balance of the loan is repaid within the agreed term of the loan;

 

  (b) extend the term of the loan; or

 

  (c) increase the amount of the final repayment instalment.

The Bank will apply any payments it receives from you against any interest before any other amounts on your account, including the outstanding principal balance of the loan. This will not apply to payments made specifically for fees and/or charges or where the Bank collects the interest and principal that make up your repayment from separate accounts.

 

  2.2 You may at any time after giving at least 5 business days’ notice to the Bank make early repayment of all or any part of the loan together (in either case) with interest accrued to the date of payment. Each early repayment of part of the loan must be of at least £5,000 (excluding accrued interest). If the loan is to be repaid in more than one amount, the Bank will decide how to apply the early repayment, either (a) by reducing subsequent repayments proportionately or (b) by applying the early repayment to the then latest scheduled repayment instalments so as to reduce the term of the loan. No amount repaid early may be borrowed again.

Increased Costs and Changes in Circumstances

 

  3.1 In running its business the Bank and any holding company of the Bank each has to comply with certain regulations and requirements laid down by regulatory and other official organisations or bodies as well as the law generally. The rate of interest quoted in the SPECIFIC TERMS AND CONDITIONS has been set in the light of how this affects the cost (to the Bank and any such holding company) of the Bank funding, agreeing to make and of making the loan available at the time the Bank signed this agreement. If, as a result of any new laws, regulations or requirements or any changes in existing ones or in the interpretation or application of any existing ones, such cost is increased, the Bank may increase the rate of interest charged on the loan to compensate for that extra cost. The Bank will advise you in writing within 30 days of such increase taking effect.

 

3.2   (a)   

If the currency in which the loan is denominated is due to be or has been converted into the euro or into any other currency as a result of a change in law, the Bank can amend any term of this agreement. Such an amendment will be only to the extent the Bank thinks necessary to comply with any generally accepted conventions and market practice in the London interbank market and otherwise to reflect the change in currency and to put the Bank in the same position, so far as possible, that it would have been in if no change in currency had occurred.

 

  (b) The Bank can also change any term of this agreement at any time (even if an Event of Default has not occurred):

 

  (i) to reflect the introduction of or any other change in law or in any code of practice which applies to the Bank or the way the Bank is regulated;

 

  (ii) to reflect any changes the Bank makes to its systems or processes; or

 

  (iii) if the change is to your advantage.

 

  (c) If the Bank makes a change pursuant to this clause 3.2 which is to your disadvantage, the Bank will give you 30 days’ prior notice. This notice may be by letter, email, text, statement inserts or messages or in any other way which is sent to you. The Bank can make any other changes straight away by telling you personally or by putting notices in a selection of national newspapers, in its branches or on its website within the next 30 days.

For the avoidance of doubt any change in Base Rate is not subject to 30 days’ notice. Base Rate may be changed at any time as specified in the definition of Base Rate set out in clause 8.11 below.

 

  (d) At any time within 60 days of receipt of the Bank’s 30 days’ notice (as referred to in paragraph (c) above) you may make early repayment of all (but not part) of the loan. Such repayment shall be in accordance with clause 2 above.


Continuation of a LOAN AGREEMENT between

LLOYDS TSB BANK PLC and MOLECULAR PROFILES LIMITED

3

 

Representations

 

  4.1 You represent that:

 

  (a) all action required or necessary to authorise the execution of this agreement and the security documents (if any) required from you by this agreement and the performance of your obligations under and in connection with this agreement and such security documents has been taken,

 

  (b) neither the execution of this agreement nor the performance of your obligations under and in connection with this agreement, including the giving of any security, will constitute or result in any breach of any agreement, law, requirement or regulation (including, for the avoidance of doubt, your constitutive documents),

 

  (c) no material litigation, administrative or judicial proceedings are presently pending or threatened against you, any of your subsidiaries or any of your or any such subsidiary’s directors,

 

  (d) there has been no material adverse change in your financial condition or that of any of your subsidiaries since the date of the financial statement received by the Bank prior to the date on which this agreement is signed by the Bank, and

 

  (e) no Event of Default (as described in clause 6.1 below) has occurred and is continuing and no circumstance has occurred which, with the giving of notice or the passing of time, could become or cause an Event of Default.

 

  4.2 You shall be deemed to repeat the above representations on each day (with reference to the facts and circumstances then existing) prior to borrowing the loan and thereafter until all amounts payable to the Bank under this agreement have been paid.

Undertakings

Prior to borrowing the loan and thereafter until all amounts payable to the Bank under this agreement have been paid:

 

  5.1 neither you nor any of your subsidiaries shall without the Bank’s consent:

 

  (a) create or allow to be in place any mortgage, charge or other security interest or encumbrance over the whole or any part of your or their business or any of the property, income or other assets of your or their business or enter into any transaction which in the Bank’s opinion has a similar effect, or factor or assign arty debts,

 

  (b) part with, sell, transfer, lease or otherwise dispose of (or attempt or agree to do any such thing) the whole or any material part of your or any of your subsidiary’s undertaking, property, revenue or assets (either by a single transaction or a number of transactions whether related or not) other than for full value on an arm’s length basis (save that no parting with, sale, transfer, lease or other disposal may be made or entered into (i) if it would breach the terms of any security document given to the Bank, or (ii) in respect of any undertaking, property, revenue or asset over which the Bank then has a fixed charge or fixed security interest),

 

  (c) change the nature of your or their business as it is now conducted,

 

  (d) agree or enter into any substantial property transaction as set out in Sections 190 to 196 of the Companies Act 2006, or

 

  (e) make any loan, give any guarantee or provide any other security as set out in Sections 197 to 214 of the Companies Act 2006 or allow any such loan, guarantee or other security to continue,

 

  5.2 you shall provide to the Bank:

 

  (a) copies of your financial statement within 210 days of the end of each financial year, and

 

  (b) copies of your quarterly management accounts in a form acceptable to the Bank within 45 days of the end of the period to which they relate. The Bank may at its option require such management accounts to incorporate an age-analysis of debtors, a schedule of all tenancies (if any) of any property held by the Bank as security at the date of the accounts, and/or a breakdown of stock in trade, and

 

  (c) copies of any financial information or information regarding any security that the Bank may from time to time reasonably request promptly on request and within any timescale reasonably required by the Bank,

 

  5.3 you and each of your subsidiaries shall maintain with reputable underwriters or insurance companies adequate insurance on and over your respective business and assets. Such insurance is to be against such risks and to the extent usual for persons carrying on a business such as that carried on by you or, as the case may be, by the relevant subsidiary and is, if so requested by the Bank at any time, to include appropriate terrorism cover. From time to time upon the request of the Bank, you shall furnish the Bank with evidence of such insurance,

 

  5.4 in respect of any pension policy or life policy held by or charged to the Bank, you agree to ensure that the premiums are paid when due and, upon request from the Bank at any time, promptly to provide the Bank with evidence that payment has been made. In the case of any such pension policy you also agree:

 

  (a) upon request by the Bank at any time, promptly to provide the Bank with evidence that the commutation proceeds will be paid to the Bank,

 

  (b) except to the extent that you have and apply other funds in repayment of the loan, to take the maximum benefit of the pension policy by way of commutation and to apply that benefit in repayment of the loan when due, and

 

  (c) not to agree to any arrangement that would reduce the commutation amount of the pension policy nor arrange for any transfer to be made from the pension policy,


Continuation of a LOAN AGREEMENT between

LLOYDS TSB BANK PLC and MOLECULAR PROFILES LIMITED

4

 

  5.5 if the purpose of the loan (as stated in the SPECIFIC TERMS AND CONDITIONS ) involves building works or works enabling building works affecting any property, you agree that promptly upon request by the Bank at any time you shall:

 

  (a) provide the Bank with evidence in a form acceptable to the Bank that you have obtained all necessary permissions and approvals for the proposed works and have entered into (in a form of contract acceptable to the Bank) all contracts necessary for the due completion of the proposed works. You will at all times ensure that any other party to any such contract (whether or not such contract has been provided to the Bank) complies with the contract in accordance with its terms. You shall not, without the consent of the Bank, agree to any modification in the terms of any contract which has been provided to the Bank, or terminate any such contract or stop work on any proposed works prior to completion of the works, and

 

  (b) provide to the Bank confirmations (each in a form and from a party acceptable to the Bank) of all expenditure on the works. The Bank may refuse to permit any borrowing of the loan if the total of all borrowings made under this agreement in respect of the works exceeds the total expenditure detailed in the confirmations, and

 

  5.6 you agree to reduce the loan (in accordance with clause 2 above) or to provide the Bank with additional security acceptable to the Bank if the ratio of the loan to the value of the security given to the Bank is at any time higher than that applicable on the date this agreement was signed by the Bank and agree to provide such evidence as the Bank may from time to time require to confirm the value of such security and to confirm that the security remains fully effective. If the loan is to be repaid in more than one amount, the Bank will decide how to apply any early repayment, either (a) by reducing subsequent repayments proportionately or (b) by applying the early repayment to the then latest scheduled repayment instalment(s) so as to reduce the term of the loan.

Default and Termination

 

  6.1 The events listed in (a) to (k) below are called “ Events of Default ”. As soon as an Event of Default happens or at any time thereafter, by giving notice to you, the Bank may cancel any obligations if has to lend money to you and may also make the loan become repayable on demand. When the loan is repayable on-demand, you must repay the loan to the Bank together with all interest which has accrued on the loan and any other amounts owing under this agreement as soon as the Bank requests you to pay these amounts. The Bank may do this at the time the loan becomes repayable on demand or at any later time.

Events of Default

 

  (a) you fail to pay when due any indebtedness owed by you to the Bank,

 

  (b) you fail to comply with any other obligation or undertaking to the Bank or with the terms of any other agreement with the Bank or an event of default arises in connection with any other agreement with the Bank,

 

  (c) any representation or statement made by you to the Bank, whether or not in connection with this agreement, proves to have been incorrect or inaccurate when made or deemed made,

 

  (d) you fail to pay when due any indebtedness owed by you to another creditor or any of your creditors changes (or obtains the right to change) the original date on which that indebtedness is or was due to be paid to an earlier date as a result of your failure to comply with obligations in connection with that indebtedness,

 

  (e) any person with a legal claim takes possession or a receiver, administrator, custodian, trustee, liquidator or similar official is appointed of the whole or any part of your business or of any of the assets of your business or an administration application is presented or made for the making of an administration order or a notice of intention to appoint an administrator is issued by you or your directors or by the holder of a qualifying floating charge or notice of appointment of an administrator is filed by any person with the court or a judgment, decree or diligence is made or granted against you,

 

  (f) proceedings are commenced or a petition is presented or an order is made or a resolution is passed for your winding up or you are or become insolvent or you stop or threaten to stop payment of your debts generally or you are deemed by law unable to pay your debts or you of your directors convene or become obliged to convene a meeting of shareholders or creditors with a view to winding up or an application is made in connection with a moratorium or a proposal to creditors for a voluntary arrangement by you or you take any action (including entering negotiations) with a view to readjustment, rescheduling, forgiveness or deferral of any part of your indebtedness,

 

  (g) you cease or threaten to cease to carry on your business in the normal course or fail to maintain or breach any franchise, licence or right necessary to conduct your business or breach any legislation relating to your business, including but not limited to any applicable environmental protection laws,

 

  (h) the persons who now control you cease to have such control,

 

  (i) any guarantee, other security or other document or arrangement relied upon by the Bank in connection with the loan ceases to be continuing or ceases to remain fully effective or notice of discontinuance is received by the Bank or if the Bank reasonably believes that the effectiveness of any such document or arrangement is in doubt or if any provision of such document or arrangement is not complied with for any reason or any favourable tax treatment afforded to any pension policy or to any life policy held by or charged to the Bank ceases to be available,

 

  (j) any of the above events occur in relation to any parent or subsidiary or any guarantor of or other provider of security for the loan or, in the case of any individual that provides any guarantee or other security for the loan, a petition is presented for a bankruptcy or sequestration order against any such individual or any such individual dies or becomes incapable of managing his or her affairs because of any lack of mental capacity, or any action is taken in any jurisdiction which is similar or analogous to any of the above events in respect of you or any of the above mentioned parties, or

 

  (k) you fail or have failed to disclose to the Bank any important information that is relevant to the loan or the security required or you undertake or are subject to any action or occurrence which the Bank reasonably believes could place at risk the payment of any amount owing to the Bank.


Continuation of a LOAN AGREEMENT between

LLOYDS TSB BANK PLC and MOLECULAR PROFILES LIMITED

5

 

  6.2 If any Event of Default happens or anything happens that might lead to an Event of Default, you shall inform the Bank immediately.

 

  6.3 If any amount payable in respect of this agreement is not paid when due (including any amount payable under this clause 6) you shall pay interest on that amount at the default rate from the date on which the amount was due until it is paid to the Bank. Interest, if unpaid, shall be added to the amount in default at monthly intervals. The default rate shall be the rate determined by the Bank to be 3% per annum higher than the rate of interest specified in the SPECIFIC TERMS AND CONDITIONS that would normally apply.

 

  6.4 You shall indemnify the Bank against any costs incurred or losses reasonably sustained by the Bank as the result of any Event of Default happening or any failure by you to pay any amount demanded by the Bank, as a result of an Event of Default.

 

  6.5 You shall also pay any costs and expenses reasonably incurred by the Bank in enforcing or perfecting any security for the loan and in enforcing or preserving its rights under this agreement.

Assignment and Securitisation

 

  7.1 This agreement is for the benefit of the contracting parties, their respective successors and permitted assigns, The agreement does not and will not confer any benefit on or be enforceable by any third party (other than by any such successor or permitted assign).

 

  7.2 The Bank may at any time and without any further consent agree or enter into a Transfer, although, without prejudice to any other type of transfer, no Transfer of the Bank’s obligations shall be effective until such time as the Transferee shall have confirmed that it is bound by the terms of this agreement. Following such confirmation you shall look only to the Transferee in respect of that portion of the Bank’s obligations transferred to the Transferee. You will not assign any of your rights or transfer any of your obligations under this agreement without the prior written consent of the Bank.

 

  7.3 The Bank may disclose any information about you or any of your subsidiaries to its auditors for the time being, to any Transferee or potential Transferee, to any rating agency or listing authority, to any advisers of any such party or of the Bank and to any other person to whom the Bank believes it is reasonable to disclose such information in connection with any proposed Transfer. This may include information about your finances or the finances of any subsidiary, the loan and any security document relating to, or other document relied on by the Bank in connection with, this agreement.

 

  7.4 You will co-operate with and assist the Bank to complete any proposed Transfer. In particular, you will assist the Bank in transferring the benefit of any security document given in connection with this agreement, whether that Transfer is to the Transferee or to a security trustee appointed by the Bank and/or the Transferee. The Bank will reimburse you for all legal and other out of pocket costs and expenses including any registration (or similar) fees incurred with the prior written agreement of the Bank in connection with requests made by the Bank pursuant to this clause 7.4.

Other

 

  8.1 This agreement and any non-contractual obligations arising from or connected with this agreement shall be governed by English law and is subject to the jurisdiction of the English Courts. The Bank may take action against you in any other jurisdiction where proceedings may be lawfully commenced.

 

  8.2 No delay or omission by the Bank in exercising any of its rights hereunder shall operate or be construed as a waiver, nor shall any single or partial exercise of any such right prevent any other or further exercise thereof or the exercise of any other right.

 

  8.3 If the loan is to be borrowed, or if any payment becomes due from you, on a day which is not a business day then the amount concerned will be borrowed or, as the case may be, will become payable on the next business day. All payments from you are to be made without any set-off, deduction or withholding of any nature.

 

  8.4 The Bank may use any credit balance there may be on any of your accounts towards payment of any amounts owed by you to the Bank under this agreement without notifying you beforehand, whether such credit balances are in sterling or any other currency or are deposited for fixed or determinable periods.

 

  8.5 Unless otherwise agreed by the Bank you shall at all times during the term of this agreement keep a current account (or other account for the purposes of meeting all payments due to the Bank under and in connection with this agreement) with the Bank and all amounts from time to time due to the Bank under this agreement may be debited to that account. You shall keep enough money in the account (or ensure that there are sufficient funds available within any agreed overdraft) to meet all such payments as they become due. If you do not at any time maintain such an account with the Bank, the Bank may (without prejudice to its rights under clause 6.1 above) add to your loan account any interest that is to be paid by you but which is not paid on the date it is due for payment. The Bank may charge interest on any amount so added to the loan account.

 

  8.6 Any security given to the Bank (whether given before the date on which this agreement is signed by the Bank or at any time in the future and whether or not specified in this agreement) shall, unless otherwise agreed by the Bank, be security not only for the loan but also for all other moneys and liabilities whether certain or contingent at any time due, owing or incurred by you to the Bank.

 

  8.7

This agreement and all communications from you to the Bank in connection with this agreement and the loan (all of which are to be sent in writing to the Bank at the address given at the heading of this agreement or to such other address as the


Continuation of a LOAN AGREEMENT between

LLOYDS TSB BANK PLC and MOLECULAR PROFILES LIMITED

6

 

  Bank may from time to time advise) shall be signed on your behalf either in accordance with the mandate given by you to the Bank, or if requested by the Bank, in accordance with a specific resolution of your Board of Directors. All communications (whether given by you or by the Bank) relating to the loan and any change to this agreement shall be in English.

 

  8.8 The Bank will not be liable for any loss, damage, interruption, delay or non-performance in connection with this agreement caused in whole or in part by events which are beyond the Bank’s reasonable control. This may include, for example, explosion, terrorism, war, riot or other civil disturbance or failure or interruption of any electronic communications system.

 

  8.9 Any change to this agreement that is not permitted in this agreement must be made in writing and be signed by the contracting parties.

 

  8.10 The SPECIFIC TERMS AND CONDITIONS and GENERAL TERMS AND CONDITIONS shall be read and construed as one agreement.

 

  8.11 References in this agreement to:

an Act or any other statutory provision shall be deemed to mean and to include a reference to any amendment to or restatement of that Act or other provision for the time being in force.

the Bank includes its successors and assigns.

Base Rate means the official bank rate of the Bank of England from time to time. Base Rate may be varied (either up or down) at any time. If Base Rate changes, the change will be immediately reflected in the rate of interest charged on the loan. Notice of changes is currently displayed in UK branches of the Bank, on the Bank’s website (www.lloydstsbbusiness.com) and in a number of daily newspapers.

a business day means a day other than a Saturday or a Sunday on which banks are open for normal business in England and Wales.

control shall have the meaning given to it in Section 995 of the Income Tax Act 2007.

financial statement means at any particular time the latest consolidated annual balance sheet and profit and loss account (being audited or signed by an independent accountant if so required by law or by the Bank at any time and being prepared on the same basis, containing a similar level of detail and in accordance with the same accounting principles as, and for an accounting reference period consistent with, the latest such balance sheet and profit and loss account received by the Bank prior to the date on which this agreement is signed by the Bank) of you and your subsidiaries together with the notes to both.

loan means, at any particular time, the total amount which may be borrowed by you under this agreement or, if appropriate, the total amount which has been debited to the loan account and remains outstanding at such time. The loan may, at any time, include any interest, costs and charges added to the loan account in accordance with this agreement.

month means a calendar month.

parent and subsidiary shall have respectively the meaning given to parent undertaking and subsidiary undertaking in Section 1162 of the Companies Act 2006. During any period in which you do not have a subsidiary , all references to your subsidiaries shall be ignored and the relevant text read and construed accordingly.

Transfer means any assignment, transfer, securitisation or other disposal by the Bank of all or any of its rights or obligations under this agreement to any other person, the sale of any participation in any such rights or obligations to any other person, and any other transaction of any nature which has the effect of transferring the economic or credit risks or rewards of the Bank under or in connection with this agreement to any other person.

Transferee means any person to whom a Transfer is made or with whom a Transfer is entered into.

 

  8.12 For the purposes of the financial covenants:

Net Worth shall mean at any particular time the aggregate of the amount paid up on your issued share capital (if you have any) and the consolidated distributable and non-distributable reserves of you and your subsidiaries but (a) after deducting the total of any debit balance on profit and loss account and the book value of goodwill and any other intangible assets, and (b) excluding any minority interests in subsidiaries and any increase in the valuation of assets subsequent to the date of the financial statement.

Use of Personal Information and Credit, Fraud and Identification Checks

When you apply to open an account, the Bank will check its own records for information on individuals who are Key Account Parties. “ Key Account Parties ” are individuals who are sole traders, proprietors, partners, directors, members, beneficial owners, trustees or other controlling officials of the business or organisation including signatories to the account. The Bank may also carry out a search through credit reference agencies on these individuals. The credit reference agencies will keep a record of this search and this record may be used by other organisations to verify their identities. The Bank may also check or share information with fraud prevention agencies to prevent fraud and money laundering.

When you apply for credit and credit related or other facilities, the Bank may carry out a search through credit reference agencies on you and/or Key Account Parties. The credit reference agencies will keep a record of this search whether or not the application proceeds. A record of the search on personal files will not be made available to other organisations. A record of the search on the business file will be made available to other organisations. The Bank may also check or share information with fraud prevention agencies to prevent fraud and money laundering.

When you have an account with the Bank, the Bank may disclose how you have run your account(s) to credit reference agencies. If you borrow and do not repay in full and on time, the Bank may tell the credit reference agencies. The Bank may make periodic


Continuation of a LOAN AGREEMENT between

LLOYDS TSB BANK PLC and MOLECULAR PROFILES LIMITED

7

 

searches of the Lloyds Banking Group records and credit reference agencies to manage your account(s) including to make decisions whether to continue or extend existing credit. The “ Lloyds Banking Group ” includes the Bank and a number of other companies using brands including Lloyds TSB, Halifax and Bank of Scotland, and their associated companies. More information on the Lloyds Banking Group can be found at www.lloydsbankinggroup.com. For these purposes “associated companies” includes Lloyds Banking Group plc and any subsidiary, affiliate or other firm directly or indirectly controlled from time to time by either Lloyds Banking Group plc or by the Bank.

The Bank may also check and share information with fraud prevention agencies to prevent fraud and money laundering.

If false or inaccurate information is provided or fraud is suspected, details may be passed to fraud prevention agencies and other relevant agencies.

If you or Key Account Parties ask, the Bank will tell you or them which credit reference and fraud prevention agencies it has used so you or they can get a copy of your or their details from these agencies.

This is a condensed guide to the use of your personal and business information by the Bank and at credit reference and fraud prevention agencies. If you would like to read full details of how data may be used, please visit the website at www.lloydstsb.com/commercial/customerdata or contact your relationship manager.

Preconditions Schedule

 

  (1) The Bank has received in form and substance acceptable to it a full appraisal of the Project, including a detailed cashflow of the Projected cost. The appraisal is to be prepared by a party acceptable to the Bank., and

 

  (2) The loan may be drawn down in amounts of no more than £200,000, provided that in respect to each drawing the Bank shall have first received confirmations (each in a form and from a party acceptable to the Bank) of all expenditure on the Project and written instructions from you specifying the account to which the proceeds are to be credited.

Security Schedule

 

  (1) an unlimited debenture from Molecular Profiles Limited,

 

  (2) a first legal charge from Molecular Profiles Limited over the freehold land and buildings at 8 Orchard Place, Nottingham Business Park, Nottingham, and

 

  (3) a deposit agreement incorporating a charge from Molecular Profiles Limited over a cash deposit in an amount of £1,000,000.


Continuation of a LOAN AGREEMENT between

LLOYDS TSB BANK PLC and MOLECULAR PROFILES LIMITED

8

 

You acknowledge having received, read and understood a copy of this agreement and, in consideration of the Bank agreeing to grant the loan, agree to the SPECIFIC TERMS AND CONDITIONS and to the GENERAL TERMS AND CONDITIONS set out above (together the “ agreement ”). You also acknowledge that this agreement comprises all the terms currently applicable to the loan and that no representation, warranty or undertaking has been made by the Bank in connection with the loan which is not set out in this agreement and, in deciding to enter into this agreement and to proceed with any transaction or project for which the loan has been sought, you recognise that the Bank has no duty to give you advice and you have not received or relied upon any advice given by the Bank.

Signed for and on behalf of Molecular Profiles Limited by

 

/s/ Nikin Patel

  (signature)    

/s/ Emma Gainford

  (signature)
*Director       *Authorised Signatory  

NIKIN PATEL

  (name)    

EMMA GAINFORD

  (name)

Pursuant to a Resolution of the Board dated 6 JANUARY 2012 #

Date 6 JANUARY 2012

 

Signed for and on behalf of the Bank by

 

    #  

This will be either the date of the account mandate,

if an appropriate resolution is contained therein, or

the date of a specific resolution passed in respect of this loan.

Manager/Authorised Signatory/      
/s/ Leo Magee      
      *   Delete as appropriate
Date  

 

     

Important note :

This agreement creates legal obligations. Before signing you may wish to take independent advice .

www.lloydstsb.com

Please contact your relationship manager if you would like this agreement in Braille, large print or on audio tape.

The Bank accepts calls made though RNID Typetalk.

Calls may be monitored or recorded in case the Bank needs to check it has carried out your instructions correctly and to help improve its quality of service.

Lloyds TSB Bank plc Registered Office: 25 Gresham Street, London EC2V 7HN. Registered in England Number 2065

Authorised and regulated by the Financial Services Authority.

Version 30092011

Exhibit 10.4

 

   Lloyds TSB Bank plc   
LOGO    Loan Servicing   
   Level 5   
   110 St. Vincent Street   
   Glasgow   
   G2 5ER    Telephone: 0845 604 9936
      Facsimile: 0845 601 2467
   Reference: SY/LOV/309618 00429838/Sharon Foulkes
The Directors      
Molecular Profiles Ltd    Date:             16 th  September 2013
8Orchard Place      
Nottingham Business Park      
Nottingham      
United Kingdom      
NG8 6PX      

Dear Sir/Madam,

A MENDMENT L ETTER

We refer to the Business Loan Agreement which was signed by us on 6 th  January 2012 (the “ Agreement ”) and to the security documents required under it from time to time. In the Agreement we agreed to make available to you, a loan of up to £1,500,000.

Following agreement with you, we confirm that with effect from the Effective Date (as defined below) the terms of repayment set out in the Repayment section of the Specific Terms and Conditions of the Agreement shall be construed so as to require the loan to be repaid in 166 consecutive monthly instalments of principal and interest commencing on 5 th  October 2013. The amount of these instalments will vary with changes in the interest rate and the number of days in the charging period. The final repayment of the loan will be made on 5 th  July 2027.

For the avoidance of doubt, we confirm that if the term of the loan is extended the total amount of interest payable by you under the Agreement may be higher.

All other terms and conditions in the Agreement remain unaltered and from the Effective Date the Agreement and this letter shall be construed as one agreement.

The Effective Date shall be the date we have received a copy of this letter duly signed by you agreeing to the amendment it contains.

 

Yours faithfully,
For and on behalf of Lloyds TSB Bank plc

/s/ Leo Magee

Manager

We confirm our acceptance of and agreement to the amendment detailed in your letter dated 16 th  September 2013.

For and on behalf of Molecular Profiles Ltd (company registered number – 03397582)

 

Signed by  

NIKIN PATEL

  (name)    

EMMA GAINFORD

  (name)
 

/s/ Nikin Patel

  (signature)*    

/s/ Emma Gainford

  (signature)*
 

19 SEPTEMBER 2013

  (date)    

19/9/13

  (date)

This letter creates legal obligations. Before signing you may wish to take independent advice.

* to be signed in accordance with the borrowing arrangements clause of the mandate given to the Bank or a specific resolution acceptable to the Bank

Lloyds TSB Bank plc Registered Office 25 Gresham Street, London EC2V 7HN. Registered in England and Wales no 2065 Telephone 020 7626 1500

Lloyds TSB Scotland plc Registered Office. Henry Duncan House, 120 George Street, Edinburgh, EH2 4LH. Registered in Scotland no 95237. Telephone 0131 225 4555

Authorised and regulated by the Financial Services Authority under numbers 119278 and 191240 respectively. Licensed under the Consumer Credit Act 1974 under license numbers 0004685 and 0198797 respectively We are members of the Financial Services Compensation Scheme and the Financial Ombudsman Service


   Lloyds TSB Bank plc   
LOGO    Loan Servicing   
   Level 5   
   110 St. Vincent Street   
   Glasgow   
   G2 5ER    Telephone: 0845 604 9936
      Facsimile: 0845 601 2467
   Reference: SY/LOV/309618 00428734/Sharon Foulkes
The Directors      
Molecular Profiles Ltd    Date:             16 th  September 2013
8Orchard Place      
Nottingham Business Park      
Nottingham      
United Kingdom      
NG8 6PX      

Dear Sir/Madam,

A MENDMENT L ETTER

We refer to the Business Loan Agreement which was signed by us on 6 th  January 2012 (the “ Agreement ”) and to the security documents required under it from time to time. In the Agreement we agreed to make available to you, a loan of up to £1,000,000.

Following agreement with you, we confirm that with effect from the Effective Date (as defined below) the terms of repayment set out in the Repayment section of the Specific Terms and Conditions of the Agreement shall be construed so as to require the loan to be repaid in 162 consecutive monthly instalments of principal and interest commencing on 9 th  October 2013. The amount of these instalments will vary with changes in the interest rate and the number of days in the charging period. The final repayment of the loan will be made on 9 th  March 2027.

For the avoidance of doubt, we confirm that if the term of the loan is extended the total amount of interest payable by you under the Agreement may be higher.

All other terms and conditions in the Agreement remain unaltered and from the Effective Date the Agreement and this letter shall be construed as one agreement.

The Effective Date shall be the date we have received a copy of this letter duly signed by you agreeing to the amendment it contains.

 

Yours faithfully,
For and on behalf of Lloyds TSB Bank plc

/s/ Leo Magee

Manager

We confirm our acceptance of and agreement to the amendment detailed in your letter dated 16 th  September 2013.

For and on behalf of Molecular Profiles Ltd (company registered number – 03397582)

 

Signed by  

NIKIN PATEL

  (name)    

EMMA GAINFORD

  (name)
 

/s/ Nikin Patel

  (signature)*    

/s/ Emma Gainford

  (signature)*
 

19 SEPTEMBER 2013

  (date)    

19/9/13

  (date)

This letter creates legal obligations. Before signing you may wish to take independent advice.

* to be signed in accordance with the borrowing arrangements clause of the mandate given to the Bank or a specific resolution acceptable to the Bank.

Lloyds TSB Bank plc Registered Office 25 Gresham Street, London EC2V 7HN. Registered in England and Wales no 2065 Telephone 020 7626 1500.

Lloyds TSB Scotland plc Registered Office Henry Duncan House, 120 George Street, Edinburgh, EH2 4LH. Registered in Scotland no 95237. Telephone 0131 225 4555

Authorised and regulated by the Financial Services Authority under numbers 119278 and 191240 respectively Licensed under the Consumer Credit Act 1974 under license numbers 0004685 and 0198797 respectively. We are members of the Financial Services Compensation Scheme and the Financial Ombudsman Service

Exhibit 31(i).1

Certification Pursuant to Rule 13a-14(a)/15d-14(a)

of the Securities Exchange Act of 1934

I, Frank C. Condella, Jr. certify that:

1. I have reviewed this quarterly report on Form 10-Q of Columbia Laboratories, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

/s/ Frank C. Condella Jr.

Frank C. Condella Jr.
President and Chief Executive Officer
DATE: November 6, 2013

Exhibit 31(i).2

Certification Pursuant to Rule 13a-14(a)/15d-14(a)

of the Securities Exchange Act of 1934

I, Jonathan B. Lloyd Jones, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Columbia Laboratories, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

/s/ Jonathan B. Lloyd Jones

Jonathan B. Lloyd Jones

Vice President, Chief Financial Officer and Treasurer

(Principal Financial and Accounting Officer)

DATE: November 6, 2013

Exhibit 32.1

Certification Pursuant to

18 U.S.C. Section 1350

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Columbia Laboratories, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Frank C. Condella, Jr., President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

/s/ Frank C. Condella, Jr.

Frank C. Condella, Jr.
President and Chief Executive Officer
Date: November 6, 2013

Exhibit 32.2

Certification Pursuant to

18 U.S.C. Section 1350

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Columbia Laboratories, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jonathan B. Lloyd Jones, Vice President, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

/s/ Jonathan B. Lloyd Jones

Jonathan B. Lloyd Jones

Vice President, Chief Financial Officer and Treasurer

(Principal Financial and Accounting Officer)

DATE: November 6, 2013